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Advances in next-generation sequencing have accelerated the rate at which novel 
gene fusions are discovered. The discovery of gene fusions such as EML4-ALK in lung 
cancer and BCR-ABL1 in chronic myeloid leukaemia have already led to changes in clinical 
care. However, important questions remain about the role of gene fusions in promoting 
oncogenic phenotypes and their relevance in drug response.  
In this study, I combine RNA sequencing, CRISPR/Cas9 screens and high-
throughput drug sensitivity data in a panel of 1,011 human cancer cell lines across 42 tissue 
types to examine the occurrence and functional relevance of gene fusions in cancer. 
Fusions were called using three algorithms and filtered to reveal 8,354 fusion events 
with a validation rate of 70%. Cell lines exhibit known fusions in their corresponding tissue 
types as well as a large number of putative passenger events and fusion recurrence across 
tissue types correlates with that found in patient samples. 
The panel of 1,011 cell lines has previously undergone high-throughput drug 
screening of 409 drug compounds. I implemented a systematic analysis to identify 
associations between fusion occurrence and drug response. It reliably recapitulates known 
associations (e.g. BCR-ABL1 and sensitivity to ABL inhibitors). However, the number of 
novel findings is low, likely due to the low numbers of recurrent fusions, a lack of prior 
knowledge of novel gene fusions as well as a narrow range of drug targets.  
Next, I developed a computational approach using whole-genome CRISPR/Cas9 
screening data for 339 cell lines. It utilises CRISPR/Cas9 data on a guide-level to 
systematically evaluate essentiality of novel gene fusions. My analysis predicts essentiality 
of known gene fusions with high accuracy and provides evidence for the oncogenic 
relevance of novel gene fusions. A gene fusions in YAP1-MAML2 represents a particularly 
interesting finding showing functionality across multiple distinct cancer types. 
Altogether, in my thesis, I demonstrate that innovative computational approaches 
leveraging new datasets can enable us to elucidate the functionality of rare gene fusions 
in human cancer. These types of discoveries may aid in the development of targeted 
therapies and supports the use of clinical basket trials to capture cancer events across 
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1 Introduction & Literature review 
1.1 General introduction and thesis outline 
1.1.1 Context and role of genomics in cancer treatment 
The advent of next-generation sequencing technologies has allowed the scientific 
community an unprecedented insight into cancer genomes. For a disease that is estimated 
to cause 28% of deaths in the United Kingdom each year (Cancer Research UK, 2015), 
insights into the biology of cancer initiation, progression, maintenance and treatment are 
crucial in helping to create a better standard of care for patients. 
Cancer has been studied in some form or another since several hundred years BC, 
when the term “carcinoma” was termed by Hippocrates. The vast majority of our 
understanding into the underlying biological causes has been developed over the last 70 
or so years, enabled by the elucidation of the DNA structure and sequencing technology. 
Now, international consortia such as The Cancer Genome Atlas (TCGA) and International 
Cancer Genome Consortium (ICGC), have already sequenced tens of thousands cancer 
genomes. An on-going effort by Genomics England aims to sequence 100,000 genomes 
of National Health Service patients with cancer and rare diseases in the United Kingdom 
(Genomics England). As of July 2018, they have sequenced their 70,000th genome. 
With the explosion of genomic data available, significant improvements are being 
made in the diagnostic, prognostic and treatment opportunities made available to patients 
today and in the future.  
 
At its’ essence, cancer describes the transformation of normal cells into a malignant 
disease that can be lethal to the host. It encompasses over 100 distinct diseases, all of 
which follow essentially the same pattern of excessive proliferation and death avoidance 
that underpin the hallmarks of cancer defined by Hanahan and Weinberg in 2000 and 
refined in 2011 (Hanahan and Weinberg, 2000, 2011). 
The genetic and genomic revolution has enabled the research that brought about 
and cemented one of the now fundamental principles of cancer research – that cancer 
arises from changes in the genome. Genomic events, such as point mutations, changes in 
copy number and others, can deregulate the function and expression levels of proteins. 
They imbalance the intricate protein signalling networks that regulate a range of basic 
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cellular functions, from response to growth factors, apoptotic blockade, cell adhesion and 
migration, immune evasion and many more. 
As genetic alterations were understood to be drivers of cancer, the resulting 
oncogenic proteins became appealing targets for chemical inhibition. The standard of care 
for most cancers diagnosed today is a combination of surgery, chemotherapy and 
radiotherapy. While they reduce overall mortality on a population level, not all patients 
respond and they often carry harsh side effects and a risk of treatment-related mortality. 
Targeted therapy is the name for a treatment that is tailored to a molecular 
alteration that underpins a specific cancer subtype. The first and best-cited example of a 
successful targeted therapy is that of imatinib, which targets the disease-defining BCR-
ABL1 fusion in chronic myeloid leukaemias (CML) (Druker et al., 2001). Imatinib became 
the first targeted treatment to be approved by the US Food and Drug Administration (FDA) 
in 2001 and five years after initial administration showed an exceptional 95% overall 
survival for CML patients (Druker et al., 2006). 
Since then, many more targeted treatments have been approved by the FDA across 
a range of tumours with varying genomic biomarkers. For example, these include BRAF-
mutated melanomas being treated with BRAF and MEK inhibitors (Flaherty et al., 2012; 
Hauschild et al., 2012), or EGFR inhibitors being used in KRAS and NRAS wild-type 
colorectal cancers and EGFR-mutated non-small-cell lung cancers (Douillard et al., 2013; 
Mok et al., 2009). Similarly, the immunotherapy agent pembrolizumab has recently been 
approved for the treatment of microsatellite instable solid tumours (Le et al., 2015). 
Unfortunately, in advanced tumours many of the targeted treatments merely slows 
down disease progression and patients often relapse and exhibit new genomic alterations 
that bypass the inhibited mechanism. Similarly, many patients simply do not have any 
actionable biomarkers for tailored treatments (McDermott, 2015).  
Thus, there is still a pressing need to further advance our understanding of the 
cellular mechanisms of different subtypes of cancer. Discoveries of new cancer drivers and 
markers can greatly benefit future patients by allowing early diagnosis, better prognoses 




1.1.2 Gene fusions in cancer research 
This PhD thesis is focused on the functional role of fusion transcripts in cancers. 
Gene fusions have formed some of the best-cited success stories in targeted cancer 
treatment, starting with the treatment of BCR-ABL1-positive tumours with imatinib. In 2011 
followed the approval of crizotinib for the treatment of ALK-fused non-small-cell lung 
cancer (Kwak et al., 2010). Aside from treatment targets, gene fusions also play major roles 
in driving tumourigenesis in various tumour subtypes.  
Since the 1970’s, sequential improvements in technology allowed the study of gene 
fusions in greater and greater detail. More recently, the invention of paired-end RNA-
sequencing (RNA-Seq) technology opened up new opportunities to study gene fusions at 
even greater scale. A paper published in March 2018 represents a further milestone, where 
fusions were called from RNA-Seq data from almost 10,000 TCGA patient tumours (Gao et 
al., 2018). With large-scale fusion detection made accessible in this age of high-throughput 
sequencing, the next challenge is to sift through biological passengers and technical 
artefacts in order to identify functional drivers of oncogenesis and markers for treatment 
response.  
To address this question, I used a panel of 1,011 genomically annotate human 
cancer cell lines. The cell lines also have been screened across over 400 drug compounds 
and a subset of cell lines also has essentiality profiles of over 18,000 genes that were 
generated through CRISPR/Cas9 whole genome drop-out screens. Our group has now 
generated RNA-Seq data for these cell lines, and analysed it with fusion-calling algorithms. 
The aim of my dissertation has been to 1) analyse and apply a set of filters to 
remove technical artefacts and arrive at a final set of fusions and 2) conduct a set of 
analyses that would attribute a functional role to fusions detected by large-scale 
sequencing approaches. This work could help us discover and inform the functional 
implications of gene fusions in cancer. 
1.1.3 PhD chapter outline 
Here in chapter 1, I will introduce the i) concept, successes and challenges of 
precision cancer medicine, ii) state-of-art of the technologies and findings on gene fusions 
in cancer and iii) the important role of cancer cell lines as experimental models of tumour 
biology and treatment response, especially in the high-throughput setting.  
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Following that, in chapter 2 I describe the development of a set of filtering criteria 
that created a working list of gene fusions with a ~72% validation rate in our cancer cell 
lines. In chapter 3, I briefly describe the landscape of the gene fusions across our panel of 
cell lines. In chapter 4, I query the association of fusion occurrence with sensitivity to over 
400 drug compounds. In chapter 5, I develop a computational method to assess 
functionality of gene fusions using the CRISPR/Cas9 whole-genome data and in chapter 6 
I present the results and provide examples of fusions as novel candidates of cancer 
maintenance and potential treatment targets. Throughout the thesis, I attempted to 
highlight not just the biological significance of the results, but also points of learnings and 
potential improvements that emerged while working with the data. Finally, chapter 7 




Figure 1.1: PhD thesis outline of identifying gene fusions in cancer cell lines. Using the extensive genomic and 
phenotypic data that is available for the cell lines, my analysis attempts to find functionally relevant gene fusions 
that may be used as targets of precision medicine. Numbers in boxes refer to the chapters in which I focus on 
certain elements of this process map.  
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1.2 Precision cancer medicine 
A central goal of cancer research is to improve the clinical outlook for cancer 
patients and to increase their survival chances while maintaining an adequate quality of 
life. The two biggest opportunities for medical intervention are 1) by providing good 
treatment options available at the time of diagnosis that will eradicate or delay disease 
progression while minimising harmful side effects and 2) achieving earlier diagnosis of 
cancer, as treatment of early-stage cancers typically has much better outcomes than at 
advanced-stages.  
Precision cancer medicine falls into the first category of improving treatment 
options. As indicated in the previous section, the standard-of-care often produces mixed 
results depending on the exact cancer diagnosis and carries the risk of harmful side-effects. 
Precision cancer medicine aims to select the treatment that produces the best survival 
outcomes for each patient according to the tumour’s molecular make-up. An important 
principle here is that of “oncogenic addiction”, whereby a cancer cell becomes dependent 
on constitutive activity of an oncogene for tumour maintenance and survival. Many 
targeted medicines aim to inhibit the oncogene and thus cause tumour regression. 
The basic concept is that when a patient presents with cancer in the clinic, a sample 
is taken and sequenced either for a panel of cancer-associated molecular alterations and 
based on the genetic changes and the current state-of-the art of cancer knowledge, a 
suitable treatment can then be selected.  
1.2.1 Case study: Non-small cell lung cancer 
A prominent example illustrating precision cancer medicine is that of non-small cell 
lung cancer (NSCLC). Lung cancer, of which 85% are classified as NSCLC, is one of the most 
common and deadly cancers world-wide, partially due to the wide-spread production and 
consumption of its main carcinogens, tobacco smoke and air pollution (Reck and Rabe, 
2017). When a patient presents at the clinic and is diagnosed with NSCLC, a biopsy is taken 
and tested for the presence of 1) activating EGFR, BRAF and KRAS mutations using 
sequencing, 2) ALK or ROS1 rearrangements using fluorescence in situ hybridisation (FISH) 
and 3) PDL-1 expression levels using immunohistochemistry. Treatment is then chosen 
accordingly (Reck and Rabe, 2017). 
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Firstly, mutations in epidermal growth factor receptor (EGFR) occur in about 10-20% 
of Caucasians and 48% of East Asians, and are a good indicator of response to EGFR 
inhibitors, such as gefitinib, afatinib and erlotinib. Compared to standard-of-care 
chemotherapy, these targeted EGFR inhibitors effectively doubled progression-free 
survival time from 5.1-6.1 months to 10.0-11.8 months (range depended on the exact 
nature of the EGFR mutation) (Lee et al., 2015a). Moreover, EGFR inhibitors tend to show 
lower toxicity than chemotherapy, with a lower percentage of patients with grade 4 side 
effects (Maemondo et al., 2010). 
Rearrangements in ALK receptor tyrosine kinase (ALK) and ROS proto-oncogene 1 
(ROS1) occur in 1-7% of tumours and qualify a patient for treatment with crizotinib, an 
inhibitor of multiple tyrosine kinases: MET proto-oncogene (MET), ROS1 and ALK. 
Treatment outcomes in terms of response rate and progression-free survival were better 
in all clinical trials using crizotinib for ALK-rearrangements for both first-line and advanced-
stage treatments (response rates of 65%-74% vs. 20%-45% using chemotherapy and 
median progression-free survival: 7.7-10.9 months vs. 3.0-7.0 months) (Shaw et al., 2013; 
Solomon et al., 2014). Advanced NSCLC with ROS1-rearrangements performed even better 
with crizotinib, with a 72% response rate and median progression-free survival of 19.2 
months (Shaw et al., 2014).  
Another 2% of patients carry a B-Raf proto-oncogene (BRAF) mutations, which is 
treated with a combination of BRAF inhibitor dabrafenib and MEK inhibitor trametinib and 
has showed a response rate of 54% in a clinical trial of advanced-stage NSCLC (Planchard 
et al., 2016).  
Conversely, a negative indicator for response is a mutation in KRAS proto-
oncogene (KRAS). KRAS mutations occur in about 30% of Caucasians (with a higher 
incidence in smokers) and mainly cause the constitutive activation of the RAF-MEK-ERK 
pathway of proliferative signalling and the PI3K-AKT pathway of anti-apoptotic signalling 
(Suda et al., 2010). Unfortunately, NSCLC patients with KRAS mutations generally have very 
poor prognosis with standard-of-care (Slebos et al., 1990) and show no response to EGFR 
inhibitors (Pao et al., 2005). KRAS itself has proven itself undruggable so far and a clinical 
trial found no added benefit of targeting downstream MEK protein in combination with 
chemotherapy compared to standard chemotherapy (Jänne et al., 2016). 
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1.2.2 Case study: BRAF mutations 
While the aim of precision medicine is to tailor the therapy to the genetic 
background of cancers, an important factor to consider is also the tissue type of origin. A 
particularly potent example of that is the example of the tyrosine kinase BRAF, an 
oncogene of the RAS-RAF-MEK signalling pathway that is mutated in various different 
tissue types, including melanoma, colorectal cancers, and ovarian carcinomas, and the 
majority of mutations are a BRAF(V600E) mutation in the activation loop (Davies et al., 
2002). 
The observation of the wide-spread mutation of BRAF across several cancer types 
lead to the development of BRAF inhibitors and vemurafanib was the first one to be 
approved after it showed a 48% response rate in BRAF-mutated advanced-stage 
melanomas, compared with 5% with chemotherapy (Chapman et al., 2011). 
However, in colorectal cancers, where about 10% of patients showed a BRAF(V600E) 
mutation, the response rate was only 5% with median progression-free survival at only 3.7 
months (Kopetz et al., 2010). Two years later, an RNA interference screen revealed that the 
mechanism of BRAF inhibitor resistance in colorectal cancer was a rapid feedback 
activation of EGFR by phosphorylation, which activates other RAF family kinases (Prahallad 
et al., 2012). The authors further showed that melanomas had lower levels of EGFR, which 
is typically expressed in epithelial tissues, and explaining their relative sensitivity to BRAF 
inhibitors. A recently published clinical trial treated 91 advanced-stage metastatic patients 
with a triple-combination of EGFR, BRAF and MEK inhibitors (Corcoran et al., 2018). They 
reported promising response rates of 21% in a disease subtype which outcomes are usually 
poor despite chemotherapy treatment (Tran et al., 2011). 
Overall, this case demonstrates how the treatment of the same genetic subtype 
requires different considerations in different cancer types. While BRAF inhibitors work well 
in melanomas with BRAF(V600E) mutations, in colorectal cancer combinations with EGFR 
and MEK inhibitors are required to suppress primary resistance. At the same time, this case 
also illustrates that in instances where monotherapy does not show a desired effect, 
combinations may be used to target resistance mechanisms.  
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1.2.3 Challenges in precision cancer medicine 
Despite promising case studies that show that an understanding of cancer biology 
can lead to better treatment options for patients, the successful deployment of precision 
cancer medicine still faces many challenges.  
Firstly, the number of genetic biomarkers used in the clinic is still small. A large 
proportion of the patient population do not present with actionable mutations and will be 
treated with the standard of care.  
Secondly, as illustrated in the examples above, even in a carefully pre-selected 
patient population, a proportion of patients do not respond to the treatment. While the 
development of better drugs can lead to improved response rates compared to initial trials, 
they are still rarely even close to 100%.  
At the same time, only a few patients show a stable disease over a prolonged time 
period and many patients eventually develop resistance to targeted medicines. For 
instance, the mitogen-activated protein kinase (MAPK) pathway forms a central node in 
proliferative signalling which involves BRAF, MEK and ERK. This pathway is commonly 
targeted using inhibitors, however resistance often develops through a variety of genetic 
alterations that lead to increased reactivation of the pathway. These include KRAS and 
NRAS proto-oncogene (NRAS) activation by mutation or amplification, BRAF(V600E) 
amplification and other mutations that either lead to mutation in the drug-inhibitor 
binding sites, hyper-activation of key pathway components or by-passing the blocked 
signalling pathways (Ahronian et al., 2015).  
In the context of acquired resistance to targeted therapies, intra-tumoural 
heterogeneity also represents a challenge as resistant subclones may already be present 
in tumours at the time of treatment (Diaz Jr et al., 2012).  
In order to combat the issue of treatment resistance, it will be important to clarify 
the exact mechanisms of resistance. In particular, cheaper, more readily available and 
reliable next-generation sequencing technologies allows the detection of genome-wide 
alterations after treatment. Improvements of liquid biopsy technologies may facilitate the 
collection and analysis of cancer DNA and cells from the blood. As illustrated with the 
BRAF/MEK/EGFR triple combination, drug combinations may delay the emergence of 
resistance by targeting multiple components of signalling pathways at once.  
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Precision cancer medicine may also benefit from combining or stratifying patients 
for treatment with immunotherapy in addition to targeted therapy. In melanoma and other 
cancer with a high mutation burden, antibodies that target negatively regulating immune 
receptors such as PDL-1 and CTL-4 have shown great promise in recent years. For instance, 
ipilimumab, an anti-CTL-4 antibody achieved a sustained 3-year progression-free survival 
rate of 21% in advanced-stage melanomas (Schadendorf et al., 2015). Thus the ability to 
predict which patients would perform better with immunotherapy vs. targeted therapy, or 
which would benefit from combining both treatment types, could make a significant 
difference in future treatment outcomes. 
Ultimately, advances in the discovery of novel cellular processes, new biomarkers 
and drug targets will rely heavily on the availability of pre-clinical models which can model 
the disease and be used as proxies for anti-tumour compound testing. Later, I will 
introduce cell lines as experimental models of cancer in section 1.4. The next section will 
first describe gene fusions, their role in cancer precision medicine to date and open 




1.3 Gene fusions in precision cancer medicine  
In order to understand how we arrived at our current understanding of gene fusions 
in human cancers, it is useful to first understand the experimental conditions that provided 
the opportunities and limitations in gene fusion analyses since the 1960’s. Thus, I will first 
provide a short overview of the seminal experimental techniques that paved the way from 
the most basic cytogenetics to next-generation sequencing. Then, I will describe the 
experimental and computational processing of samples for fusion-calling from RNA-Seq 
to highlight currently available tools and their limitations.  
Finally, in this chapter I will provide context on the current state of knowledge of 
the types of fusions known to contribute to cancer progression and give an overview of 
recent efforts to provide landscapes of fusions across large cancer cohorts.  
1.3.1 Brief history of technological advances in gene fusion analysis 
In the 1960, only five years after Peter Harper discovered that the number of human 
chromosomes is 46, Peter Nowell and David Hungerford characterised a recurrent 
abnormally small chromosome in patients with chronic myeloid leukaemia (Nowell and 
Hungerford, 1960). This “minute” chromosome was soon dubbed the Philadelphia 
chromosome, named after the city in which it was discovered. It was the first time that a 
specific genetic alteration was found to be so strongly recurrent in patients of a given 
tumour subtype. Fast forwarding through the years with the development of new 
cytogenetic techniques, the Philadelphia chromosome was of course later identified as a 
translocation between chromosomes 9 and 22, which resulted in the fusion of breakpoint 
cluster region (BCR) to ABL proto-oncogene 1 (ABL1) (Groffen et al., 1984; Rowley, 1973).  
At a time when the community believed that viruses were one of the key causes of 
cancer, Nowell and Hungerford’s finding provided early evidence to support the 
hypothesis that a critical single genetic change could give rise to a tumour (Nowell, 2007).  
 
The analysis of chromosomal translocations and gene fusions in cancer evolved 
significantly throughout the years, from 1960 to today. In the 1960’s, Peter Nowell 
discovered by serendipity that rinsing cells with tap water made the chromosomes expand 
(Nowell and Hungerford, 1960). In the following two decades, chromosomal banding 
techniques enabled scientists to distinguish different chromosomal regions based on their 
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banding patterns. The study of these disrupted and rearranged banding patterns led to 
further discovery, such as t(8;14)(q24;q32), i.e. IGH-MYC, in Burkitt lymphoma (Zech et al., 
1976), or t(11;22)(q24;q12), i.e. EWSR1-FLI1 in Ewing’s sarcoma (Aurias et al., 1983). From 
the 1980’s onwards, developments in DNA cloning, capillary sequencing and fluorescence 
in situ hybridisation (FISH) provided further tools to study chromosomal translocation at 
ever higher resolution.  
The first step into the direction of high-throughput fusion analysis came with the 
invention of array-based genetic tools, in particular gene expression and copy number 
arrays. For instance, in 2005, Tomlins and colleagues used microarray gene expression data 
to identify the now widely studied transmembrane serine protease 2 (TMPRSS2) fusions in 
prostate cancers (Tomlins et al., 2005). They did this by first mathematically identifying 
gene expression outliers in individual samples in publicly available data. Among the top 
results were recurrent outliers in the ETS transcription factor ERG (ERG) and ETS variant 1 
(ETV1) genes, which are members of the ETS transcription factor family to which also Fli-1 
proto-oncogene (FLI1) (of the EWSR1-FLI1 fusion) belongs. Further sequencing in cell lines 
with the same expression patterns then revealed the mechanism of high expression to be 
a fusion of the 5’ untranslated region (UTR) to that of the androgen-regulated TMPRSS2 
gene. The discovery of the TMPRSS2-ERG was further significant, as it was the first fusion 
found in an epithelial-derived tumour, while previously oncogenic fusions were thought to 
be exclusive to blood cancers and sarcomas. 
Now, next generation sequencing has opened up a new frontier in high-throughput 
analyses of gene fusions. For the first time an unguided discovery of gene fusions at large-
scale and with nucleotide-level resolution was possible in a single experiment.  
First, whole genome sequencing (WGS) allowed researchers to look at structural 
rearrangements on a genomic level. In a seminal study, Campbell and colleagues used 
paired-end DNA sequencing data from two lung cancer cell lines (Campbell et al., 2008). 
For paired-end sequencing, sequencing adapters are fitted to both ends of a DNA 
fragment of a defined length (often ~200-400 bp). When paired nucleotide sequences 
consistently map to genomic regions that are further apart than the expected fragment 
length, there is strong evidence for structural rearrangements. Applied on a whole genome 
level, these types of computational analyses allowed researchers to create a map of 
structural rearrangements across the entire genome of a single sample.  
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In 2009, Maher and colleagues published the first paper that identifies gene fusions 
from whole transcriptome sequencing, i.e. RNA-Seq, from both single long reads  and 
paired-end reads (Maher et al., 2009a, 2009b). Unlike WGS, where there is no information 
on whether a structural rearrangement results in an expressed transcript or not, analysis 
using RNA-Seq data only detects expressed transcripts. At the same time, RNA-Seq data 
can report instances where gene splicing events leads to alternative transcripts. 
While the first studies focused on small panels of a handful of cell-lines at a time, 
since then the number of tumours that have been sequenced by RNA-Seq increased 
dramatically. A review written in 2015 by Mertens and colleagues highlighted that of the 
~10,000 gene fusions known in tumours that year, over 90% were discovered by deep-
sequencing approaches (Mertens et al., 2015). More recently, a paper published in March 
2018 found almost 24,000 distinct gene fusions in over 9,500 TCGA patient samples (Gao 
et al., 2018).  
In order to facilitate the interpretation of the huge amount of RNA-Seq data that 
has been generated so-far, numerous computational tools have been developed. A 
particular challenge is that RNA-Seq data interpretation is error-prone and thus new 
algorithms aiming to provide robust fusion-calling function are continuously being 
developed, with varying degrees of success. In the next section, I will review the difficulties 
of calling fusions in RNA-Seq data and some of the methods available to solve them.  
1.3.2 RNA-Seq data generation and analysis 
1.3.2.1 A note on terminology 
In order to establish a common vocabulary for the comparison of multiple RNA-
Seq processing algorithms, in my thesis, these terms should hereby be defined as following. 
Also see Figure 1.2 for an illustration of selected definitions.   
Transcript: a full length RNA strand that represents a uniquely expressed unit in 
the cell. 
Fragment: generated by breaking up transcripts, often into a few hundred base-
pair long strands. Fragments are physically captured in their entirety as part of the 
sequencing reaction.  
(Sequencing) read: a part of a fragment that is actually sequenced. Reads can be 
sequenced from both ends of a fragment (paired-end RNA-Seq), or from a single-end. The 
27 
 
length of the sequenced read depends on the machine and approach used for sequencing, 
but is typically 30-100 bp long.  
Alignment: computationally generated by comparing the read sequence to a 
reference genome to identify the genomic location from which a read is predicted to 
originate. Due to sequence homology in the genome, a single read can have multiple 
alignments that fit perfectly or with a low number of base mismatches.  
Fragment insert: For paired-end sequencing, the sequence between the read pairs 
that is not sequenced on the sequencing platform. Where read pairs map on a genomic 
location that is approximately the size of the fragment length this sequence is inferred.  
Spanning reads: a pair of reads that map onto genomic regions that are further 
apart than the expected fragment length. This suggests that a fusion has occurred, and 
that the breakpoint is inferred to be within the fragment insert sequence.  
Splitting reads: a pair of reads, for which one read maps onto a standard genomic 
region. The other read maps directly across the fusion breakpoint, thus revealing the exact 
breakpoint sequence. 
Cluster (of reads): multiple splitting and spanning reads that are predicted to be 
derived from the same fusion transcript and are thus grouped together. 
 
 
Figure 1.2: (A) Basic concept of paired-end sequencing. (B) Spanning reads and splitting reads are defined by 
whether or not the fusion breakpoint is captured in the read sequence. 
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1.3.2.2 Brief overview of RNA-Seq data generation from samples 
In order to collect the RNA used for sequencing, cell are first grown for several days 
in order to achieve adequate cell volume. To extract the RNA, centrifugation generates a 
concentrated cell pellets which are then lysed and homogenised to release the cell 
contents. Proteins are separated from nucleic acids by treating the lysate using a standard 
phenol:chloroform technique (Sambrook and Russell, 2006). Then, typically using 
commercially available kits, the nucleic acid mixture is passed through a spin column that 
contains a membrane that selectively binds and retains RNA while DNA is washed out. 
DNA can be further removed using DNAse enzymes that selectively digest DNA inside the 
spin columns. To further increase purity of RNA mixture and to remove any other potential 
forms of contaminants, an extra step of RNA-clean-up is provided by kits such as 
Agencourt’s RNAClean XP kit, which uses magnetic beads that bind to RNA molecules and 
removes excess nucleotides, salts and enzymes from the solution. Next, RNA is converted 
to cDNA prior to sequencing, amplified and fragmented into fragments of several hundred 
base pairs. Finally, in order for the fragment to be recognised by the sequencing platform, 
adapters are fitted on both ends of each fragment and the fragment is then processed for 
next-generation sequencing (typically sequencing-by-synthesis).  
Sequencing identifies the nature and order of nucleotides on the captured 
fragments. Due to a higher likelihood of sequencing errors at greater distances from the 
sequencing adaptors, reads are typically 30-100 bp long. In order to identify the location 
of the genome from which a read originates, computational tools called “aligners” compare 
the read sequence to a reference genome and output “alignments” that indicate the most 
likely area from which a read originates (see definitions in section 1.3.2.1). 
The computational methodology and tools that predict the presence of fusions 
from RNA-Seq alignments will be discussed in the next section.  
1.3.2.3 Computational fusion-calling tools 
Since the invention of RNA-Seq in 2008, over 20 different computational algorithms 
for fusion-calling have been produced (Carrara et al., 2013; Haas et al., 2017; Kumar et al., 
2016). The methodology of fusion-calling can be distilled into a simple principle: to identify 
sequenced reads (whether single or paired) which partially map onto two different regions 
of the genome. In general, computational fusion-calling tools all follow three basic steps: 
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1) Chimeric transcript identification: this is done by finding reads that map onto 
two distinct regions in the genome. Some algorithms (e.g. deFuse and Maher 
et al’s method) do this by mapping all RNA-Seq normally and then finding 
spanning reads, i.e. paired-end reads that map onto two different regions. 
Other algorithms (e.g. TopHat-Fusion and STAR-Fusion) first identify splitting-
reads, i.e. reads that contain a potential fusion-breakpoint and thus do not map 
perfectly onto any genomic region, which they then split into several smaller 
segments which can then be aligned to unique regions. While conceptually 
both approaches are logical ways of identifying the same fusion transcripts, in 
practice they use different read pools to flag potentially chimeric reads, and 
may thus lead to different final results.  
Additionally, fusion algorithms use different methods of resolving 
ambiguous alignments. For instance, while Maher’s script and STAR-Fusion use 
only the best-matching alignment for each read, TopHat-Fusion removes any read 
with more than two alignments, and deFuse uses a “maximum parsimony” solution 
which considers all alignments and chooses the one matching the most likely fusion 
transcript. Again, these differences in read processing can lead to different final 
results.  
2) Grouping of reads to resolve final fusion breakpoint: In order to retrieve the 
full sequence around the putative fusion breakpoint, reads are grouped, 
typically based on genomic mapping location either before or after 
identification of the chimeric reads. Here, some algorithms (e.g. deFuse) take 
advantage of the paired-end system, by searching for reads that map the 
predicted fragment length away from the putative fusion boundary region – 
the paired read is likely to reveal the exact fusion boundary. 
3) Further filters to exclude likely false positives: This step is perhaps one of 
the most differentiating points between algorithms. Filtering the initial results 
can reduce the number of candidate fusion events by almost 99% (Kim and 
Salzberg, 2011; McPherson et al., 2011). Many algorithms devise extensive 
filters, but some considerations are commonly observed among most 
algorithms, e.g.: i) the minimum number of reads that provide evidence for the 
breakpoint, ii) homology in nearby regions that may cause mapping errors, iii) 
30 
 
differential alignment coverage and gaps in the genomic area immediately 
surrounding the putative breakpoint.  
Notably, while on the perfect data-set, fusion-calling algorithms should yield 
similar results, in practice the output is often vastly different. For instance, different 
algorithms can yield from 10 to over 5,000 fusion calls on the exact same sets of RNA-Seq 
data (Carrara et al., 2013). Applied by different groups on different samples, the same 
algorithm can also output anything ranging from a handful to several 100,000. (For a more 
extensive comparison and benchmarking of fusion-calling algorithms, see Chapter 2). 
Aside from intrinsic differences in the methodology, these differences likely also reflect 
that small changes in the algorithm parameters can have large effects on the effectiveness 
of the filters.  
1.3.2.4 Challenges and limitations 
Since fusion-calling by definition is the unguided detection of non-standard 
fragments, standard methods that recognise and remove abnormal nucleotide sequences 
in WGS are not useful in RNA-Seq. Possible artefacts can arise from all steps from sample 
preparation to the alignment.  
For instance, during sequencing-by-synthesis, usually a single fluorescent 
nucleotide is integrated per each sequencing cycle. If either none or multiple bases 
integrate in one cycle, this can lead to so-called “phasing”-errors. Similarly, an effect called 
“cross-talk” can arise when fluorescent emission spectra are insufficiently resolved by the 
sequencing machine (Ledergerber and Dessimoz, 2011). In the short-reads that are 
generated from NGS, small mismatches can thus lead to misalignments in later steps.  
 
Another source of error comes from the fact that in order to be sequenced on NGS 
platforms, RNA is first converted to complementary DNA (cDNA) using reverse 
transcriptase enzymes. Previous analyses have shown that the enzymes are relatively error-
prone, for example adding artefactual single-base substitutions and occasional frameshifts 
(Roberts et al., 1989). Spontaneous template switching of the reverse transcriptases can 
lead to chimeric transcripts (Cocquet et al., 2006) introduced after sample collection that 
could be misinterpreted as real gene fusions. Furthermore, contamination of either DNA 
or other organisms can add artefacts as algorithms permissively align multiple regions.  
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While higher sequencing depth should add more support to real gene fusions, the 
larger number of RNA particles may also increase the number of false positives. 
Unfortunately many of the fusion-calling algorithms have been developed with and 
benchmarked against test data-sets with similar ranges of read number (around 20-30 M 
reads per sample), and to the best of my knowledge no formal analysis has been performed 
to show the influence of increased read depth on the number of fusions detected.  
 
In summary, issues with error-prone RNA-Seq sample processing and sequencing 
differences in fusion-calling algorithm design can lead to vastly different outputs for the 
same tested sample. Further, there is a lack of clear, empirically-determined guidelines for 
parameter and tool choice for RNA-Seq data-sets of different read depths and fragment 
sizes, which is exemplified and perhaps aggravated by the observation that algorithms can 
show different accuracies whether benchmarking is performed on simulated or real RNA-
Seq data (Haas et al., 2017). 
A trend is recently emerging, where instead of using a single algorithm on its 
default setting, researchers now use multiple fusion-calling algorithms for the same study 
and tailor filtering criteria based on their own data. Indeed, in our study we use three 
different algorithms, the processing steps for which I will describe in chapter 2. In our data, 
we do find that fusions that are picked up by multiple fusion-calling algorithms had very 
high validation rates by polymerase chain reaction (PCR) and most known oncogenic 
fusions that we find in our data sets are supported by multiple algorithms. However, when 
using only the overlap of multiple different algorithms, one runs the risk of discarding real 
putative fusions that perhaps due to low expression are only picked up by single algorithms.  
Overall, fusion-calling from RNA-Seq data still represents a highly promising and 
perhaps the only way to call fusions in a high-throughput setting with nucleotide-level 
resolution. Improvements in technology, e.g. direct sequencing of RNA without the 
conversion into cDNA and longer read lengths, will likely allow improved sensitivity and 
specificity for computational algorithms. Until then, one should be careful not to over-
interpret fusions called from RNA-Seq data and validate promising candidates using 




1.3.3 The structural and functional context of gene fusions 
This section is dedicated to understanding how gene fusions can occur and how 
they are able to modulate gene function in driving oncogenic processes.  
1.3.3.1 Structural and non-structural changes can lead to the formation of gene fusions 
The best-understood examples of oncogenic fusions arise from structural 
rearrangements in the genome, and often from balanced rearrangements. These changes 
refer to rearrangements such as translocations, insertions and inversions, in which a 
genomic region is transferred to another location in the genome. Unlike in unbalanced 
rearrangements such as deletions, duplications and aneuploidies, in balanced 
rearrangements the overall copy number does not change.  
While specific initiation factors for gene fusions are largely unknown, previous 
research has indicated that DNA double-strand breaks (DSB) are required for gene fusions 
(Aplan, 2006). Inherited syndromes that are associated with genetic instability and the 
inability to efficiently repair DSBs can lead to a predisposition of chromosomal 
translocations and hematologic cancers, e.g. in Nijmegen’s breakage syndrome patients 
that show nibrin (NBN) mutations. NBN is normally involved in non-homologous end-
joining (NHEJ), one of the main mechanisms of DSB repair (Digweed and Sperling, 2004). 
Similarly, knocking out other NHEJ-related genes in mice induced high rates of 
chromosomal translocations and cancer development (Aplan, 2006). Chemotherapy agents 
that inhibit DNA topoisomerase II can also cause increased occurrences of therapy-related 
chromosomal translocations. DNA topoisomerase II normally play a role in untangling DNA 
loops and supercoils by creating and later re-ligating DSBs. In vitro treatment of cells with 
the chemotherapy agent etoposide has shown that stabilisation of the cleaved complex 
created by DNA topoisomerase II could lead to chromosomal translocations between 
different stalled cleaved complexes (Zhou et al., 1997). 
Furthermore, DNA-region specific factors are also believed to play a role in causing 
recurrent chromosomal translocations. These include proximity of different genomic 
regions in the nucleosome during interphase. But also sequence-specific features can play 
a role – for example alternating purine and pyrimidine tracts create a special helical 
structure that tends to be found in inter-nucleosomal regions and may thus be especially 
prone to DSBs (Garner and Felsenfeld, 1987; Thandla et al., 1999). Similarly, the lysine 
methyltransferase 2A (KMT2A) and super elongation complex subunit (MLLT3) loci that are 
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commonly fused in leukaemias and lymphomas were found to be nuclear scaffold-
associated regions that are thought to be attachment sites for chromosomal loops, and 
thus especially sensitive to DSBs in the context of topoisomerase II malfunction (Stanulla 
et al., 2001). 
In terms of unbalanced structural rearrangements, fusion transcripts may 
commonly result from deletions and amplifications. Deletions of regions within tumour 
suppressors can lead to the expression of aberrant transcripts that are most likely to have 
lost the original function (e.g. in our panel, we find several fusions that involve the 
phosphatase and tensin homologue (PTEN) tumour suppressor). Amplifications are 
similarly one of the common mechanisms by which oncogenes are overexpressed; well-
known examples include erb-b2 receptor tyrosine kinase 2 (ERBB2), EGFR, MYC proto-
oncogene (MYC) and fibroblast growth factor receptor (FGFR). The repeated breaking and 
re-joining of DNA that pre-date amplifications is likely to facilitate the formation of fusion 
transcripts. Indeed a survey of 14 breast cancer cell lines showed that a large proportion 
of detected gene fusions map to amplicons, although it is possible that the majority of 
these types of events are passenger events without cancer-related functionality (Kalyana-
Sundaram et al., 2012).  
 
Other than structural changes that hard-code gene fusions into the genome, 
fusions have also been detected that have no detectable underlying structural 
rearrangements. So-called transcription-induced gene fusions (TIGF) can occur through 
either cis-splicing or trans-splicing events. Cis-splicing, also known as gene read-throughs, 
occurs when neighbouring genes are transcribed and then spliced together to produce a 
chimeric transcript. An example of a cis-spliced TIGF is a fusion transcript found in prostate 
cancer samples between solute carrier family 45 member 3 (SLC45A3) and ETS transcription 
factor (ELK4), which is another member of the ETS family of transcription factors that ERG 
belongs to (e.g. in TMPRSS2-ERG and EWSR1-ERG) (Rickman et al., 2009). The two genes 
are located approximately 50 kb apart from each other and the fusion transcript was not 
accompanied any detectable structural rearrangements. Further research showed that 
SLC45A3 and chimera expression similar to the TMPRSS2-ERG fusion is androgen-
regulated, that SLC45A3-ELK4 expression correlated with more advanced stages of 
prostate cancer and that siRNA knock-down of SLC45A3-ELK4 significantly reduced cell 
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line growth (Zhang et al., 2012). In 2011, a paper that surveyed TIGF events using deep 
sequencing techniques showed that TIGF’s are common events in both tumour and normal 
samples and that they are associated with high expression of the 5’ fused gene partner 
(Nacu et al., 2011).  
In contrast to cis-splicing events between neighbouring genes, trans-splicing 
events can occur between genes that are further apart and even on separate chromosomes. 
These result when mRNA are expressed separately for two genes and subsequently spliced 
together before translated into a chimeric protein (Finta and Zaphiropoulos, 2002). One 
example in cancer is the fusion transcript of exons 1-3 of JAZF zinc finger 1 (JAZF1) and 
exons 2-16 of polycomb repressive complex 2 subunit (SUZ12), which are found on 
chromosomes 7 and 17 respectively (Li et al., 2008). JAZF1-SUZ12 had previously been 
found in endometrial stromal sarcomas that presented a chromosomal translocation, and 
expression of the transcript in HEK cells had shown suppression of hypoxia-induced 
apoptosis (Li et al., 2007). Intriguingly, an expressed JAZF1-SUZ12 transcript was also found 
in non-neoplastic endometrial cell lines, however extensive analysis of the cellular DNA, 
FISH and karyotyping showed no evidence underlying translocation or rearrangements (Li 
et al., 2008). It is important to note that an independent study was unable to verify the 
presence of a JAZF1-SUZ12 transcript in the endometrial cell line, which suggests that if 
true, these events may be transiently expressed only in specific circumstances 
(Panagopoulos, 2010). 
While the presence of TIGFs is well validated, overall there are only few replicated 
examples of transcription-induced gene fusions with a cancer-related role. Nonetheless, 
they are likely to make up a significant proportion of fusion transcripts detected from RNA-
Seq data and their potentially transient nature may explain discrepancies between fusions 




1.3.3.2 Gene fusions in deregulating normal protein function 
Known oncogenic gene fusion events perform their function using two main 
mechanisms: they either create a translated chimeric protein, or deregulate mRNA 
expression through the fusion of regulatory untranslated regions (UTR’s) (Figure 1.3).  
Chimeric proteins make up the most common and best understood examples. 
Most commonly, one of the gene partners has normal activity as a kinase or transcriptional 
co-activators, and the fusion either removes a self-inhibitory domain and/or adds a domain 
that facilitates activation of the catalytic domains. Next, I describe two examples to 
illustrate some of the mechanisms of oncogenic activity. 
In the case of the BCR-ABL1 fusion, ABL1 contains three retained SRC homology 
(SH) domains that facilitate protein-protein interaction and tyrosine kinase activity (Figure 
1.4). Also retained in the chimeric protein is a nuclear localisation domain and actin binding 
domain. Conversely, the fusion eliminates an N-terminal inhibitory cap and a 
myristoylation site, both of which stabilise an inactive conformation of ABL1 (Colicelli, 
2010). On the other hand, the N-terminal fused portion of BCR contains a coiled-coil 
domain, which allows the formation and kinase activity of BCR-ABL1 homotetramers 
(McWhirter et al., 1993). Aside from BCR, ABL1 is also found to be fused to multiple other 
 
Figure 1.4: Known breakpoints of selected ABL1 fusions. BD = binding domain. C = coiled-coil domain. 
Adapted from De Braekeleer et al. (2011) 
 
Figure 1.3: Two main types of oncogenic gene fusion. 
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proteins in rarer subtypes. Many of the other fusion partners, for instance nucleoporin 214 
(NUP214), echinoderm microtubule associated protein like 1 (EML1) and RCSD domain 
containing 1 (RCSD1), also carry similar coiled-coil domains or helix-loop-helix domains 
that allow oligodimerisation (Braekeleer et al., 2011). Similarly to this mechanism, the 
oncogenic activity of ALK fusions (e.g. NPM1-ALK, EML4-ALK) results from constitutive 
activation of the ALK tyrosine kinase domain by fused partner genes which encourage 
dimerisation (Mossé et al., 2009). 
An example where the fusion involves a transcriptional co-activator is the fusion 
between CREB regulated transcription coactivator 1 (CRTC1) and mastermind like 
transcriptional coactivator 2 (MAML2), which is found in about 50% of mucoepidermoid 
head and neck carcinomas, with transforming activity in cell lines (Chen et al., 2014). 
MAML2 normally acts as a transcriptional co-activator with NOTCH receptors, with an N-
terminal domain that enables it to bind to Notch receptors and a C-terminal transcriptional 
activation domain which facilitates transcription of down-stream Notch pathway genes 
(Wu et al., 2002). Conversely, CRTC1 is a co-activator of the CREB pathway which plays 
multiple roles in cell proliferation, differentiation and apoptosis (Sakamoto and Frank, 
2009). In this chimeric protein, the N-terminal CREB-binding domain of CRTC1 and the C-
terminal transcriptional activation domain of MAML2 are brought together and lead to 
transforming activity by constitutive CREB pathway activation (Wu et al., 2005). 
 
Another type of oncogenic transformation is enabled by transcriptional 
deregulation, which can occur at various regulatory regions. For instance, the fusion of 
TMPRSS2 to ETS family transcription factors in prostate cancer occurs at the 5’ untranslated 
region (UTR) (Tomlins et al., 2005). Expression levels of TMPRSS2 are regulated by androgen, 
and thus in prostate tissue with high androgen levels this type of “promoter switching” 
leads to overexpression of the ETS genes. Consequently, this has downstream effects on 
differentiation, and cellular invasion (Tomlins et al., 2008).  
In Burkitt lymphomas and many other B-cell related cancers, a translocation 
between MYC and various immunoglobulin loci (IGH/IGK/IGL) is common. This puts MYC 
under the regulatory control of immunoglobulin enhancers and leads to stark 
overexpression of the MYC transcript (Dalla-Favera et al., 1983). Similar scenarios are found 
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in T-cell related cancers, where oncogenes are commonly fused to regulatory elements of 
T-cell receptor genes (Vlierberghe and Ferrando, 2012).  
A haematological oncogene, TAL bHLH transcription factor 1 (TAL1), can be fused 
at both the 5’ and 3’ UTRs. Indeed, the first discovered case of a TAL1 fusion in patients 
was a translocation that lead to a fusion at the 3’ UTR of TAL1 with regulatory elements of 
the TCR locus in a T-cell leukaemia (Begley and Green, 1999). A second mechanism of TAL1 
activation is through a 90 kb deletion that fuses the coding regions of TAL1 to the 5’ 
regulatory regions of the ubiquitously expressed STIL gene (Brown et al., 1990). 
Notably, structural rearrangements that lead to transcriptional deregulation of 
oncogenic genes do not necessarily lead to chimeric transcripts. Chimeric transcripts can 
be detected for fusions that involve transcribed untranslated regions such as TMPRSS2-
ERG, however immunoglobulin and TCR translocations are often only detectable on a 
structural level, since only the surrounding regulatory regions and not transcribed regions 
are fused.  
 
Finally, structural rearrangements may perform cancer-driving function by silencing 
tumour suppressors effectively by gene truncation. For example, individual cases have 
been reported whereby a translocation caused the complete inactivation and loss of 
expression of tumour suppressors cyclin dependent kinase inhibitor 2A (CDKN2A) in a B-
cell leukaemia (Duro et al., 1996) and a biallelic inactivation of NF1 in sporadic 
neurofibromas (Storlazzi et al., 2005). Similarly, a survey of 180 TCGA acute myeloid 
leukaemia samples found several truncating fusions across various samples, including 
some of the tumour suppressor runt related transcription factor 1 (RUNX1) (Cancer 
Genome Atlas Research Network et al., 2013). 
 
In summary, in the above section I described the structural and non-structural 
mechanisms by which functional fusions transcripts can be formed in cancer cells. Further, 
functional fusions generally exert their functionality either by producing an aberrant and 
typically constitutively activated chimeric protein, or by transcriptional deregulation that 




1.3.4 Gene fusions in cancer 
Throughout the previous sections, I have already given various examples of gene 
fusions that throughout the last three decades have been found to play a role in cancer. In 
this section, I would like to take a more detailed look at currently relevant developments 
of gene fusion research, in particular 1) current approaches and efforts on using RNA-Seq 
data to identify cancer-relevant gene fusions and 2) the role of gene fusions in precision 
cancer medicine.  
1.3.4.1 New learnings from large-scale RNA-Seq fusion landscaping studies 
As outlines in section 1.3.2, fusion-calling from RNA-Seq data is a relatively new 
field, with the first algorithms being developed and refined only about 10 years ago. Since 
then, this technology has enabled researchers to look for gene fusions in an unbiased 
manner without pre-requisite knowledge and in ever larger number of samples.  
Many of the early analyses were conducted in a tissue-specific manner and perhaps 
one of the first important learnings was that expressed fusion transcripts were common 
without necessary playing an obvious role in carcinogenesis. For instance, in 2010 Berger 
and colleagues gave the first account of gene fusions in melanoma, with a small panel of 
8 patient samples and 2 cell lines (Berger et al., 2010). The authors found 11 fusion 
transcripts which all validated by RT-PCR of which none had strong evidence for oncogenic 
functionality.  
Focussing on known cancer driver genes did help to identify previously unknown 
oncogenic fusions. In 2010, Palanisamy and colleagues analysed paired-end RNA-Seq data 
of prostate cancers without the classic ETS gene fusions (Palanisamy et al., 2010). The 
authors found rearrangements that involved BRAF and Raf-1 proto-oncogene (RAF1), 
which deleted the proteins’ auto-inhibitory domain, and were able to induce tumour 
formation in mice and were also sensitive to RAF inhibitors. Targeted sequencing of larger 
tumour panels confirmed that BRAF and RAF1 fusions could be found in about 1-2% of 
prostate carcinomas (Palanisamy et al., 2010). Similarly, RNA-Seq analyses were also able 
to identify FGFR3-TACC3 fusions as a rare subtype that occur in about 3% of glioblastomas 
(Singh et al., 2012). 
Later on, RNA-Seq panels were further expanded to include several hundred, and 
then even thousands of samples within a single study. In 2014 Stransky and colleagues 
published a paper that focussed on recurrent kinase fusions in over 6,800 TCGA patient 
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samples (Stransky et al., 2014). This resulted in the discovery of novel fusions involving 
known fused oncogenes (e.g. BRAF and MET proto-oncogene (MET)) and also novel fusions 
with kinase genes which were previously not implicated in cancer. In 2015, Yoshihara and 
colleagues sequenced 4,366 patient samples in 13 tumour types and found over 7,800 
fusion events (Yoshihara et al., 2015). While largely descriptive, the authors noted that only 
few fusions are recurrent (n = 263) and the relatively enrichment of kinase fusions in thyroid 
cancer and an enrichment of chromatin modifier fusions in acute myeloid leukaemias.  
The fast rate of fusion gene discovery that came with next-generation sequencing 
technologies has also led to the establishment of databases to record cancer-associated 
fusion transcripts. The currently largest data base is likely ChimerDB, which was created in 
2006 and regularly updated since then. At the time of the latest publication in January 2017, 
ChimerDB listed over 33,000 fusions, of which 1,066 were mined from other databases, 
2,760 retrieved through text mining from PubMed and over 30,000 from TCGA RNA-Seq 
data from ~4,500 patients detected by combining the results of 2 different fusion-calling 
algorithms (Lee et al., 2017). It is important to point out that similar to most other large-
scale efforts of annotating gene fusions, the fusions listed in ChimerDB should also be 
approached with a degree of caution, as the authors themselves acknowledge that the 
false positive rate of the fusions called from RNA-Seq data may be around half of those 
predicted.  
Recently, in March 2018, Gao and colleagues published the analysis that 
encompasses the so-far largest number of samples with ~9,600 TCGA patient tumours in 
33 cancer types (Gao et al., 2018). Notably, they are also one of the first large-scale papers 
to analyse their data using three different fusion-calling algorithms. The authors also 
integrated gene expression data and showed that oncogene and kinase fusions tended to 
be overexpressed, while tumour suppressor fusions tend to be underexpressed. 
Notably, with ever easier method that facilitate fusion detection, it has become 
clear that fusion transcripts themselves are common and may result as passenger events 
of structural rearrangements. With larger studies and tens of thousands fusions detected, 
the functional assessment of fusions becomes more difficult. Many of the above cited 
papers are mainly descriptive, but often it remains unresolved whether fusions involving 
known cancer-related genes have occurred by chance or are indeed functional. A paper in 
2017 by Lu and colleages describes a protocol with which they engineered 20 novel fusion 
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genes into in vitro cell models to functionally characterise them (Lu et al., 2017). However, 
engineering fusion genes into cells to observe their impact on growth, transformative 
ability and sensitivity to drug inhibition is a time-intensive process, which is unrealistic to 
conduct on the tens of thousands fusions observed in each large-scale study.  
As existing studies tend to focus on fusions involving known cancer-related genes, 
true oncogenic fusions may have remained hidden needles in the haystack. This thus 
reveals a need for a method to study the functionality of gene fusions in cancer in an 
unbiased manner on a large-scale, which is one of the main aims of my PhD thesis.  
1.3.4.2 Clinical relevance of gene fusions 
The functional assessment of gene fusions is critical for the understanding of cancer 
biology as well as clinical opportunities. Already, gene fusions have played a major role in 
the development of precision medicine (Table 1-1).  
As mentioned before, the treatment of BCR-ABL1 fused cancers with Imatinib has 
become one of the best-cited success stories for treatment based on genetic biomarkers 
as patient survival chances improved vastly with the new therapy. At the same time, the 
treatment of ALK-fused non-small cell lung cancers with ALK inhibitor crizotinib was FDA-
approved after a phase 3 trial showed a 65% response rate (vs. 20% with chemotherapy), 
an increase in median progression-free survival from 7.7 months vs. 3.0 months and better 
quality of life (Shaw et al., 2013).  
Kinase-fused tumours often show signs of “oncogene addiction”, i.e. they require 
the continuous activity of the kinase for cellular survival. Thus, many other fusion genes 
make appealing targets for inhibition with compounds that are either existing or currently 
in development. For example, many ALK inhibitors are also potent inhibitors of ROS1, a 
closely related tyrosine kinase (Shaw et al., 2013). ROS1-rearranged cancers have shown 
promising initial response rates to crizotinib in an on-going Phase I clinical trial (Ou et al., 
2013). In early 2018, the treatment of ROS1-positive advanced-stage non-small cell lung 
cancer has been recommended as per the official guidelines of NICE, the National Institute 
for Health and Care Excellence which submits guidance to the UK National Health Service 
(NICE, 2018). Similarly, BRAF and RAF1 fusions have been shown to respond well to 
inhibition by RAF inhibitors, of which there are several already approved by the FDA for 
treatment of BRAF-mutated melanoma (Palanisamy et al., 2010). Other promising targets 
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that are currently under clinical investigation include neurotrophic receptor tyrosine kinase 
(NTRK), ret proto-oncogene (RET), and FGFR fusions (Shaw et al., 2013). 
Other than as pharmacological targets, fusion genes may also aid in the diagnosis 
and prognosis of cancers. For instance, the KMT2A-rearranged acute myeloid leukaemias 
with different fusion partners had vastly different progression-free survival curves ranging 
from very favourable 92% at 5-years for some subtypes to 16% for others (Balgobind et al., 
2009). At the same type, advances in liquid biopsies mean that it may soon become 
possible to diagnose patients and monitor disease progression from circulating tumour 
DNA and cells in the blood (Crowley et al., 2013; Krebs et al., 2014). Due to their non-
invasive nature, these methods would be well-suited to be used at regular time-points to 
test for disease recurrence and the emergence of resistance tumour subclones. Already, 
research has shown that ALK-fusions in non-small cell lung cancer could be successfully 
identified in patient populations using circulating tumour cell technology (Pailler et al., 
2013). 
Overall, improvements in the clinical care of cancer patients, be it in the diagnosis, 
prognosis, monitoring or treatment, relies on the continuous discovery and improved 
understanding of cancer genetics. Therefore, being able to separate true cancer-related 
functional gene fusions from non-functional fusion transcript may reveal currently 
unknown opportunities in this area.  
Table 1-1: Summary table of selected clinically relevant fusions. CML = chronic myelogenous leukaemia. 
NSCLC = non-small cell lung cancer. 
Fusion Predominant cancer types Clinical characteristics 
BCR-ABL1 CML Treated with imatinib and other ABL1-
targeting drugs 
EML4-ALK NSCLC Treated with crizotinib and other ALK-
targeting drugs 
KMT2A fusions Haematological malignancies Favourable/unfavourable prognosis 
depending on fusion partner 
NPM1-ALK Anaplastic large cell lymphoma In clinical trials for ALK-targeting drugs 
ROS1 fusions NSCLC In clinical trials for ALK/ROS1-
targeting drugs 
RAF1/BRAF fusions Various solid carcinomas In clinical trials for RAF inhibitors.  
NTRK fusions Various solid carcinomas and sarcomas In clinical trials for larotrectinib (TRK 
inhibitor) 
RET fusions Papillary thyroid cancer, NSCLC In clinical trials for cabozantinib (RET 
inhibitor) 
FGFR1/2/3 fusions Various solid carcinomas In clinical trials for various FGFR 




1.4 Cell lines as experimental models of cancer 
1.4.1 Overview of different types of cancer cell models 
Cancer research relies heavily on experimental models, as the ability to study 
cancers in patients is limited to biopsies and treatment outcome statistics. In general, 
cancer models are divided between in vivo, i.e. animal models, and in vitro, i.e. cells 
cultivated in plastic dishes.  
In vivo models are most often mice. Tumours can generally either be induced, e.g. 
with the use of carcinogens, irradiation or genetic manipulation, or are transplanted, which 
involves the injection of tumour-derived tissue or cell lines into the animal. Mouse models 
are widely regarded to most accurately represent the human disease in the lab, since they 
provide a complex microenvironment and extra-cellular matrix interactions. An exception 
is the lack of immune capabilities in immunosuppressed mice. Genetically engineered 
mouse models are also a powerful method of modelling the consequences of genetic 
modifications on a whole living system. However, in vivo models are time consuming, 
expensive, technically challenging to maintain and there are ethical issues around using 
live animals. This means that in vivo experiments are mainly recommended for relatively 
advanced stage of research or where there are no other viable alternatives.  
Conversely, in vitro models, in particular cancer cell lines, are widely accessible and 
have fewer ethical implications1. Immortalised cancer cell lines give an essentially unlimited 
supply of cells with a highly similar genotype and phenotype.  
There are some concerns that genomic instability, culture conditions and 
contamination of cell lines can limit how representative cancer cell lines are of the original 
disease. However, most of these issues can be avoided with proper quality control. For 
example, regular mycoplasma testing and DNA barcoding of cell lines prevent 
contamination and mix-ups. Keeping the cells in passage for no longer than 3 months also 
minimises genetic drift.  
Human cancer cell lines transplanted into immunodeficient mice have the ability to 
generate tumours, and the histopathology has been shown to faithfully correlate with that 
of the tumour of origin (Fogh et al., 1977). Gene expression patterns of cell lines also cluster 
                                                 
1 Note: in this thesis, by “cancer cell lines” I always refer to human cancer cell lines, as 
opposed to cell lines derived from other model animals. 
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according to their tissue of origin, which indicates that culture conditions are not sufficient 
to overwrite the tissue-specific gene expression program (Ross et al., 2000). The genotypes 
of cancer cell line panels are also largely representative of those of the original cancer type. 
The alteration frequencies of the most common gene alterations in tumours correlates 
significantly with that of cell lines. Similarly, there is a high concordance in terms of the 
classification by alteration subclass, i.e. whether alterations in the tumour type of origin are 
predominantly mutations, copy number alterations, or hypermethylated regions (Iorio et 
al., 2016). Altogether, the evidence suggests that with proper quality control, cancer cell 
lines are a useful and representative tool to study cancer tissues and specific cancer-related 
genetic alterations.  
There are certain caveats to using cancer cell lines. For one, immortal cancer cell 
lines are difficult to derive and advanced-stage cancers have higher success rates of 
immortalisation (Masters, 2000). This means that early-stage cancers are likely to be 
underrepresented in cancer cell line panels. Due to a lack of a complex microenvironment, 
cancer cell lines also only represent a simplified view of cancer biology.  
Better models of cell-cell interaction and microenvironments may be cell line 
cultures grown in 3D. They better reproduce the differential exposure to oxygen, nutrients 
and growth factor within tumour masses, which can influence proliferation rate, gene 
expression and drug uptake (Lin and Chang, 2008).  
Even more recently, we have seen the development of cancer organoids, which are 
derived from tumour cells that expand into a 3D structure that closely resembles the tissue 
architecture, cell type composition and self-renewal dynamics (Sato et al., 2009). They have 
been found to recapitulate the genetic background of tissue donors and to be amenable 
to high-throughput drug screening, which opens up future possibilities of ever-closer 
personalisation of cancer treatments (van de Wetering et al., 2015). 
While the use of 3D in vitro cultures as experimental models of cancer is likely to 
become increasingly important in future pre-clinical studies, for now standard protocols 
for the derivation, maintenance, genetic manipulation and high-throughput screening are 
still being written. Thus, 2D cancer cell lines are still favoured by many as pliable models 
for novel techniques and discoveries, such as high-throughput drug screening, 
CRISPR/Cas9 whole genome drop-out screening and more. 
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In the next section, I will provide a brief overview of human cancer cell line panels 
that have featured prominently in modern cancer research, their origin and large-scale 
data sources that are available and being generated today. 
1.4.2 NCI60: The first drug screening panel 
The first large cancer cell line panel was established in the 1980’s by the National 
Cancer Institute in the USA, in the form of the NCI60. It consisted of 60 cancer cell lines of 
9 distinct tissue types that were characterised by karyotype banding to exclude cell lines 
that were derivatives of HeLa or one another (Shoemaker, 2006). The purpose of this panel 
was to act as the first in vitro screening platform for cancer compounds. Before that, anti-
cancer compounds were typically screened against leukaemia mouse xenografts, which 
were unreliable at predicting growth response in solid tumours (Weinstein et al., 1997). 
The NCI60 on the other hand were faster to screen and could act as the first stage of a 
drug discovery pipeline to identify the activity of potential anti-cancer compounds. From 
its establishment in the 1980’s to 2000, more than 300,000 compounds were screened 
across this panel (Shoemaker, 2006). The NCI60 panel has since been deployed to identify 
the mechanism of action of potent unknown natural compounds and discovery of novel 
anti-cancer compounds. For instance, bortezomib is now a FDA-approved chemotherapy 
compound and the first proteasome-inhibitor to be used in humans (Adams et al., 1999). 
Later, molecular characterisation of the cell lines was integrated, which enabled further 
important biological discoveries, for example that overexpression of ABC family membrane 
transporter could confer resistance to specific compounds (Szakács et al., 2004). The 
sensitivity of BRAF(V600E)-positive cell lines to MEK inhibitors was also discovered using 
the NCI60 cell lines panel in 2006 (Solit et al., 2006).  
1.4.3 Expanding the number of cell lines and genomic biomarker analyses 
In March 2012, two papers were published in the same issue of Nature, both 
describing drug screening pipelines in even larger panels of cancer cell lines. The first paper 
described the Genomics of Drug Sensitivity in Cancer (GDSC) cell lines panel at the 
Wellcome Sanger Institute in the UK and the other the Cancer Cell Line Encyclopedia (CCLE) 
at the Broad Institute in the USA (Barretina et al., 2012; Garnett et al., 2012). Unlike the 
NCI60, these two studies drug screened an excess of 600 and 400 cell lines respectively. 
With an increased number of cell lines, the newer panels are able to represent a larger 
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number of tissue types and genomic variety, overall and within tissue types. By annotating 
the cell lines for mutations in cancer-related genes, copy number alterations (CNAs), and 
gene expression, the studies provided the statistical power for the unguided identification 
of genomic biomarkers of drug sensitivity. Both cell line panels were able to replicate many 
known biomarker-drug associations, e.g. BRAF-mutations with BRAF/MEK inhibitors, 
ERBB2-mutations with EGFR/ERBB2 mutations and others. Additional, the GDSC panel was 
able to identify a novel sensitivity of Ewing’s sarcoma cell lines with EWSR1-FLI1 gene 
translocations to PARP inhibitors, while the CCLE panel found that an aryl hydrocarbon 
receptor (AHR) gene expression signature in NRAS-mutated cell lines correlated with 
sensitivity to MEK inhibitors.  
To-date, both the GDSC and CCLE have expanded the number of models further, 
with now over 1,000 overlapping cancer cell lines screened and annotated by both panels. 
With improvements in technology, it has also become easier, cheaper and faster to 
sequence cell lines for more detailed genomic annotations, perform high-throughput drug 
screening at larger scale and to genetically engineer cell lines for a richer data set.  
Next, I will provide a brief overview on technologies that produced these data-sets. 
At the Wellcome Sanger Institute, my work is based on the GDSC cell line panel, and 
therefore they will be my main focus in the next few paragraphs.  
1.4.4 Genomic characterisation of cell line panels 
As sequencing technologies have become cheaper, the genomic characterisation 
of cell lines has expanded accordingly. For the original paper in 2012, the authors 
sequenced the full coding exons of 64 commonly mutated cancer genes in about 600 cell 
lines. Now, the GDSC cell line panel has whole exome sequencing data and single-
nucleotide polymorphism (SNP) called for over 1,000 cell lines (Iorio et al., 2016). This also 
includes targeted PCR sequencing or FISH analysis for three selected translocations (BCR-
ABL1, EWSR1-FLI1 and EWSR1-ERG). The molecular annotation was expanded to include 
hypermethylated regions, as called using Infinium HumanMethylation450 BeadChip arrays. 
RNA-sequencing data now also provides gene expression data for the entire transcriptome, 
rather than selected genes from microarray expression data. An overview of the data types 
available for each cell line is given in Figure 1.5. 
Analysing too many potential genomic alterations dilutes the statistical power for 
biomarker analysis and also likely contains alterations that are only found in cancer cell 
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lines but not patient tumours. To identify patient-relevant genomic alterations, Iorio and 
colleagues processed genomic annotation available from over 6,000 human tumours and 
statistically identified alterations that are likely to be cancer-related. This involved the use 
of algorithms that evaluated the i) recurrence and functional impact of SNPs (MutSigCV, 
OncodriveFM and Oncodrive-CLUST) ii) recurrence and size of CNA regions (ADMIRE), and 
iii) methylated regions that show multi-model distribution in at least one cancer type (Iorio 
et al., 2016). This produced a reference set of clinically-relevant cancer functional events 
(CFEs) and only alterations that matched this list were considered for further downstream 
analyses.  
The authors then showed that panels of cell lines captured the genomic variety of 
tumours on a tissue type level, since 1) the percentage of cell lines altered for specific 
cancer-associated pathways and 2) the class of the dominant genomic alterations within 
tissue types both correlated well. Additionally, out of 1,273 CFEs identified in the tumour 
samples, 86% (n = 1,063) occurred in at least one cell line. There are the caveats that this 
is lower for CFEs that are present in < 5% of patient samples and only around 79% of CFEs 
are found in at least three cell lines (Iorio et al., 2016). Biomarker analyses often require at 
least 2-3 samples with a specific genotype to have adequate statistical power to separate 
signal from noise. This thus suggests that expanding the in vitro models collection beyond 
the existing 1,011 models has the potential to reveal further trends in rare cancer subtypes. 
1.4.5 High-throughput drug screening and identification of biomarkers of drug response 
The original NCI60 platform screened 100,000’s of compounds across 60 human 
cancer cell lines, which enabled researchers to query the general anti-cancer activity of 
compounds (Shoemaker, 2006). Conversely, the GDSC and CCLE studies screen fewer 
compounds but across many more cell lines, which provided the resolution to identify rarer 
cancer subtypes that are particularly sensitive to certain compounds. Screening fewer 
compounds does mean that they are typically selected more carefully, e.g. only testing 
those that have already shown anti-tumour activity in smaller sets of cell lines. Nevertheless, 
technological advances have enabled a rapid growth in the number of compounds and 
cell lines screened is rapidly growing. From 2012 to 2016, the number of compounds/cell 
lines screened increased from 130/639 to 265/990 (Garnett et al., 2012). My thesis will 
include drug sensitivity data for > 400 drug compounds.  
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To briefly describe the protocol for cell line screening: cell lines are grown in multi-
well plates for 4 days. 24 hours after plating, cell lines are exposed to a certain 
concentration of the drug compound, titrated with a dilution series. Viability is tested 72 
hours after exposure using fluorescent chemical assays that measure the nucleic acid 
content (Syto60), or in later studies, metabolic activity (CellTitre Glo). Viability is normalised 
to negative control (DMSO) and positive control wells (media only). The percentage 
viability from each experimental well is then fitted onto a viability curve from which an 
inhibitory concentration at which viability is 50% (IC50) and an area under the curve (AUC) 
can be calculated. Lower values for both IC50 and AUC mean that a lower concentration of 
a drug can elicit the same loss of viability and therefore represents a sensitivity to a given 
drug.  
Across the years, developments in technology have increased the pace of screening. 
Notably, while 96-well screening plates were used for the NCI60 and the 2012 GDSC screen, 
the 2016 GDSC screen used 384-well plates. In 2018, the 1536-well plate is now standard 
in our group, effectively increasing the screening throughput 16-fold. Robotic platforms 
have also been invaluable in reducing the amount of manual handling needed. Tasks for 
which a person requires several hours can now be carried out in the span of minutes, e.g. 
evenly dispensing cell-line containing media evenly across screening plates, drug titration, 
and pipetting nano litres of drug directly into screening wells. To-date, the platform is 
powerful enough to screen 900 new compounds across a core-set of 750 cell lines per year.  
 
Figure 1.5: Summary of the data types available for the GDSC panel of 1,011 cancer cell lines used for my 
thesis. RNA-Seq data is available for all cell lines. CRISPR/Cas9 whole genome drop-out screening data is 
available from multiple sources (see chapter 5 for details and references). Number at the right represents the 
number of cell lines a given data type is available for. 
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For the identification of biomarkers of drug sensitivity, analyses statistically test 
whether the IC50’s, i.e. drug sensitivity, for cell lines of a given genotype are significantly 
different from all other cell lines. For instance, cell lines with a BCR-ABL1 rearrangement 
on average have a much lower IC50 when exposed to Imatinib than the bulk of cell lines 
(see chapter 4.3.1.2). The analysis of biomarkers in the GDSC panel is typically performed 
using a multivariate analysis of variance model (MANOVA), which tests the association of 
each CFE to each drug and also controls for tissue type and MSI status of cell lines as co-
factors (Garnett et al., 2012; Iorio et al., 2016). Other computational algorithms have been 
developed that use variants of machine learning to deconvolute associations of combined 
features (e.g. RAS OR RAF mutations both lead to MEK inhibitor sensitivity). However, the 
significant associations returned by these models are often combinations of the gene 
expression of large sets of genes, which can be difficult to interpret for biological and 
clinical relevance. 
So far, the GDSC high-throughput drug-screens have shown that in vitro systems 
can recapitulate many known associations (e.g. with genetic alterations involving BRAF, 
EGFR, ABL, tumor protein p53 (TP53), fms related tyrosine kinase 3 (FLT3), etc.). In the 2016 
publication, Iorio and colleagues also report > 100 novel associations, though the meaning 
and biological significance of many of these is yet to be understood (Iorio et al., 2016). 
1.4.6 Current developments and future outlook 
As the above paragraphs have hopefully shown, high-throughput drug screens in 
genomically annotated cancer cell line panels are a valuable tool for the unguided 
exploration of cancer biology and treatment opportunities. Implementing novel 
techniques in the existing pipeline can further broaden the opportunities for discovery.  
For one, our group and others have deployed CRISPR/Cas9 whole genome drop-
out screens in cancer cell line panels (Behan et al., 2018; Meyers et al., 2017; Wang et al., 
2017). The CRISPR/Cas9 system was originally discovered in bacteria and is now a widely-
used technique for creating gene knock-outs in mammalian cells (Jinek et al., 2012; Mali et 
al., 2013). In the drop-out screens, a short guide RNA (sgRNA) library targeting about 
17,000-20,000 different genes is transduced into Cas9-expressing cell lines. Those sgRNA 
that induce a loss-of-fitness phenotype will be statistically depleted after several weeks in 
culture. Compared to drug compounds, these screens can reveal a much broader spectrum 
of genetic dependencies of cancer cells, as they have two major advantages: 1) the sgRNA 
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can be designed to have low off-target activity and 2) they can essentially target any, even 
undruggable, gene in the genome.  
CRISPR/Cas9 technologies are also evolving beyond just knock-outs, as more 
complex phenotypes such as double knock-outs and transcriptional activation are being 
achieved. This further opens up possibilities in querying the biology of cancer in in vitro 
systems. In chapters 5 and 6, I will show how CRISPR/Cas9 whole genome drop-out screens 
data can be leveraged to examine the functionality of gene fusions in the context of my 
thesis. 
Secondly, finding potent drug combinations is another area of interest for cell line 
screening. As illustrated in the example of BRAF(V600E) mutated colorectal cancer (see 
section 1.2.2), well selected drug combinations can overcome innate and acquired drug 
resistances (Al-Lazikani et al., 2012). The sheer number of combinations that can be created 
using currently available drugs is staggering, especially when considering triple and even 
quadruple combinations. Nonetheless, high-throughput cell line panels can be a first step 
in the search for drug combinations. In our group, we have so far screened 1,800 unique 
combinations in a subset of the cancer cell line panel. Cancer cell line co-dependencies 
may also be identified in knock-out screens. For example an RNA interference screen found 
that alterations of PI3K/PTEN may confer resistance to anti-HER2 antibody trastuzumab in 
breast cancers (Berns et al., 2007).  
Finally, the dominant type of in vitro model used in large-scale screens may also 
see some changes in the near future. High-throughput drug screening protocols are 
currently being developed for cancer organoids in our lab and others. Similarly, 
improvements in technology have made it possible to derive experimental models such as 
patient derived tumour organoids in the span of several weeks. This may provide future 
opportunities for direct feedback from the bench back into the clinic (Pauli et al., 2017).  
Altogether, while high-throughput drug screening has historically been a tool for 
the discovery of new drugs and biomarkers, new developments may allow it to soon 





1.5 Final introductory words 
In the past chapter, I have reviewed the concepts of precision cancer medicine, the 
role of gene fusions as cancer oncogenes and large cell line panels as experimental models 
for cancer research.  
In summary, it is clear that precision medicine has had an overall positive impact 
on the treatment opportunities open to eligible patients today. At the same time, not all 
cancer patients are diagnosed an actionable biomarker, and many treated tumours 
develop secondary resistances, which underscores a persisting need for novel research.  
Gene fusions have so far been shown to be important cancer oncogenes as well as 
excellent markers of diagnosis, prognosis and drug sensitivity. Thanks to new technologies 
such as RNA-Seq that have enabled the unguided large-scale discovery of gene fusions 
across thousands of samples, the number of known gene fusions has been growing 
exponentially. Now, while the identification of gene fusions was once a limiting factor, it is 
the functional annotation that presents a challenge.  
Large cell line panels in the past have been valuable models for anti-cancer 
compound discovery and genetic biomarker analysis. Over the next few chapters in my 
thesis, I would like to examine the hypothesis that they can be used to assist in identifying 
the functional relevance of oncogenic fusions.  
My thesis has the following structure to address the question: 
1) Create a filtering pipeline to annotate fusions in 1,011 human cancer cell lines. 
2) Brief description of the landscape of fusions as we find them in the cell lines. 
3) Using extensive drug-screening data, I examine the use of gene fusions as 
biomarkers of drug response. 
4) Set-up and explore the results of an unguided computational approach to 
examine the functionality of individual gene fusions using CRISPR/Cas9 whole-
genome drop-out screening data.  
With that, I hope that the following pages represent a small contribution to the 
grand challenge that is the continuous improvement in the well-being of future patients 




2 Filtering gene fusions in 1,011 cancer cell lines 
The first step required in the study of gene fusions in cancer cell lines is to create a 
reliable catalogue of all fusion transcripts found in the same cell lines.  
As discussed in the introduction chapter, for an unguided fusion transcript 
discovery in large number of samples, RNA-Seq analysis followed by the computational 
devolution of fusion transcripts is the best option. At the same time, fusion calling 
algorithms are highly error-prone, both due to sequencing artefacts and variable methods 
used by fusion-calling algorithms.  
For this reason, our fusion-calling pipeline uses three different fusion-calling 
algorithms to analyse our RNA-Seq data. These algorithms are DeFuse, Tophat Fusion and 
STAR. The reasoning behind the decision was that the fusion-calling algorithms could 
either validate or complement each other.  
Thus, the first aim of my thesis is to examine the output produced by the Wellcome 
Sanger Institute’s Cancer, Aging and Somatic Mutations (CASM) program’s fusion-calling 
pipeline and to put together a set of filtering criteria that would produce a catalogue of 
high-confidence gene fusions in our 1,011 cancer cell lines. In this chapter, I first introduce 
the data available, the pre-processing steps and the three filtering algorithms which were 
used in our analysis. I then show two ways of benchmarking the fusion transcripts called 
by our fusion-calling pipeline. Based on these, I evaluate how effectively proposed filters 
retain true positive fusion transcripts while reducing false positives.  
2.1 Initial data processing and overview of fusion algorithms 
2.1.1 Note on terminology 
Throughout this thesis, the term “fusion” refers to any joining of two specific 
partner genes, with the first-named gene being the 5’ and the second-named gene being 
the 3’ partner. The term “fusion event” refers to the presence of a given fusion in a specific 
cell line. “Fusion transcript” refers to a fusion event with a specific breakpoint. Thus, 
multiple fusion transcripts of a single fusion event may occur in a given cell line.  
2.1.2 1,011 cancer cell lines 
The panel of 1,011 human cancer cell lines have been collected from publicly 
available repositories and private collections and are curated by the Genomics of Drug 
Sensitivity in Cancer (GDSC) project team at the Wellcome Sanger Institute. They span 42 
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different cancer types in 29 different tissue classifications (Figure 2.1; Supplementary Table 
1). 
The cells lines have previously been extensively characterised via whole exome 
sequencing (EGAD00001001039) and Affymetrix SNP6-based copy number analysis and 
genotyping (EGAD00010000644). To identify the cancer-relevant mutations, copy number-
altered and hypermethylated regions, each cell line is also annotated for a set of cancer 
functional events (CFE’s), which represent genomic alterations that are recurrently altered 
in TCGA tumour samples (Iorio et al., 2016). 
Further, high-throughput drug-screening data for 997 cell lines is available for 
more than 400 drug compounds. CRISPR/Cas9 screening data is available through several 
in-house and publically available resources for 371 cell lines. 
These data resources will be leverages in chapters 3 and 4 to query the functional 
relevance of the identified fusion transcripts.  
2.1.3 Data pre-processing 
Prior to my joining the project, RNA-Seq data was generated in-house for 447 cell 
lines and downloaded from CGHub for 587 cell lines. This data set includes 1,011 unique 
cell lines. For 23 of those, we obtained RNA-Seq data from both sources. The cell lines had 
 




a median of 77.6M read pairs (range: 40M-175M) in the CGHub data (median: 36X; range: 
7X-83X) and 227M read pairs (range: 79M-543M) in the in-house data (median: 89X; range: 
16X-206X).  
Fusion calling was performed using the cgpRna pipeline developed by the Cancer 
Genome Project at the Wellcome Trust Sanger Institute (Cancer IT, 2018a). RNA-Seq reads 
were mapped onto the GRCh38 human reference genome (Ensembl version 82 gene model) 
via three independently developed pipelines using their default options: STAR, TopHat-
Fusion and deFuse (Dobin et al., 2013; Kim and Salzberg, 2011; McPherson et al., 2011). 
The outputs of all three fusion calling algorithms are compiled into a single list and the 
pipeline then employs the Gene Rearrangement AnalySiS (GRASS) algorithm to predict 
consequences of gene fusions, including whether fusions are in coding or non-coding 
regions and their frames (Cancer IT, 2018b). 
The cgpRna pipeline automatically combines fusions identified by multiple 
pipelines into a single entry. After splitting the entries into individual fusion calls, we found 
that the cgpRna pipeline yielded 1,934,711 putative fusions transcripts across the 1,011 cell 
lines (Table 2-1). Overall, fusion calls by STAR made up the bulk of putative transcripts (N 
= 1,576,062), with TopHat-Fusion calling the smallest number of putative transcripts 
identified by a single algorithm (N = 58,397). Only 14,118 (0.9%) of putative transcripts 
were called by more than one algorithm.  
2.1.4 Fusion-calling algorithms 
The basic principles of fusion-calling algorithms is already described in the 
introductory chapter in section 1.3.2. Here, I would like to briefly outline algorithm-specific 
characteristics and the results from previous attempts at benchmarking the algorithms.  
Table 2-1: Number of putative fusions called by individual or multiple algorithms. (D = DeFuse, T = TopHat-
Fusion, S = STAR-Fusion.) 
Algorithm (unique) Number of Fusions Algorithm (shared) Number of Fusions 
D 286,134 DTS 5,959 
T 58,397 DT 1,770 
S 1,576,062 DS 2,856 




2.1.4.1  DeFuse 
This fusion-caller was created in 2009 by McPherson and colleagues at a time when 
few alternatives existed (McPherson et al., 2011). It was the first aligner to take into account 
multiple alignments for a single read pair, while other aligners typically either discard any 
read pair with multiple alignments, or choose the alignment with the highest alignment 
score. DeFuse does this by applying a so-called “maximum parsimony” approach, which 
picks the alignment which supports a putative fusion transcript which has the highest 
support from other read alignments.  
The deFuse algorithm was tested in 44 samples (40 ovarian cancer patient samples, 
3 sarcoma patient samples and 1 ovarian cancer cell line), which mainly contained 17-45 
M read pairs. The algorithm detected 20,237 candidate fusion transcripts, i.e. a mean of 
460 per sample.  
The authors then designed 11 additional filters which characterise the fusions and 
perform statistical tests to evaluate the distribution of reads across a predicted breakpoint, 
the most likely distribution of fragment lengths and potential confounding factors, e.g. 
homologous nucleotides at the fusion boundaries. In total, 268 fusion transcripts (1.3%) 
passed these additional filters. 
In order to validate the efficacy of these filters, the authors then performed PCR 
validation for selected fusion transcripts. Of 46 fusions that pass all additional filters, 42 
validated. 14 that failed at least one of the additional filters also failed the PCR validations. 
Of 40 randomly selected fusion transcripts, only one validated using PCR.  
While the additional filters appear to perform well at selecting true positive fusions, 
some known positive fusions did not pass. The authors also acknowledge that the lack of 
reliable positive and negative controls still represent a challenge when designing fusion-
calling algorithms. Similarly, as the filters were trained on this dataset, it is unclear how 
they will perform in independent datasets.  
2.1.4.2 TopHat-Fusion 
This algorithm was developed by Kim and Salzberg in 2011 as an algorithm that 
only uses gene annotations to identify known intron boundaries at a later step, which 
speeds up the analysis significantly (Kim and Salzberg, 2011).  
To do this, TopHat first identifies any reads that do not map entirely within exons 
and then splits them into 25 bp segments which are aligned independently. Fusions are 
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separated from introns by whether or not two segments align at a genomic distance of 
more than 100,000 bp apart. TopHat then stitches reads together to reconstruct the full 
600 bp window around the putative fusion breakpoint and filters out those that show any 
gaps in this window.  
An advantage over algorithms that only recognises fusions from reads mapping to 
two different annotated genes, TopHat-Fusion can derive fusion products from known 
genes, unknown genes and unannotated splice variants.  
The authors tested their algorithm on four breast cancer cell lines and one prostate 
cancer cell line, which contained 7-21 M read pairs. Compared with previous analyses of 
the same data, TopHat-Fusion found 44 of 47 known fusion events in the same cell lines 
and an additional 61 novel fusion events. It is important to note that individual splitting 
and spanning read thresholds were implemented for each sample based on the a priori 
known fusions, which could enrich for true positives while providing little guidance for 
setting thresholds for samples that were not previously tested. 
The authors estimated their false positive rates by hypothesising that non-
neoplastic tissue should have no fusion transcripts. In two normal tissue samples, they 
found 10 fusion events, albeit with more stringent supporting read thresholds that the 
authors devised due to a higher number of total read pairs in those samples.  
The authors also compared the output of their algorithm to that of deFuse for two 
cell lines. There, they found that both programs found seven out of nine previously 
reported fusion events, but with TopHat-Fusion predicting 42 and deFuse 1,670 fusions 
events in total.  
Thus, TopHat-Fusion’s algorithm predicts many of the expected fusions in the cell 
lines that they examined, and a lower number of unexpected events compared to deFuse. 
However, the authors still faced the same challenge as the authors of deFuse faced: namely 
that the lack of gold-standard true-positives and true-negatives makes it difficult to predict 
the likelihood of the unexpected fusion-calls to represent true fusion events. 
2.1.4.3 STAR 
This fusion-caller is an in-built function of STAR aligner, an ultra-fast aligner for 
RNA-Seq data on reference transcriptomes (Dobin et al., 2013; Haas et al., 2017). The 
chimeric read detection algorithm in STAR follows the following basic steps of 1) creating 
“local genomic windows” by stitching together alignments that align perfectly to the 
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reference transcriptome, 2) identify reads that align partially to these local genomic 
windows and 3) aligning the overhang of partially aligning reads to other local genomic 
windows. These partially aligning reads are thus splitting reads that support the presence 
of fusion transcripts.  
At the time of release, the built-in chimeric read detection algorithm of STAR was 
only a small component of overall tool and was minimally benchmarked. In 2017 the 
authors of STAR released a bioRxiv pre-print for STAR-Fusion, an additional stand-alone 
tool that uses the output of the chimeric sequence detection programme in STAR and adds 
an additional set of criteria to further dissect the results. These include filters that discard 
fusion transcripts that do not have sense-sense orientation of the genes, are not supported 
by at least 1 splitting read and 2 total reads, do not have a fully aligned genomic window 
of 23 bp either side of the breakpoint, isoforms with low read evidence, fused genes with 
high sequence homology and genes that are commonly fused across the same sample.  
Importantly, with the publication of STAR-Fusion, the authors also perform a 
comprehensive comparison of the performance of 15 other fusion-calling algorithms, 
including deFuse and TopHat-Fusion, which highlight some of the variations between 
fusion-calling algorithms.  
 
2.1.4.4 Variations in accuracy of fusion-calling algorithms 
In the previous section I have outlined three different fusion-calling tools that are 
available for RNA-Seq data. The exact methodology, as well as the filters applied have a 
large impact on the final list of fusions. For instance TopHat-Fusion’s filters cut down the 
fusions called in 6 data sets from > 10,000 to several hundred. Similarly, only about 1% of 
fusions passed deFuse’s additional filters.  
Several papers have now compared the performances of over 20 fusion-calling 
algorithms, the most notable by Carrara et al in 2013, Kumar et al in 2016 and Haas et al 
in 2017, examining 8, 12 and 16 different algorithms respectively (with some overlap) 
(Carrara et al., 2013; Haas et al., 2017; Kumar et al., 2016).  
In general, all three papers used a combination of 1) simulated RNA-Seq data in 
which fusion transcripts were planted across different expression levels and 2) real RNA-
Seq data, for which the benchmark was either based on previously detected fusions in 
these samples (Carrara and Kumar), or the concordance across different algorithms (Haas).  
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All three reviews found large variations both in the sensitivity and specificity of the 
algorithms in the simulated data, as well as the total number of fusions in the real RNA-
Seq data sets. In the simulated data, fusion-calling algorithms have varying levels of 
success in extracting true positives (sensitivities ranging from 4% to 88% in assays by 
Kumar and Carrara) but with generally low false positives rates (10-20%).  
Real data sets are much messier to interpret. For instance, in the same sample, 
Kumar et al. found that different fusion calling algorithms identified anywhere from 0-10 
to over 5,000 fusion transcripts. Carrara et al. extracted 11-73,000 different fusion 
transcripts in the same sample using different algorithms. Moreover the analysis 
sometimes had highly variable findings, while deFuse and TopHat-Fusion found on 
average 34 and 3 fusions per sample under Kumar, the number was much higher at 454 
and 43,301 under Carrara. These numbers stand in further contrast to the study by Kim 
and Salzberg, where deFuse identified 32x more fusions than TopHat (Kim and Salzberg, 
2011). Furthermore, while EricScript had good sensitivity and specificity under Kumar et al., 
but had underwhelming performance in Haas et al.’s analysis. Haas et al. also highlighted 
discrepancies in the performances of the same fusion-calling algorithms in the simulated 
and the real data sets. For instance, nFuse and ChimeraScan perform well in the simulated 
sets, but had much lower accuracy than other calling algorithms in the real data set.  
Overall, the unpredictability of RNA-Seq fusion-calling algorithms is important to 
consider when assessing the choice of method. No one tool emerges as being consistently 
reliable at calling expected fusions without introducing large numbers of false positives. 
Similarly, different interpretations of reliability of the same algorithms across different 
papers is likely a result of a lack of consensus guidelines on how tools should be best 
applied across samples with different characteristics (e.g. number and length of reads, etc). 
In general, these findings supports the use of multiple fusion-calling algorithms in order 
to minimise unpredictable results from individual algorithms. 
 
2.2 Filtering approach 
As outlined in the previous section, algorithms for fusion calling from RNA-seq data 
suffer from noisy results with a large number of false positives due to sequencing artefacts.  
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In order to create a catalogue of fusion transcripts in our cancer cell lines, I 
examined the expected true positive and false positive rates of our putative fusion 
transcripts. To do this, I utilised three sets of benchmarking data that were generated 
before I started the work on this thesis.  
2.2.1 Benchmarks 
We developed three benchmarks that were subsequently used to gauge the 
effectiveness of individual filters, as well as the quality of our final list of fusions. These 
consist of: 1) 945 putative transcripts that were validated by PCR, 2) comparisons of fusion 
events called from cell lines with RNA-Seq data obtained both in-house and from TCGA 
and 3) fusions described in the same cell lines in previous literature.  This following section 
describes these benchmark datasets 
2.2.1.1 PCR validations 
945 putative fusions transcripts (798 fusion events) in 23 cell lines were selected for 
validation through PCR of cDNA libraries using two different sets of primers per transcript2. 
PCR reactions confirmed the presence of 51% fusion transcripts while 49% failed. Of 
putative fusions predicted by single algorithms, those predicted by deFuse had the highest 
rate of successful validations (56.2%), while those predicted by STAR had the lowest 
validation rates (14.4%). Putative fusions predicted by all three fusion calling algorithms 
                                                 
2 PCR validations were planned by Graham Bignell and carried out by Elizabeth Anderson. 
Both were core members at CASM facilities. For methods, see Picco* & Chen* et al. (manuscript 
under review). See supplementary table 2. 
Table 2-2: Validation success across 945 putative fusion transcripts. D = Defuse, T = TopHat Fusion, S = STAR. 
Combinations of letters denote a combination of multiple algorithms.  
Algorithm Total # fusions 
(%) 
Total PCR  
reactions 
% passed (#) Adj. pass rate 
D 286,134 (14.8) 192 56.2% (108) 8.3% 
T 58,397 (3.0) 107 33.6% (36) 1.0% 
S 1,576,062 (81.5) 111 14.4% (16) 11.7% 
DT 1,770 (0.1) 90 61.1% (55) 0.06% 
DS 2,856 (0.2) 107 58.9% (63) 0.09% 
ST 3,533 (0.2) 112 48.2% (54) 0.09% 
DST 5,959 (0.3) 226 78.8% (178) 0.24% 




had the highest rates of validations overall (Table 2-2). The set of PCR validations served 
as guide lines when deciding on thresholds for fusion filters.  
Note, that fusion transcripts that were selected for validation are not evenly 
distributed across different fusion-calling algorithms and combinations thereof. For 
instance, there is a clear overrepresentation in fusion transcripts that are called by multiple 
fusion-calling algorithms, which only represent less than 1% of all fusion calls. Similarly, 
both median and mean splitting reads is higher in the subset of fusion events that are PCR 
validated, compared to the overall set of fusion calls (median: 11 vs. 1, mean: 60.2 vs. 8.4). 
This is partially due to fusion transcripts called by multiple algorithms generally having 
higher numbers of splitting reads.  
Since validation rates vary considerably between the calling methods, when 
approximating the overall PCR validation rate of a set of samples, it is advisable to adjust 
it to the proportion of fusion transcripts called by a given calling method (e.g. if the 
proportion of fusions called are: 70% by STAR, 20% by DeFuse, 10% by TopHat, then 
calculate validation rate as: 0.7*14.4% + 0.2*56.2% + 0.1*33.6%, etc.). Plugging in the actual 
numbers for the validation rates given in Table 2-2, I find an adjusted PCR validation rate 
of 21.2% across the pool of 1.9 M fusions. Note also, that this number is likely to still be an 
overestimate, due to the overrepresentation of fusion transcripts with higher number of 
splitting reads.  
At the same time, it may be important to keep in mind that there may be technical 
reasons for the failure to validate fusions by PCR, in particular since most fusions do not 
have positive control samples that can confirm the efficacy of a pair of PCR primers. In fact, 
out of the 945 fusion transcripts tested, only for 791 (84%) were the two different primer 
sets in agreement. For the other 154 transcripts, one primer set failed while the other 
passed. Since negative controls test that a PCR product is not a false positive, it is likely 
that in these 16% of cases, the failed primer set was in fact a false negative. Thus, while the 
PCR validation is a useful benchmark for the downstream analysis, this caveat should be 
born in mind.  
2.2.1.2 Comparison of TCGA and in-house RNA-Seq data 
In order to measure biological replicability of our pipeline, for 23 cell lines we 
performed both in-house RNA-Seq and used data from CGHub. Both sequencing data sets 
were then processed by the same downstream pipeline using cgpRna.  
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In total, 76,358 fusion transcripts were found in the 46 datasets. Although, the in-
house RNA-Seq data was associated with significantly more read pairs in sequencing data 
(paired t-test: t: -11.1, p < 1 x 10-10; Figure 2.2A), there was no significant difference 
between the number of putative fusions identified (paired t-test: t = -2.0, p = 0.06; Figure 
2.2B). With the unfiltered output, the mean proportion of shared fusion events was 6.7% 
(SD = 2.2%; median across cell lines = 6.8%) (Figure 2.2B).  
The relatively small proportion of overlapping fusion events indicates a highly noisy 
dataset and suggests that only a minority of the unfiltered putative fusion events are 
reproducible. Ideally, our filtering process should enrich our list of putative fusion events 
for those that are shared.  
 
Figure 2.2: Relationship of (A) read pairs for each data set and (B) number of fusions identified. Lines connect 
the pair of datasets (CCLE or in-house sequencing) for the same cell lines. (C) Overlap of fusions called from 
two separate RNA-Seq data sources by cell line. 
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2.2.1.3 Fusions described in literature 
Finally, a list of previously reported fusions events in the same cell lines that are 
used in our analysis was manually compiled by Graham Bignell through ChimeraDB, 
Mitelmann DB, the Atlas of Genetics and Cytogenetics in Oncology and Haematology and 
TICdb. It includes 1,916 previously reported fusion events across 417 samples from 91 
sources.  
While some of these fusion events were a result of high-throughput, little-filtered 
landscape studies, the list also includes 253 annotated fusion events that were validated in 
either a second study, or through high-confidence methods such as FISH and capillary 
sequencing. These annotated fusion events include well known oncogenic drivers, for 
example 20 instances of EWSR1-FLI1, 7 instances of BCR-ABL1 and 1 instance of TMPRSS2-
ERG. 
Due to the inherently high error rate in calling true fusion transcripts as well as 
incomplete coverage, this list is not necessarily comprehensive or free of false-positives. 
However, it serves as a helpful tool to compare how many previously reported fusion 
events are captured using our pipeline. Similarly, whether these previously reported fusion 
events are preferentially retained by our filtering process can give an indication of the 
filters’ effectiveness in retaining true positives. 
 
Overall, it is important to recognise that all benchmarks cover a subset of the fusion 
transcripts/cell lines that are examined in my thesis. The PCR validations are conducted on 
945 fusions transcripts, which represents less than 0.5 percent of all fusions called within 
our pipeline. Meanwhile, the analysis of shared fusions between replicates covers 23 cell 
lines, i.e. 2.3% of our entire panel. Similarly, the fusions described in literature also cover 
only 1,916 fusion events in 417 samples. While the curation of this benchmarking data is 
nevertheless a valuable resource, the representation should be born in mind when 
interpreting the downstream analyses. 
2.2.2 Evaluation of suggested set of filters 
In the next section, I describe how I evaluated the set of filters that were suggested 
prior to my participation in this project. For that, I benchmarked the impact of filters using 
the benchmarks described above, mainly with the aim of removing fusion transcripts and 
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events that do not pass PCR validations and that are not shared in the independently 
sequenced datasets. 
2.2.3 Split read filter 
The split read filter sets the requirement that a putative fusion transcript must be 
supported by a certain number of sequencing reads that align directly onto the breakpoint 
and is standard for fusion calling algorithms. In the cgpRna pipeline, only TopHat-Fusion 
and DeFuse apply such a filter by default, while STAR reports putative fusion transcripts 
even when supported only by a single read or read pair. This likely explains the large 
number of fusion transcripts found by STAR (81.5% of total), opposed to other fusion 
calling algorithms. In fact, out of the 1,588,410 putative fusion transcripts found by STAR, 
only 102,958 (6.5%) had at least 3 splitting reads. 
The assumption underlying the split read threshold is that putative fusion 
transcripts with little supporting evidence from single sequencing reads may be false-
positives resulting from technical artefacts.  
First, I examine the total putative fusions retained at a given splitting read threshold, 
and the number and proportion of passing and failing PCR validation. By increasing the 
splitting read threshold, the proportion of PCR validating fusions increases substantially 
(Figure 2.3). Even a basic threshold of 3, which removes 80% of all fusion transcripts, we 
remove 38.2% of false-positives tested by PCR, while retaining 92.9% of those that do 
 
Figure 2.3: Impact of a splitting read filter. At any threshold (x-axis), the plot shows (A) the number and 
percentage of PCR validated fusion transcripts, as well as the total number of fusion transcripts that pass that 
threshold. (B) The percentage of fusion transcripts that are retained from a given category (validating, non-
validating and total) at each threshold. 
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validate (Figure 2.3B). On the other end of the spectrum, at very stringent threshold of 25 
splitting reads, 74% of putative fusion transcripts validate, but only 40% of validating 
transcripts are retained.  
Even true fusion transcripts can have varying numbers of supporting splitting reads, 
which can be explained by varying transcript expression levels, i.e. true fusions that are 
expressed lowly may only have limited number of sequencing reads supporting it. 
Since no clear division exist between true positive and false positive fusions, the 
ideal threshold would likely depend on the study and in particular the read depth of 
samples. Because my project aims to discover novel fusions, which will be validated in later 
experiments, I decided to implement a relatively permissive threshold of 4 splitting reads, 
as it strikes a compromise by removing approximately 45.6% of false-positives while 
retaining 89.7% of validated putative fusion transcripts in a single filtering step. Overall, 
this retains 370,210 (19%) of 1,930,425 fusion transcripts.   
2.2.4 Multi-algorithm filter 
At the time that the cgpRna script was developed, most research articles used only 
a single fusion-calling algorithm. Like more recent papers that tend to use multiple 
algorithms to call fusion transcripts (Gao et al., 2018), for this project the decision was 
made to implement three separate algorithms, with the reasoning that: 1) multiple 
algorithms may capture fusions that are missed by single algorithms 2) fusions called by 
multiple algorithms have more streams of supporting evidence and therefore are more 
likely to be true positives rather than technical artefacts.  
To examine if these assumed benefits hold true, I again examined to our PCR 
validation data, as well as the data on 23 cell lines obtained from different sources. 
First, I broke down the 945 PCR validation by which algorithm called a given 
putative transcript (Figure 2.4A). Notably, none of the algorithms or combinations showed 
100% validation rates by PCR. The data for the most part supports the assumption that 
fusions called by multiple algorithms are more likely to be true positives, as they validate 
in higher proportion by PCR. Notably, deFuse outperforms STAR and TopHat in terms of 
true positives. Nonetheless, deFuse’s validation rate at 56.2% still suggests that more than 
two in five fusion calls may represent a false positive.  
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We hypothesised that the low threshold for splitting reads may have caused the 
low validation rates particularly for STAR and TopHat fusions. After applying our suggested 
filter of 4 splitting reads (Figure 2.4B), the proportion of validating fusions per algorithm is 
increased across almost the entire dataset, but with the most striking improvements in 
STAR and TopHat-Fusion, where the validation rates rose to 47.1% and 47.8% from 14.4% 
and 33.6% respectively. Overall, for fusion transcripts called by single algorithms, our 
validation rate is 39.0% before filtering and 54.9% after filtering by splitting reads. 
Validation rates across fusion transcripts with multiple supporting algorithms also rose 
substantially, with the average validation rate for those fusions that are found by more 
than two algorithms increasing from 65.4% to 69.2%.  
 
Next, I examined the fusion calls obtained by analysing RNA-Seq data from two 
separate sources in 23 cell lines. In section 2.2.1.2, I showed that when unfiltered, few fusion 
transcripts overlap between the two sources, which indicates that the data is highly noisy. 
Figure 2.5 shows that after applying the filters which were identified as effective in the 
previous sections, we can increase the proportion of shared fusion calls. Unfiltered, the 
proportion of shared transcripts is merely 6.7%. Implementing the split read filter with a 
minimum threshold of 4 splitting reads already increases the proportion to 33.7%. When 
considering only fusions called by multiple algorithms, the proportion of shared transcripts 
is 64.6%. Finally, when I combine both the split-read filter and the multiple algorithm filter 
 
Figure 2.4: Breakdown of 945 PCR validations by algorithm either on the unfiltered list (left), or after applying 
a basic splitting read threshold of 4 (right). 
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together, I observe a much improved proportion of 70.4% shared fusion transcripts. On a 
per cell line level, the median cell line has an even higher proportion of 77.8% shared fusion 
transcripts. The overall mean is likely lower due to a few outlier cell lines that have 
particularly low overlap. 
Thus, by limiting our list of putative fusion transcripts to only those that are called 
by two or more algorithms, I see substantial improvements in proportion of validating 
fusions from PCR analysis. Perhaps more importantly, the proportion of shared fusions 
called from biological replicates is more than doubled to 70.4%. In the interest of ensuring 
that I am working with a biologically replicable dataset, I therefore decided to implement 
the multi-algorithm filter to obtain our final dataset. It is nonetheless important to keep in 
mind, that a large amount of fusions that do validate by PCR are removed in the process, 
which is a caveat that is unfortunately difficult to avoid when analysing fusion calls from 
RNA-Seq data.  
 
Figure 2.5: Breakdown of fusion calls from the analysis from two separate sources in 23 cell lines. Colour of 
the bar shows whether a specific putative fusion is called from both sources (Shared: blue), or if it is uniquely 
called from either the in-house data (red) or the CGHub data (green). Each panel shows the data after a 
different filtering method was applied. The number in the panel represents the percentage of shared fusions 




2.2.5 Fusions discovered in normal tissues 
Next I examined fusions called in normal tissues, since we believe that true 
oncogenic fusions are unlikely to be present in non-neoplastic tissues. RNA-Seq data for 
245 non-neoplastic tissues was downloaded from the Genotype-Tissue Expression project 
(GTEx) (GTEx Consortium, 2013) and fed into the cgpRna pipeline. The raw output 
contained 126,897 putative fusion transcripts. After filtering by number of splitting reads 
(≥ 4) and removing any putative fusions that were called only be a single algorithms, our 
dataset retained 78 fusion transcripts. No sample showed more than one fusion transcript 
and approximately 1 fusion transcript was found per every 3.1 GTEx samples (Figure 2.6A).  
Of the 78 fusions found in GTEx samples, 6 fusions were also found in our cancer 
cell line panel, including the three most common GTEx fusions. Interestingly, one 
pancreatic sample carries a fusion in TMPRSS2-ERG, a well-known pancreatic cancer driver 
fusion (Figure 2.6B). The presence of this fusion may indicate that the sample originated 
from a pre-malignant lesion, although recent literature shows that non-neoplastic tissue 
can show surprisingly high frequencies of cancer driver alterations without leading to 
obvious oncogenic transformation (Martincorena et al., 2015). 
 
Figure 2.6: Histology and fusions in 245 GTEx samples. (A) We detected fusions in 58 of 245 GTEx samples. 




With the exception of TMPRSS2-ERG, I did not observe any other potentially 
oncogenic fusion events (i.e. those matching the COSMIC fusion curation) within the GTEx 
sample results. As fusions that occur recurrently in GTEx samples are unlikely to play 
significant functional roles, we removed the small number of recurrent GTEx fusions from 
our list of putative fusions in cancer cell lines (n = 29).  
2.2.6 Summary and overview of a framework for fusion filtering 
In the above paragraphs, I examined the effectiveness of a set of filters in removing 
technical artefacts from our list of putative fusion transcripts. Overall, I found that using a 
splitting read threshold of at least 4 splitting reads per transcript increased the projected 
true positive rate from 51% to 63% (Figure 2.3). Also, only using fusion calls supported by 
two or more algorithms significantly increased the biological replicability. Finally, I also 
removed a small number of fusions that were recurrently found in a set of non-neoplastic 
GTEx samples.  
Note, that during the course of my PhD, I also examined the efficacy of a further 4 
filters, that examine false positives filtered by 1) regions of high repeats, 2) ratios of 
splitting reads to spanning reads, 3) the deFuse additional filters and 4) highly recurrent 
fusions. No efficacy was found for those filters (keeping in mind the limitations of my 
benchmarking approach) and for the sake of brevity, the data is not shown.  
Thus, for our final filtering pipeline summarised in Figure 2.7, I decided to 
implement only the splitting read and multi-algorithm filters, as they showed the greatest 
efficacy in increasing the proportion of true positives.  
Implemented across our 1,011 cell lines, of the 1,934,711 putative fusion transcripts 
outputted by cgpRna, 10,514 (0.5%) pass my filtering process (Supplementary Table 3). 
 
Figure 2.7: Overview of the filtering and annotation pipeline to identify our final catalogue of gene fusions in 
1,011 cancer cell lines. 
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This represents 8,354 fusion events, i.e. unique cell line/fusion combinations. PCR 
validations performed on a subset of these fusion transcripts (n = 474) yields a projected 
69.2% pass rate. In terms of the 23 cell lines that were RNA-Seq’d at two independent 
sources, applying the two filters substantially improved the proportion of shared fusions 
from 6.7% to 70.4%. 
Finally, I compared our filtered list of fusions with the list of fusion events described 
in literature (see section 2.2.1.3). Our raw output contained 84.13% of ‘validated’ and 52.6% 
of all remaining fusion events described in literature. After filtering, we still matched 74.21% 
of validated and 39.74% of the remaining fusion events. Although we lost a small number 
of fusion events that had previously been validated, overall considering that 99.95% of 
putative fusion events were removed, our filtering strongly enriches our set with previously 
observed fusion events, i.e. likely true positives.   
 
Although my set of filters provides a vast improvement over the validation rate of 
our set of fusion transcripts, it is clear that separating true positive from false positive 
fusions with high reliability remains a challenge. A high validation rate suggests a high 
specificity of a calling and filtering approach in excluding false negatives. However, in many 
instances implementing our filtering pipeline also reduces the sensitivity, as fusion 
transcripts that validate by PCR are filtered out. 
At the same time, a limitation of my approach are the benchmarking tools that are 
available to test filters against. While performing the PCR validations for 945 was without 
a doubt a big effort, these only represented a fraction of the fusion transcripts called. 
Similarly, they under-represent certain types of fusion calls which may have created a skew 
in the analysis. For instance, the vast majority of PCR validations were performed on fusion 
transcripts that were called with more than 4 splitting reads and there was an 
overrepresentation of fusion transcripts called by multiple algorithms. 
Similarly, the analysis of shared fusions across the same 23 samples from different 
RNA-Seq sources was extremely valuable. It highlighted how single fusion-calling 
algorithms often called fusion transcripts that were not replicated in another sequencing 
source. Some variability observed between different cell lines is currently unexplained but 
may be related to data quality from either RNA-Seq data source.  
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The difficulty in obtaining a list of fusions that comprehensive and free from false 
positives is not unique to our data-set. As mentioned in the introduction, multiple 
publications that examined RNA-Seq fusion calling algorithms agreed that there is a room 
for improvement in the sensitivity and specificity of the algorithms (Carrara et al., 2013; 
Kumar et al., 2016). It is possible that a certain degree of noise in the data is unavoidable 
with the current tools available, especially as fusion-calling relies on the detection of non-
standard read alignments that may be particularly error-prone. Notably, very few papers 
that conduct fusion-calling from RNA-Seq data report any validation rates beyond the 
validation of a selected few high-confidence hits. The recent TCGA analysis reports a 
validation rate of 63.3%, based on a subset of samples with available whole-genome 
sequencing data (Gao et al., 2018). Their method of validation differs from my method of 
benchmarking fusion transcripts based on 945 PCR validations and the overlap of shared 
fusions in 23 different samples. Nonetheless, the ~70% validation rate from our methods 
suggest that our fusion-calling and filtering approach performs relatively well. At the same 
time, this analysis shows that working with data produced by single fusion-calling 
algorithms can be extremely unreliable and caution should be used when multiple 
algorithms are not used.  
Future research may yield more insight into the nature and causes of sequencing 
and fusion-calling artefacts and could lead to advances in the sensitivity and specificity of 
computational fusion-calling algorithms and associated filters. Thus, in the future, it may 
be useful to reanalyse the RNA-Seq data for fusion calls, as any improvements in sensitivity 






3 Landscape of fusions in cancer cell lines 
Our final list of fusions comprises 10,514 unique fusion transcripts identified in 
1,011 cancer cell lines. This corresponds to 8,354 unique fusion events, i.e. fusion/cell line 
combinations, as the merged transcripts are likely to represent alternative splicing events.  
Of the 1,011 cell lines examined, 52 cell lines showed no fusions. These cell lines do 
not appear to be particularly enriched within specific tissue types (Figure 3.1A). For all other 
cell lines, the number of fusions detected per cell line ranged from 1 to 96, with a median 
of 8. Notably, there was a significant correlation between sequencing depth and number 
of fusions detected in the cell line (spearman correlation, rho = 0.15, p < 2.7*10-6) and also 
a small but significant difference in the mean of fusions found in CGHub data (median = 
 
Figure 3.1: (A) Number of cell lines examined by cancer type. (B) Mean number of fusions by RNA-Seq data 
source. (C) Number of identified fusions for each cell line, split by tissue type.  
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7.2) compared to in-house sequenced samples (median = 9.6) (t-test: t = -4.3, p < 1.8 * 10-
5). This suggests that sequencing depth can influence the number of fusions detected in a 
sample, potentially due to improved sensitivity to detect transcripts that are expressed at 
a low levels. 
3.1 Recurrence of fusions by cancer type 
First, I examined the distribution of gene fusions across different cancer types 
(Figure 3.1C). Osteosarcoma and breast cancer showed the highest prevalence, with a 
median of 21 and 18.5 fusions per cell line respectively. They are followed by stomach and 
cervical cancers that present a median of 16 fusions per cell line. At the other end of the 
spectrum, a handful of non-cancerous cell lines showed a median of 2 fusions per cell line. 
Burkitt lymphomas, kidney cancers and B-lymphoblastic leukaemias all showed a median 
of 3 fusions per cell line.  
In line with this, genomic landscape studies often find that breast cancers show one 
of the highest number of structural variation compared to other cancer types (Yang et al., 
2016). This tendency may be due to a high frequency of BRCA mutations that are 
associated with genomic instability (Nik-Zainal et al., 2016; Sedic et al., 2015). Interestingly, 
in our data we indeed find that BRCA1 mutations are significantly associated with a higher 
number of fusions in cell lines (p < 0.01, fdr = 13.4%. Controlled for tissue type and MSI 
status. Corrected for testing against 724 cancer events) (Figure 3.2).  
 
Figure 3.2: BRCA1 mutation status is significantly correlated with number of fusions detected in cell lines (p 
< 0.0086, fdr = 13.4%. (Left) number of fusions in a given cell line by BRCA1 mutational status across 952 
cell lines. (Right) Same plots broken down by tissue categories with frequent BRCA1 mutations. 
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Osteosarcomas are rarely part of multi-tumour landscape papers, and their overall 
genomic instability is therefore difficult to directly compare against other cancer types. 
Nonetheless literature suggests that osteosarcomas distinguish themselves from other 
sarcomas due to large cytogenetic alterations and chromosomal instability (Cleton-Jansen 
et al., 2005; Lorenz et al., 2015). This may therefore explain a markedly above average 
occurrence of fusion genes.  
Recently, Lorenz et al. characterised gene fusions in 11 osteosarcoma cell lines by 
RNA-Seq and whole genome sequencing (Lorenz et al., 2015). They validated 17 of 502 
putative fusion transcripts by Sanger sequencing, with a validation rate of 76%. 
Interestingly, only 7 of the validating fusions detected by RNA-Seq were supported by 
structural changes predicted by whole genome sequencing, suggesting that the remaining 
gene fusions may result from non-structural changes (e.g. transcription-induced gene 
fusions). One of their examined cell lines, MG-63, is also part of our cell line panel. 
Interestingly, while Lorenz et al.’s pipeline returns 101 fusion transcripts in this cell line, our 
own analysis lists only 13. Both pipelines recapitulate all six fusions that are predicted by 
structural variation, however no fusions overlap that are not supported by structural 
changes. While the sample size is in this case small, and the data processing approaches 
are different (their pipeline constitutes of two fusion-mapping algorithms for which they 
combined any transcripts that have more than 3 split and 8 spanning reads), this finding 
puts into question whether the fusion transcripts not resulting from structural changes are 
stably expressed in time and across different experimental conditions, and their relevance 
in an oncogenic context.  
3.1.1 Fusion recurrence in cell lines vs. patient tumours 
Next, I wanted to compare the median number of fusions found in cell lines to 
those found in patient samples. For that, I mapped the tissue types reported by Gao et al 
for their ~10,000 TCGA samples to those we assign to our cell lines. TCGA tissue types were 
split into 33 different categories with letter codes and I manually retrieved the definitions 
from their website (NCI Genomic Data Commons, 2018). On the other hand, the cell line 
panel is split into 41 cancer types. I found corresponding TCGA tissue types for 26 different 
cancer types. Cancer types that were not represented included a number of haematological 
cancers (e.g. chronic myeloid leukaemia, Hogkin’s lymphoma and lymphoblastic leukaemia) 
and some solid cancers (e.g. small cell lung cancers, Ewing’s sarcoma or neuroblastomas). 
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For 22 TCGA tissue types, I found a direct match (e.g. BRCA – breast carcinoma, OV – 
ovarian carcinoma, LUSC – squamous lung cell carcinoma). For 5 TCGA tissue types, I had 
to find approximate matches, i.e. I combined KIRC (kidney renal clear cell carcinoma) and 
KIRP (kidney renal cell papillary cell carcinoma) to match the “Kidney Carcinoma” cancer 
type, which includes cell lines matching both of the TCGA categories. I also mapped ESCA 
(Esophageal carcinoma) to both Esophageal Squamous Cell Carcinoma and Esophageal 
Adenocarcinoma in our cancer type annotation, and the SARC (sarcoma) category was 
mapped to both Osteosarcoma and Rhabdomyosarcomas cell lines. Within these 26 
mapped categories, the mean number of fusions per cell line to patient samples correlates 
significantly (R-square = 0.4 and p-value < 0.005) (Figure 3.3).  
It is important to note that the scale differs – where patient samples show a range 
of 1.4-10 mean fusions per TCGA tissue, our cell lines have a range of 5.2-27.2. This 
difference is also observed on a data-set level, as our cell lines have a mean of 8.7 (range: 
2-92) fusions per sample, while TCGA samples have a mean of 4.2 (range: 1-96) fusions per 
sample (t-test, p < 2*10-16). 
The higher range could potentially be due to cell line-specific biases. However, as 
in the previous chapter I show that higher sequencing depth is associated with a higher 
number of fusions, this may also be due to the exceptionally high sequencing depth at 
which RNA-Seq was performed for our samples. Unfortunately, the paper published by 
Gao and colleagues does not report sequencing depth of the tumours. Further, the real 
 
Figure 3.3: The mean number of fusions found in patient samples and cell lines correlate significantly. 
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sequencing depth in cell lines can be expected to be even higher than that of primary 
tissues, as there would be no contamination from non-tumour cells.  
3.1.2 Tissue type specific fusions 
Generally, I also find known oncogenic fusions in the tissue types in which they 
were previously reported in patients. For instance, BCR-ABL1 and NUP214-ABL1 fusions 
are found exclusively in blood cancers, e.g. chronic myelogenous leukaemia (n = 9), T-
lymphoblastic leukaemias (n = 2) and B-lymphoblastic leukaemia (n = 1). Similarly, EML4-
ALK fusions are only in lung adenocarcinomas (n = 2) while NPM1-ALK is found in T-cell 
non-Hodgkin’s lymphoma (n = 4). KMT2A fusions are also mainly found in blood cancer 
cell lines, e.g. KMT2A-MLLT1 (n = 1), KMT2A-MLLT3 (n = 4), KMT2A-MLLT4 (n = 1) and 
KMT2A-AFF9 (n = 1) are all in leukaemia cell lines. EWSR1-FLI1 fusions are mainly found in 
Ewing’s sarcoma cell lines (n = 22), with the exception of one fusion event in the SK-NEP-
1 cell line, which is annotated as a kidney cancer. However, a recent paper shows that this 
cell line was in fact misclassified and originates from Ewing’s sarcoma (Smith et al., 2008). 
TMPRSS2-ERG (n = 2) are also found exclusively in prostate carcinoma cell lines.  
 
Overall, the above data shows that cell lines represent tissue types reasonably well, 
at least in the relative recurrence of fusions events, as well as the tissue type-specificity of 
well-known oncogenic fusions. The latter observation in particular suggests that cancer-
related fusions are faithfully represented in cell line model systems, in terms of their 
occurrence and functionality. 
3.2 Fusion recurrence 
To understand the recurrence of fusion events, I examined the number of samples 
in which a given fusion is present. Of 7,430 fusions, I found that the vast majority (n = 7,028; 
94.6%) occur in only a single cell line. Moreover, only 1.3% of fusions are present in at least 
three cell lines or more (Figure 3.4A).  
I found the same trend for fusions detected in the 9,624 TCGA patient tumours 
(Gao et al., 2018) (Figure 3.4B). There, of 23,999 fusions, 96% (n = 23,056) are called in only 
a single tumour and 1% (n = 237) fusions are recurrent in three samples or more.  
Overall, the observation that only a small proportion of fusions are recurrent in 
both cell lines and patient fusions suggests that most fusion events are passenger events 
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that result from wide-spread structural rearrangement, and that only a minority are driver 
events selected for during oncogenic processes.  
3.3 Cancer-related fusions and recurrence 
Here, I annotated cancer-related fusions that belong into one of 3 categories: 1) 
known oncogenic fusions that have previously been causally implicated in cancer initiation 
and development, 2) fusions that have previously been observed in a subset of patient 
samples, and 3) fusions that involve known cancer-driver genes.  
Fusions that have previously been causally implicated in cancer development and 
progression are important and useful tools in my study of functional gene fusions. As their 
oncogenic function is pre-established, they serve as valuable positive controls and 
benchmarks in my downstream analyses. To annotate known oncogenic fusions, I used the 
manually and expert-curated COSMIC gene fusion database 
(https://cancer.sanger.ac.uk/cosmic/fusion). The version downloaded in May 2018 contains 
295 fusions. 
Similarly, annotating fusions that have been observed in patient samples can help 
to put fusions that are found in cancer cell lines into context, as only fusions that actually 
occur in the patient population will be relevant for therapeutic applications. It also gives 
us an indication on the proportion of fusions observed in patients that we can functionally 
assess in our cancer cell lines. For this purpose, I use the recent paper published by Gao 
and colleagues, which analysed 9,624 TCGA tumour samples and found 25,664 gene 
 
Figure 3.4: Recurrence of fusions in (A) cell lines and (B) patient samples (data from Gao et al, 2018). 
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fusions (Gao et al., 2018). Fusions are considered as “observed in patients”, if the same 
gene partners are fused in the same position (5’/3’) in any of the samples analysed there.  
Finally, fusions that involve known cancer driver genes may activate oncogenic 
functionality. For example, the fusion of a looped-coil domain to the kinase domain of ALK 
leads to constitutive kinase activation. Similarly, fusion genes involving known tumour 
suppressors can indicate knock-out of tumour-suppressor function. To annotate known 
cancer genes, I used the COSMIC Cancer Gene Census database, an expert-curated 
database that documents genes in which alterations have been causally implicated in 
cancer (https://cancer.sanger.ac.uk/census). My version of the database was downloaded 
in August 2017 and contains 609 genes. Of those, 91 were further annotated to be tumour 
suppressor genes, 116 were annotated as oncogenes and 37 genes have dual roles.  
 
Of the 8,354 fusion events, 14.2% (n = 1,184) contained a cancer gene, 1.2% (n = 
98) are known oncogenic fusions and 5.6% (n = 471) were previously detected in patients.  
Known oncogenic fusions listed in the COSMIC fusion census show a tendency to 
have a higher recurrence than the rest, with the three top-most recurrent fusion in the 
 
Figure 3.5: Recurrence of known oncogenic fusions in (A) cell lines and (B) patient samples (data from Gao 
et al, 2018). 
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TCGA data set being TMPRSS2-ERG (n = 191), FGFR3-TACC3 (n = 33) and CCDC6-RET (n = 
24). Similarly, EWSR1-FLI1 is with 24 cell lines one of the most commonly fused fusions 
(Figure 3.5A-B).  
When looking at the top 40 most recurrent fusions overall, I find that within cell 
lines, there is less of an enrichment for COSMIC fusions and fusions that involve COSMIC 
cancer genes than in the patient samples (Figure 3.6A-B). This is likely because the authors 
removed any fusion that recurs in 10 or more samples unless they were reported in 
previous TCGA studies (Gao et al., 2018). Although the number of fusions that were 
removed with this filter is not reported in the manuscript, considering that only 40 fusions 
recurred in 5-9 different samples (Figure 3.4B), it is likely to be small.  
In cell lines, two of the top three recurrent fusions, TSHZ2-SLC35A1 and NCOR2-
UBC, have been described before, but never characterised (Obholzer et al., 2015; Roberts 
et al., 2012). Some of the top recurrent fusions contain entirely uncharacterised genes (e.g. 
CTD-2334D19.1 and RP11-120D5.1) and long intergenic non-protein coding RNA (e.g. 
LINC01340). These fusions tend not to be tissue-type specific and are often not in-frame, 
which suggests that they are less likely to perform oncogenic functionality.  
It is notable that of the COSMIC fusions found in our cell lines, only a subset (28%) 
are observed in Gao’s patient samples. Well known oncogenic fusions that are not 
observed in Gao’s patient samples include EWSR1-FLI1, NPM1-ALK and BRD4-NUTM1. The 
 
Figure 3.6: Top 40 most recurrent fusions in (A) cell lines and (B) patient samples (data from Gao et al, 2018). 
Red bars indicate that the fusion is listed in the COSMIC fusion data base, dark yellow bars indicate that one 
of the genes is listed in the COSMIC cancer gene census. 
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opposite is also true, e.g. no cell lines show ETV6-NTRK3 fusions, even though those are 
among the most recurrent in the patient samples. Furthermore, a large number of well-
understood driver events also occur at only very low frequencies (e.g. KMT2A-MLLT3 only 
being in a single patient sample and PML-RARA only occurring in a single cell line). This 
likely reflects the biases of tissue selection within both data sets, e.g. there being no Ewing’s 
sarcoma samples analysed in the TCGA data set. It also supports the argument that fusions 
are exceedingly rare events, and that even with almost 10,000 samples sequenced, we are 
still far off from being able to provide a comprehensive landscape of oncogenic fusion 
transcripts. Similarly, it demonstrates that while recurrence is now commonly used as a 
predictor for the oncogenic functionality of single-nucleotide variations, with the current 
resources available, fusions recurrence alone is currently insufficient in assigning 
functionality.  
3.4 Predicted frame of fusion transcript 
GRASS (Gene Rearrangement AnalySiS) is an algorithm developed by CASM IT at 
the Wellcome Trust Sanger Institute that predicts the impact that a breakpoint has on the 
formation of potential fusion constructs based on the ensemble gene annotation (Cancer 
IT, 2018b). It is automatically run with the cgpRna pipeline and outputs a number code 
(“flag”) that annotates fusion transcripts with relevant features, including frame (e.g. in-
frame, out-of-frame, stop codon) and breakpoint region (i.e. intronic, extronic or UTR). 
In total, there are 49 different grass flags, which represents different combinations 
of frame, breakpoint region etc (e.g. an in-frame transcript where the breakpoint is in an 
intron has a code of 910, while an in-frame transcript with an exonic breakpoint has a code 
of 900). The original 49 grass flags were designed for an algorithm to predict breakpoints 
in whole genome sequencing (Cancer IT, 2018c), and are not applicable to transcriptome 
data. 26 codes appear for the fusion transcripts called by our pipeline, and these can be 
summarised in 7 categories (Table 3-1). Four categories affected coding regions: In-frame, 
ambiguous frame, out-of-frame, stop-codon introduced. A fifth category annotates any 
transcript that involves a fusion at an untranslated region (UTR). Two further categories 
annotate, where a fusion involves “something else” or “no fusion”. These two categories, 
together with the “ambiguous frame” mentioned above, are usually assigned in situations, 
where the ensemble annotation on coding regions or gene boundaries is ambiguous. 
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Unfortunately, the documentation for GRASS does not provide further detail on the specific 
circumstances in which a fusion is assigned “ambiguous frame”, “something else” or “no 
fusion”, and an attempt to reach out to the original authors of the code was unsuccessful. 
I broke down all fusion events by the 7 GRASS flag categories – where several fusion 
transcripts exist for the same fusion event, I assigned the GRASS flag with the highest value 
(i.e. the outcome that is most likely to have functional significance) to the event. I found 
that 26% of all transcripts are annotated as in-frame (Figure 3.7A). Fusions events in coding 
regions make up 50.8% of all events, another 14.6% are fused in UTR’s and the remainder 
are fusions that fall into the “something else” or “no fusion category”.  
When looking specifically at fusion events that involve COSMIC fusions, I find that 
the vast majority (91%) are in-frame events (Figure 3.7B). Only 9 fusion events do not fall 
Table 3-1: 26 GRASS codes and their descriptions. The first column (“category”) is the custom categories I 
divided the codes into to simplify interpretation of the GRASS flags. 
Category GRASS flag Type Breakpoint region Gene 
orientation 
In-frame 910 in-frame exon same 
900 in-frame intron same 
Ambiguous frame 740 ambiguous intron same 
520 ambiguous exon different 
540 ambiguous intron different 
500 ambiguous coding different 
Out-of-frame 710 out-of-frame exon same 
700 out-of-frame intron same 
Stop codon 715 stop-codon 
 
same 
UTR fusion 860 5' UTR to 5' UTR 
 
same 
820 5' UTR to coding 
 
same 
660 5' UTR to 3' UTR 
 
same 
620/600 3' UTR to coding 
 
same 
440 3' UTR to 5' UTR 
 
same 
400 3' UTR to 3' UTR 
 
same 
360 5' UTR to 5' UTR 
 
different 
580/570 5' UTR to coding 
 
different 
320 5' UTR to 3' UTR 
 
different 
560 3' UTR to coding 
 
different 
280 3' UTR to 5' UTR 
 
different 
No fusion 0 No Fusion 
 
NA 
Something else 200 intron to something else 
 
NA 
180 something else to intron 
 
NA 







into this category. A TMPRSS2-ERG fusion in a prostate carcinoma cell line shows the 
standard phenotype, where a fusion to the 5’ UTR region of androgen-regulated TMPRSS2 
drives overexpression of ERG (Tomlins et al., 2008). A further 5 of not in-frame fusions 
(PLXND1-TMCC1 in two cell lines, IL6R-ATP8B2, NFIX-MAST1, RBM14-PACS1) were 
originally identified in high-throughput landscape papers for which no functional 
validation has been performed. In fact, in a later chapter, I show evidence to argue that 
these fusions should not be included in the COSMIC fusion census (see chapter 6.3).  
Two more fusion events, FGFR3-TACC3 in RT4 and EIF3E-RSPO2 in ESO51 are both 
annotated as “ambiguous frame”. In later chapters, I show that the FGFR3-TACC3 is likely 
to be functional, as RT4 is sensitive to FGFR3 inhibitor PD173074 (see chapter 4.3.1.5). On 
the other hand, EIF3E-RSPO2 fusions have previously been found to be sensitive to 
porcupine inhibitors in colorectal cancer, and to which ESO51, an oesophageal cancer cell 
line showed no response, suggesting that this fusion event is non-functional. 
The final not in-frame fusion event is an UBE2L3-KRAS fusion detected in DU145, a 
prostate adenocarcinoma cell line that is annotated as “something else”. In fact, this fusion 
in the same cell line was already previously functionally characterised by another group 
and showed attenuated xenograft growth and cell invasion when knocked-down (Wang et 
al., 2011). I found the break-point reported by our fusion-calling pipeline to be identical to 
the one described by the authors, which suggests that in this case, the GRASS algorithm 
failed to correctly annotate the fusion.  
Thus overall known oncogenic fusions listed in the COSMIC database where 
overwhelmingly in-frame, except in the case of the 5’ UTR fusion of TMPRSS2-ERG. 
Next, in the subset of fusion events that involve a COSMIC cancer gene, I see a 
much wider range of predicted outcomes (Figure 3.7C). In general, the pattern follows that 
of all other fusion events, though with a slightly higher proportion of in-frame fusion 
events (33% vs. 26%). This proportion of in-frame events is even higher when looking at 
just the subset of COSMIC genes that are annotated as “onocogene” (41%), while in 
COSMIC genes annotated as “tumour suppressor genes” (TSG), the proportion of in-frame 
events is just 29% (Figure 3.7D-E). Although not all in-frame fusion events will necessarily 
be functional, an enrichment of them in fusion events involving cancer driver oncogenes 
could suggest positive selection. For instance, these events include two in-frame RAF1 
fusions, MBNL1-RAF1 and ATG7-RAF1, which will be discussed in chapter 6.5, where a 
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fusion most likely acts by removing an N-terminal auto-inhibitory domain of RAF1. At the 
same time, the nonetheless large proportion of COSMIC cancer gene-carrying fusion 
events that are out-of-frame or with ambiguous mapping suggests that one should be 
careful not to over-interpret the occurrence of a cancer gene in a fusion transcript. 
Notably, the subset of fusion events that are also seen in patient samples has an 
even higher proportion of in-frame fusion events (41.5%) (Figure 3.7F). Furthermore 
compared to all fusion events, an even smaller proportion of fusion events fall into the 
 
Figure 3.7: Break-down of fusion transcripts/events by GRASS flag category for (A) all fusions transcripts, (B) 
fusion events matching COSMIC fusions, (C) fusion transcripts involving COSMIC cancer genes and (D) fusion 
events that were observed in patient samples. Numbers next to bars represent the number of fusion events 
that fall into a given category. 
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“something else” (9.6% vs. 22.2%) and “no fusion” (5.5% vs. 12.3%) categories. In the future, 
it could be interesting to examine the predicted impact across the entire list of fusion 
transcripts called in patient fusions, to see whether this difference is representative of 
fusion transcripts found in patients, or due to biased subsetting. As of now, it is unclear 
whether ambiguous fusions are artefacts that arise from cell culture, differences in 
sequencing and fusion-calling techniques, or simple an effect of subsetting. Either way, for 
future iterations, a deeper understanding of the mechanisms that cause ambiguous fusion 
events could potentially help to filter out artefacts from the fusion calling pipeline.  
 
3.5 Chapter summary 
In this chapter, I attempted to briefly characterise the list of fusions obtained. I find 
that 1) median number of fusions varies by tissue type of origin in a manner that correlates 
significantly with that found in patient samples. 2) Fusions are exceedingly rare events and 
the majority of fusions (~95%) occur only in a single cell line. I also found that recurrence 
alone is a poor predictor of functionality. 3) Although known oncogenic fusions are almost 
exclusively in-frame events, in-frame events make up a relatively low proportion of fusions, 
suggesting that the proportion of true functional fusions may be low.  
Known oncogenic fusions serves as a useful positive control, although they only 
make up only around 1% of all detected fusion events. They are largely found in cell lines 
with the expected cancer type of origin (e.g. BCR-ABL1 found exclusively in blood cancers). 
This gives us confidence that our cell lines present a good model system for truly cancer-
relevant fusions.  
Thus the next challenge lies in finding a method of separating functional fusion 
events from passengers of structural rearrangements. In the up-coming chapters, I will 
describe two analysis that are aimed to identify novel functionality and therapeutic 
potential for previously uncharacterised fusions. Firstly, I use the high-throughput drug-
screening data of > 400 drug compounds to examine the use of fusions as biomarkers of 
drug response. Secondly, I developed a system to leverage CRISPR/Cas9 whole genome 








4 Identification of fusion genes as biomarkers for drug response 
Having identified 8,388 gene fusions in our panel of 1,011 cancer cell lines, my next 
aim was to identify the potential of using fusion genes as biomarkers of drug response. 
Fusion genes are already playing a major role in helping to provide the best treatment to 
given patients, e.g. patient with BCR-ABL1 have the best treatment outcomes when treated 
with ABL1 inhibitors and EML4-ALK fusions are best treated with ALK inhibitors. Novel 
fusion-drug associations may lead us to discover more therapeutic opportunities. At the 
same time, a fusion-drug association can indicate functionality in novel fusions.  
The panel of 1,011 cancer cell lines has previously undergone extensive high-
throughput drug screening across hundreds of drug compounds (Garnett et al., 2012; Iorio 
et al., 2016). I implemented this with an ANOVA framework and considered well-
understood cancer functional events (CFEs) as confounding factors.  
Finally, I ran three distinct analyses: 1) An ANOVA including only CFEs that would 
provide a basis for 2) a fusion-level and 3) a gene-level ANOVA.  
4.1 Set-up and data-sets 
4.1.1 ANOVA model 
I tested high-throughput drug sensitivity measurements for 409 drug screening 
data sets against any gene fusion that occurred in 2 or more cell lines (n = 412) under the 
following ANOVA model: 
It was tested for all combinations of a drug screening data set (𝐼𝐶50𝐷) and relevant 
gene fusions (𝐹𝑢𝑠𝑖𝑜𝑛𝐹), for a total of 168,508 combinations.  
The 42 tissue types and MSI status were used as covariates in the model, as a large 
amount of variance from drug response can be attributed to these features6,7. Further, I 
implemented a co-variate (𝐶𝐸𝐷), which controls for other non-fusion genetic alterations 
that have a significant association with drug response (see section 4.2). 
4.1.2 409 drug IDs 
For this analysis, I utilised 409 drug screening data sets, each with a distinct drug 
ID. These data sets included data for 379 unique chemical compounds, of which some were 
𝐼𝐶50𝐷 ~ 𝑇𝑖𝑠𝑠𝑢𝑒 𝑇𝑦𝑝𝑒 + 𝑀𝑆𝐼 𝑆𝑡𝑎𝑡𝑢𝑠 + 𝐶𝐸𝐷 + 𝐹𝑢𝑠𝑖𝑜𝑛𝐹 
Equation 1:  Fusion ANOVA model 
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screened multiple times. Since duplicated measurements were taken several years apart 
on different screening formats (e.g. in 384-well plates vs. 1,536-well plates), I decided to 
keep them separate for my analyses. To maximise cell line coverage, multiple drug 
screening data sets for the same drug compounds were included where they covered 
different sets of cell lines. For the sake of simplicity, unique drug screening data sets are 
referred to “drug IDs” within this thesis.   
All drug IDs were screened as part of the GDSC1000 high-throughput drug 
screening pipeline at the Wellcome Sanger Institute (Cancerrxgene.org; Garnett et al., 2012; 
Iorio et al., 2016). They span 279 unique drug targets and are categorised into 24 effector 
pathways. A subset of 77 compounds are FDA-approved, while further subsets are 
currently in clinical trials, or still experimental (Figure 4.1; Supplementary Table 4). The 409 
drug IDs had a median coverage of 805 cell lines (range: 42-947).  
4.2 Cancer Functional Events ANOVA  
Another covariate included in the model is CFED. This denotes the occurrence of 
other cancer functional events (CFEs) that significantly correlate with sensitivity to a given 
drug. With this approach, I aim to minimise potential false positives associations that can 
 
Figure 4.1: Overview of 379 drug compounds that make up the drug-screening data. (Top) The total number 
of cell lines tested for each of the 379 drug compounds, with black bar colour indicating FDA-approved drugs. 
(Bottom) Tree-map of 24 major effector pathways that are targeted by the panel of drug compounds. Size of 
the field is proportional to number of drugs with a given target. 
87 
 
occur when gene fusions by chance co-occur with CFEs that confer sensitivity to a given 
drug.  
To define the set of known associations between CFEs and drugs, I ran a separate 
ANOVA under the model described in the following equation across the same 409 drugs 
(𝐼𝐶50𝐷) against a set of 717 recurrent cancer functional events (𝐶𝐹𝐸𝐷):  
The ANOVA model was run across all combinations of drugs and CFEs. I adjusted 
p-values for significance of the CFE using the Benjamini-Hochberg method to calculate a 
False Discovery Rate (FDR) (Benjamini and Hochberg, 1995). 
4.2.1 Cancer Functional Events 
CFEs were defined on our cell line panel by Iorio et al. (Iorio et al., 2016), by 
overlaying recurrent gene alterations found in a large set of patient samples with those 
found in our cell lines. The binary annotation was downloaded from 
cancerrxgene.org/gdsc1000. Methylation data was filtered to include only those segments 
that were annotated to contain a known cancer driver gene compared against the Cancer 
Gene Census. The final input data includes mutation status for 281 genes, copy number 
alteration for 424 segments and methylation status for 12 segments.  
𝐼𝐶50𝐷~ 𝑇𝑖𝑠𝑠𝑢𝑒 𝑇𝑦𝑝𝑒 + 𝑀𝑆𝐼 𝑆𝑡𝑎𝑡𝑢𝑠 + 𝐶𝐹𝐸𝐷 
Equation 2: Model for CFE ANOVA 
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4.2.2 Incorporating significant results in the gene fusion analysis 
As in the paper published by Iorio et al. (2016), I considered any result with an FDR 
< 25% and both positive and negative Glass Delta > 1 as large-effect association. The Glass 
Delta is a measure of effect size and is calculated by dividing the difference in mean log 
IC50 of the two groups by the standard deviation of one of the groups (hence each 
association has two Glass Delta’s, one genetic-alteration-positive and one negative). A 
Glass Delta of > 1 shows that the difference in mean log IC50s is larger than the standard 
deviation. In total, 101 combinations of CFE and drug sensitivity passed these criteria 
(Supplementary Table 5). For the gene fusion ANOVA, I implemented for any drug involved 
in a significant association, the status of associated CFEs in cell lines as a covariate as shown 
in Equation 1. 
 
Figure 4.2: Volcano plot of all significant results from the CFE ANOVA. Results that do not meet our criteria 
for FDR and Glass Delta are represented in grey. Effect size denotes the minimum Glass Delta for a given 
association. Size of circle is relative to number of cell lines with a given CFE.  
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4.2.3 Characterisation of significant findings 
Our results show 62 resistant and 39 sensitising associations. Results with the 
highest p-values include prominent well-known associations. TP53-mutations, for example, 
are associated with resistance to Nutlin-3a, a compound that induces tumour suppression 
by inhibiting the MDM2-interaction with p53 (Vassilev et al., 2004). Similarly, BRAF-
mutations typically lead to enhanced kinase activity and activation of the down-stream 
MEK pathway, and are associated with sensitivity to several BRAF-inhibitors, including 
Dabrafenib and PLX-4720 (Hauschild et al., 2012; Kopetz et al., 2010). 
The results recapitulate 88% of those shown in Iorio et al. (2016). Small differences 
are to be expected, as an updated annotation of cancer tissue types was used in my analysis 
that annotated over 300 cell lines that were previously unannotated by Iorio et al.  
Novel associations not reported in Iorio et al. (2016) include 16 sensitivities and 40 
resistances. Of the sensitivities, 4 represented new drugs targeting the same targets as 
known associations (e.g. BRAF-mutation associating with MEK/ERK-inhibitors and an 
ERBB2-amplification with an EGFR-inhibitor).  
 
Figure 4.3: Known associations between CFEs and drug compounds. (A) TP53-mutation and MDM2 inhibition 
(B) BRAF-mutation and BRAF-inhibition (C) Amplification of ERBB2 and EGFR/ERBB2-inhibition. 
90 
 
One interesting novel finding is the association of EPH receptor A2 (EPHA2) with 
sensitivity to a PI3K-alpha inhibitor, GNE-317 (Figure 4.4A-B). EPHA2 is suggested to act 
with PI3K in tumour vascularisation (Wang et al., 2016). Further, EPHA2-signalling in a 
PI3K/AKT dependent manner can be upregulated as a potential mechanism to evade BRAF-
inhibition in melanoma (Paraiso et al., 2015). In our analysis, EPHA2-mutations are found 
in a variety of cancer types of origin, suggesting that EPHA2-altered tumours may benefit 
from PI3K-pathway inhibitors across several cancer types. Although not all significant, 
when ranking all associations involving the EPHA2-mutation by FDR, there is a significant 
enrichment of inhibitors targeting PI3K or AKT (ROC AUC: 0.654, p = 0.0075 with 10,000 
permutations; Figure 4.4C).  
4.2.4 Using significant CFEs as covariate in the fusion ANOVA 
Implementing the CFEs as covariates, where the associations fit the previously 
described filters (FDR < 25% and Glass Delta’s > 1), I assigned co-variates to 73 drug IDs. 
  
Figure 4.4: EPHA2-mutational status is significantly associated with sensitivity to PI3K-alpha inhibitor GNE-317. 
LogIC50 by mutation status (A) by tissue and (B) across all cell lines. (C) When ranked by FDR, top drug IDs tested 
for association with EPHA2-mutational status are enriched for drugs targeting either PI3K or AKT. 
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After running the fusion ANOVA model (Equation 1) with and without the covariate 𝐶𝐸𝐷, 
the significance of the majority of associations is largely unchanged (Figure 4.5A), although 
eleven associations are significant at FDR < 25% are returned as not-significant when 
including the covariate.  
Covariates that cause a shift in significance fall into one of two patterns. In some 
cases, fused cell lines are a subset of those with the covariate. For example, in the 
association of the NKD1-ADCY7 fusion with BRAF-inhibitor Dabrafenib, the cell line that 
  
FEATURE Drug Name Drug Target CFE covariate(s) FDR Uncorr. 
FDR 







BIRC5 HGF-mut, RPGR-mut 73.7 3.8 
KMT2A-
MLLT3 
Sorafenib PDGFR, KIT, 
VEGFR 
U2AF1_mut 62.1 21.0 
LRBA-
SH3D19 
Nutlin-3a (-) MDM2 TP53-mut 45.1 6.7 
NKD1-
ADCY7 
Dabrafenib BRAF BRAF-mut 40.9 9.5 
NKD1-
ADCY7 
SCH772984 ERK1, ERK2 BRAF-mut 43.2 20.0 
NPM1-ALK Alisertib AURKA loss:cnaPANCAN425 38.4 18.5 
RCC1-SNX5 Idelalisib PI3Kdelta MYC-mut 33.7 21.0 





Dabrafenib BRAF BRAF-mut 91.9 13.0 
ZAK-
RAPGEF4 
AR-42 HDAC1 TBX3-mut, CCND1-mut 78.9 14.5 
Figure 4.5: (A) False discovery rates of fusion-drug associations with and without including the CFE covariate. 
(B) Dabrafenib sensitivity by NKD1-ADCY7 fusion (C) Nutlin-3a sensitivity by LRBA-SH3D19 fusion for 




shows the highest sensitivity also harbours a BRAF-mutation, which likely drives the 
association (Figure 4.5C).  
In other cases, a covariate may have a large effect on the variance of a drug 
response. After having mean-centred for the covariate, the variance for the remaining cell 
lines could be greatly reduced. For example in the case of LRBA-SH3D19 and Nutlin-3a, 
TP53-mutated cell lines are significantly less sensitive than non-mutated cell lines. As the 
two LRBA-SH3D19 fused cell lines are non-TP53-mutated, their drug sensitivity is expected 
to be low (Figure 4.5B). A further two associations that became more significant by 
including the CFE covariate also fall into this latter category. 
The number of cases affected by including the CFE covariate is low. Nonetheless, 
after manual inspection of all 11 cases, I concluded that the quality of the results is 
improved by its inclusion by removing false-positives such as the ones outlined above.  
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4.3 Fusion ANOVA 
To run the fusion ANOVA, I use Equation 1 to query the associations between 409 
drug IDs and 431 fusions. As before, I adjust p-values for multiple-hypothesis correction 
by calculating an FDR. From 176,279 potential combinations, 324 had a FDR < 25%, of 
which 227 were large-effect associations that also had Glass Deltas of > 1 (Supplementary 
Table 6). Of those, 172 were sensitising and 55 resistant associations. 
 
Figure 4.6: Volcano plot of all significant results from the fusion ANOVA. Results that do not meet our 
criteria for FDR and Glass Delta are represented in grey. Effect size denotes the minimum Glass Delta for a 
given association. Size of circle is relative to number of cell lines with a given fusion. 
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4.3.1 Known fusion-drug associations 
Known fusion-drug associations make up a large portion of large-effect 
associations. Below follows a brief review of the most commonly studied fusions and their 
representation in my analysis. 
4.3.1.1 ALK fusions 
ALK is a tyrosine receptor kinase that is commonly found altered in many 
haematological and solid cancers. While sometimes mutated, e.g. in a subset of 
neuroblastomas (Chen et al., 2008), more often the tyrosine kinase domain of ALK is fused 
to the C’-terminus of another protein. Partner genes in the ALK fusion encourage 
dimerization in absence of a ligand and therefore lead to activation of the ALK kinase 
domain (Mossé et al., 2009). In normal development, ALK is specifically expressed in the 
neural system, mainly in neonates (Iwahara et al., 1997), with a suggested role in neuronal 
differentiation. In cancer, the ALK fusions encourage cell cycle progression, survival, cell 
shaping and has transforming ability.  
In anaplastic lymphomas and some T-cell non-Hodgkin’s lymphomas, ALK is 
commonly fused to nucleophosmin 1 (NPM1), which contributes a nuclear localisation 
domain to the chimeric protein. ALK fusions are also commonly found fused in 3-6% of 
non-small-cell lung cancer with echinoderm microtubule associated protein like 4 (EML4) 
(Koivunen et al., 2008; Perner et al., 2008).  
Small molecule inhibitors targeting the tyrosine kinase of ALK show great response 
rates in in vivo experiments, and clinical trials for several ALK-inhibitors are underway 
(Mossé et al., 2009).  
My analysis recapitulates these previous findings robustly. The 5 T-cell non-
Hodgkin’s lymphoma cell lines that carrying an NPM1-ALK fusion, and the two lung 
adenocarcinoma cell lines with an EML4-ALK fusion, significantly associate with sensitivity 
to numerous ALK inhibitors, including crizotinib, alectinib and XMD14-99 (all at p < 0.001 
and FDR < 0.01%; Figure 4.7). 
4.3.1.2 ABL1 fusions 
The fusion between BCR ABL has been known since the 1960s with the discovery 
of the Philadelphia chromosome, a minute chromosome resulting from a translocation of 
chromosomes 9 and 22 t(9;22)(q34;q11), in chronic myeloid leukaemia patients (Braekeleer 
et al., 2011). The fused, C-terminal domain of ABL1 contains the SH1 tyrosine kinase 
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domain as well as a nuclear localisation domain (Colicelli, 2010). The N-terminal partner 
gene, BCR, facilitates dimerization through a coiled-coil domain and thus leads to 
constitutive activation of the tyrosine kinase of ABL1 through reciprocal phosphorylation 
(McWhirter et al., 1993).  
The BCR-ABL1 fusion is a hallmark of chronic myeloid leukaemia, but is also found 
in other haematological malignancies, such as a small subset of B-lymphoblastic 
leukaemias. A rare subtype in about 5% of T-lymphoblastic leukaemias carries a variation 
on the fusion (Braekeleer et al., 2011). There, ABL1 is fused to the N-terminal NUP214, 
resulting in the NUP214-ABL1 fusion. Similar to BCR, NUP214 carries a coiled-coil domain 
which would encourage dimerization of the fusion protein.  
Small molecule inhibitors targeting the ATP-binding domain of ABL1 show great 
efficacy in patients and to date, three ABL1 inhibitors, imatinib, nilotinib and dasatinib, 
have been FDA-approved for clinical use for the treatment of BCR-ABL1-fused cancers 
(McDermott, 2015). Pre-clinical studies suggest that NUP214-ABL1-fused cancers would 
similarly benefit from treatment with ABL1-inhibitors (Deenik et al., 2009; Quintás-Cardama 
et al., 2008).  
Again, our data recapitulates previous literature. The 11 cell lines, 9 of which are 
chronic myeloid leukaemias, that were identified to carry the BCR-ABL1 gene fusion are 
also significantly sensitive to multiple ABL-inhibitors including imatinib, ponatinib and 
dasatinib (all at p < 0.001 and FDR < 0.01%; Figure 4.7). Moreover, the same drug 
compounds are significantly associated to the same thresholds with the NUP214-ABL1 
fusion detected in two T-lymphoblastic leukaemia cell lines, despite the small sample size 
(Figure 4.7). 
4.3.1.3 EWSR1-FLI1 fusions 
The fusion of Ewing’s sarcoma breakpoint region 1 (EWSR1/EWS) to Friend 
leukaemia virus integration site 1 (FLI1) is a characteristic fusion of Ewing’s sarcoma, a 
childhood soft tissue tumour with poor prognosis (Janknecht, 2005). In this fusion, the C-
terminal DNA-binding domain of FLI1 is fused to the N-terminal transcriptional activation 
domain of EWSR1, which constitutively activates a transcriptional program that leads to 
transforming and tumorigenic activity in vivo and in vitro (Janknecht, 2005). While the 
EWSR1-FLI1 fusion is prevalent in about 80% of Ewing’s sarcomas, alternative fusions of 
EWSR1 to other members of the ETS gene family to which FLI1 belongs are also observed, 
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and found to activate transcriptional activity through the conserved DNA-binding domain 
in a similar fashion (Janknecht, 2005).  
Previous high-throughput drug screens from our lab showed that cell lines carrying 
a EWSR1-FLI1 fusion are highly sensitive to inhibition of poly(ADP-ribose) polymerases 
(PARP), a component of the DNA-damage response pathway to repair single-strand DNA 
breaks (Garnett et al., 2012). Although in vivo experiments show efficacy of the drug in 
mouse xenografts (Brenner et al., 2012), clinical trials testing PARP inhibitors in Ewing’s 
sarcoma patients have so far failed to show efficacy (Choy et al., 2013). Since then, follow-
up studies showed that using the DNA alkylating agent temozolomide in combination with 
PARP-inhibitors may increase PARP-trapping and enhance cytotoxicity in vitro and in vivo 
(Gill et al., 2015; Murai et al., 2014; Stewart et al., 2014). Several clinical trials are currently 
underway to test the combination in Ewing’s sarcoma patients (NCT02044120, 
NCT01858168 and NCT02116777). 
 
Figure 4.7: Known associations of fusions and drugs are recapitulated well, such as in the cases of (A) 
NUP214-ABL1 and (B) BCR-ABL1 with ABL1 inhibitors nilotinib and imatinib, and (C) NPM1-ALK and (D) 
EML4-ALK with ALK-inhibitors crizotinib and alectinib. Similarly, associations with small sample sizes are 
also identified, e.g. for CRTC1-MAML2 and cetuximab and FGFR3-TACC3 and PD173074 (latter only showing 
bladder carcinoma cell lines). 
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Our cell line panel exhibit 24 detected cases of EWSR1-FLI1 and 4 cases of EWSR1-
ERG fusions. Of those, the majority is found in Ewing’s sarcoma cell lines, however I observe 
isolated cases with the same conserved breakpoints also in SK-NEP-1, a kidney carcinoma 
(EWSR1-FLI1), TASK1, a cell line of peripheral nervous system origin (EWSR1-FLI1) and EB-
3, a Burkitt’s lymphoma (EWSR1-ERG) cell line. SK-NEP-1 and TASK1 were unfortunately 
not screened as part of the high-throughput screening process, but EB-3 showed no 
enhanced sensitivity to PARP-inhibition (Figure 4.8A), which suggests that the sensitivity 
may be specific to Ewing’s sarcomas carrying the fusion.  
It is worth noting that unlike in the original screen, where EWSR1-FLI1 and PARP-
inhibition showed a highly significant association, I do not reproduce the statistical 
significance in my analysis. This is due to a slight change in the tissue type input into the 
model. Ewing’s sarcoma cell lines in the previous study were part of a set of 300 cell lines 
whose tissue type was uncurated. For my analysis, I compiled an updated annotation that 
extended the number of tissue types from 28 to 42, and created a tissue type specifically 
for Ewing’s sarcoma. Using this input, although a t-test of EWSR1-FLI1 with Olaparib 
outputs a highly significant result (F = 37.8, p < 0.001), the ANOVA model attributes most 
of the variance due to tissue type (Tissue type: F = 13.1, p < 0.001; EWSR1-FLI1: F = 0.08, p 
= 0.77) (Figure 4.8B). 
 
Figure 4.8: (A) The Burkitt’s lymphoma cell line EB-3 does not respond to PARP-inhibition despite harbouring 
the EWSR1-ERG fusion. (B) The association of EWSR1-FLI1 fusion status is significant in a t-test (F = 37.8, p < 
0.001), but not when tested in our ANOVA model that uses tissue type as a covariate (Tissue type: F = 13.1, p 




Two of our cell lines also carry a CRTC1-MAML2 fusion, which has a known 
transforming activity and was originally described in mucoepidermoid carcinomas (Enlund 
et al., 2004). The fusion brings together a CREB-binding domain in CRTC1 and a 
transcriptional activation domain of MAML2 and activates constitutive transcription of 
CREB downstream genes (Wu et al., 2005). One of the downstream targets of CREB-
transcription is amphiregulin (AREG), a ligand for EGFR. Overexpression therefore leads to 
constitutive EGFR activation, and thus aberrant growth and survival signalling with 
decreased apoptosis and increased proliferation and metastasis signalling (Chen et al., 
2014). 
As has been demonstrated in previous studies (Chen et al., 2014), both cell lines 
with CRTC1-MAML2 fusions show significant sensitivity to EGFR-inhibition in my analysis 
(Figure 4.7). 
4.3.1.5 FGFR3-TACC3 
We call three fusions that involve an N-terminal part of FGF receptor 3 (FGF). All 
three are bladder carcinomas; SW780 harbours a fusion of FGFR3 to BAI1 associated 
protein 2 like 1 (BAIAP2L1), while in RT-112 and RT4 FGFR3 is fused to transforming acidic 
coiled-coil containing protein 3 (TACC3). The fusions in the exact same three cell lines were 
previously characterised to demonstrate FGFR3 fusions as an alternate means of activating 
FGFR3 in bladder cancers, where overexpression and activating mutations are common 
(Williams et al., 2013). Since then, evidence for FGFR3-TACC3 fusions have since been 
found in patient populations (Nassar et al., 2018) as well as other cancer types, such as 
glioblastoma and head and neck carcinomas (Singh et al., 2012).  
Our analysis shows a highly significant association of between the FGFR3-TACC3 
fusion and sensitivity to the FGFR3-inhibitor PD173074, which is in line with results from 
previous studies (Singh et al., 2012). Aside from the FGFR3-TACC3-fused cell lines, SW780 
shows the third-highest sensitivity to PD173074 (Figure 4.7).  
 
In my analysis, six fusions (NPM1-ALK, EML4-ALK, BCR-ABL1, NUP214-ABL1, 
CRTC1-MAML2 and FGFR3-TACC3) involving the known fusion oncogenes described 
above represent 67 of the 227 significant large-effect associations (30%). This is largely 
due to the large number of ALK (n = 8) and ABL-inhibitors (n = 10) screened in our high-
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throughput screening set and the variations of partner genes with the same central fusion 
oncogene. The results therefore demonstrate that my analysis is able to identify clinically 
relevant fusion-drug associations.  
4.3.2 Novel associations 
Disregarding the 67 associations known a priori, I find a strongly depleted 
landscape of significant interactions. Further removing from considerations fusions that 
have never been identified in a patient sample, those that are not in-frame, excluded 
fusions that are unlikely to be causative and those that are unlikely to be relevant for clinical 
use. This retains 35 novel associations, of which 24 are sensitising and 11 are resistant 
(Figure 4.9). The remaining fusion-drug associations are listed in (Table 4-1).  
Upon closer inspection, I find that 7 fusion-drug associations show potentially 
confounding factors. For instance, the two cell lines, MFM-223 and KATOIII, which carry a 
FGFR2-ATE also carry duplication of FGFR2 (amplification > 14) (Figure 4.9B) (Forbes et al., 
  
Figure 4.9: (A) Volcano plot of significant fusion ANOVA interactions after annotating known (grey), not-in-
frame (blue) and non-patient fusions (beige). Often, associations have confounding factors, as in the case of 
(B) FGFR2-ATE with FGFR2-inhibitor and (C) PEX1-CDK6 with ABL inhibitor.  
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2017), which is more likely to explain their sensitivity to FGFR2-inhibitors. In the association 
of PEX1-CDK6 and the ABL-inhibitor nilotinib, one of the two cell lines with the fusion, ALL-
SIL, carries a NUP214-ABL1 fusion (Figure 4.9C). In a similar vein, the association of STK24-
DOCK9 and EGFR inhibitors Gefitinib and Afatinib is confounded by an EGFR-amplification 
in 1 of the two cell lines. One of the cell lines harbouring the ARID1A-RPS6KA1 fusion 
sensitive to various MET inhibitors also carries a MET amplification. 
KMT2A-MLLT3 
Of the remaining novel associations, those involving KMT2A-MLLT3 were significant 
across four distinct drugs, which target a range of tyrosine kinases, but all share VEGFR 
inhibition (Figure 4.10). Translocations of KMT2A, also known as MLL, with over 60 different 
fusion partners occur in about 5%-10% of acute leukaemias (Meyer et al., 2009). KMT2A-
MLLT3 (also known as MLL-AF9) fusions make up about 8.5% of MLL fusions (Meyer et al., 
2009). Unlike most tumours with KMT2A-translocations that are associated with aggressive 
 
Figure 4.10: Significant associations between the KMT2A-MLLT3 fusion and various VEGFR-inhibitors. 
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disease and poor prognosis, tumours with KMT2A-MLLT3 fusion have a favourable 
outcome (Grimwade et al., 2010).  
Upon closer inspection of the associations of KMT2A-MLLT3, it appears that of the 
4 acute myeloid leukaemia cell lines harbouring the fusion, only two are highly sensitive 
across all drugs: MONO-MAC-6 and MOLM-13. In the association of KMT2A-MLLT3 and 
JAK3-inhibitor WHI-P97, the two most sensitive cell lines are MOLM-13 and THP-1.  
Vascular endothelial growth factor receptors (VEGFR) are typically targeted for its 
role in endothelial cell proliferation and angiogenesis (Ferrara et al., 2003). Although VEGFR 
expression has shown to be a factor in leukaemia development (Song et al., 2012), my 
literature search did not reveal any known associations of KMT2A activity with VEGFR. Since 
only a subset of KMT2A-MLLT3 carrying fusions exhibit heightened sensitivity, the 
sensitivity may present itself due to other shared factors within the cell lines that may be 
unrelated to the KMT2A-MLLT3 fusion.  
Upon further inspection, I found no significant upregulation of the VEGF receptor 
fms related tyrosine kinase 1 (FLT1), fms related tyrosine kinase 1 (FLT4) and kinase insert 
domain receptor (KDR) in any of the 4 fusion-containing cell lines using voom-normalised 
gene expression data. I then looked for any fusions or CFEs which coincide only the VEGFRi 
responsive cell lines, but not of the non-responsive cell lines, but found none matching the 
criteria. Finally, I analysed the gene essentiality profiles derived from CRISPR/Cas9 data3, 
but found that none of the guides targeting the three VEGFR genes were significantly 
depleted in MOLM-13 (no data available for MONO-MAC-6). The drug compounds may 
still lead to loss of viability by inhibiting several targets at once, however this finding 
strongly suggests that the sensitivity to VEGFRi does not result from the inhibition of an 
individual VEGFR protein. 
Thus, I conclude that the interest of the association is inconclusive and that further 
research is needed to determine whether sensitivity to VEGFR inhibitors is truly enriched 
in a subset of KMT2A-MLLT3 fused cell lines, or is caused by other non-determined 
confounding factors.  
                                                 
3 I derived the binarised gene essentiality data using BAGELR from CRISPR/Cas9 whole 
genome drop-out screening data from Wang et al (Wang et al., 2017). Further information on data 
processing to follow in chapter 0. 
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On another topic relating to KMT2A-MLLT3, previous studies show that DOT1 like 
histone lysine methyltransferase (DOT1L) is required in the tumorigenicity and cell 
proliferation of KMT2A-MLLT3 fusions in vivo and in vitro, and sensitive to DOT1L inhibition 
using EPZ-5676 in mice and cell lines (AML cell lines NOMO-1 and MOLM-13) (Daigle et 
al., 2013; Nguyen et al., 2011). In contrast, my analysis finds no statistically significant 
association of KMT2A-MLLT3 and any of the DOT1L inhibitors (EPZ5676, SGC0946 and 
EPZ004777), as most of the variation is attributed to the differential sensitivity of tissue 
types. As our screen also screens NOMO-1 and MOLM-13 for this interaction, a possible 
explanation to these opposing results may be related to differences in screen design. In 
particular, previous studies exposed cell lines to EPZ5676 for 14 days, while our high-
throughput screen uses a 72-hour assay (Daigle et al., 2013).   
 
Once interactions with confounding factors and those involving KMT2A-MLLT3 are 
removed, 12 sensitising and 11 resistant hits remain. The fusions involved in the remaining 
associations have so far not been characterised and the respective partnering genes are 
largely unknown. At the same time, no particular patterns emerge in the drugs that they 
associate with, making calls of their clinical importance difficult at this stage.  
With the information to be published into the public domain, with improvements 
in the knowledge of the role of the fusions proteins or the respective cancer pathways, the 
importance of the associations may be revealed at a future time point. As it stands so far, 
although our fusion ANOVA recapitulates prominent known fusion-drug sensitivities very 





Table 4-1: Novel associations in fusion ANOVA. Conf: confounded. Descr: described in text. 
Notes FEATURE DRUG_NAME DRUG_TARGET CL # FDR Type 
 
AFAP1--ABLIM2 GSK269962A ROCK1, ROCK2 4 9.5 resistant 
 
AFAP1--ABLIM2 Vorinostat HDAC inhibitor Class I, IIa, IIb, IV 3 11.9 resistant 
 
LDLR--SMARCA4 ZG-10 JNK1 2 13.2 resistant 
 
PLXND1--TMCC1 Epirubicin Anthracycline 2 13.2 resistant 
 
PLXND1--TMCC1 Luminespib HSP90 2 21.9 resistant 
 
RCOR1--TECPR2 Tanespimycin HSP90 2 16 resistant 
 
SLC12A7--TERT BX796 TBK1, PDK1 (PDPK1), IKK, 
AURKB, AURKC 
2 24.7 resistant 
 
SWAP70--WEE1 Piperlongumine Induces reactive oxygen species 2 4.8 resistant 
 
SWAP70--WEE1 PFI-1 BRD4 2 21.7 resistant 
 
UBQLN1--GKAP1 Bortezomib Proteasome 2 21.9 resistant 
 
UBQLN1--GKAP1 Sabutoclax BCL2,  BCL-XL,  BFL1, MCL1 2 22 resistant 
(Conf.) ARID1A--RPS6KA1 Savolitinib MET 2 0.1 sensitive 
(Conf.) ARID1A--RPS6KA1 Cabozantinib VEGFR, MET, RET, KIT, FLT1, 
FLT3, FLT4, TIE2,AXL 
2 1.8 sensitive 
 
ARID1A--RPS6KA1 Bicalutamide AR 2 3.7 sensitive 
 
ARID1A--RPS6KA1 BMS-345541 IKK1, IKK2 2 7 sensitive 
 
ARID1A--RPS6KA1 WIKI4 TNKS1, TNKS2 2 11.9 sensitive 
(Conf.) FGFR2--ATE1 PD173074 FGFR1, FGFR3 3 4 sensitive 
(Descr) KMT2A--MLLT3 Linifanib VEGFR1, VEGFR2, VEGFR3, 
CSF1R, FLT3, KIT 
4 0 sensitive 
(Descr) KMT2A--MLLT3 Cabozantinib VEGFR, MET, RET, KIT, FLT1, 
FLT3, FLT4, TIE2,AXL 
4 4 sensitive 
(Descr) KMT2A--MLLT3 Sorafenib PDGFR, KIT, VEGFR, RAF 3 5.1 sensitive 
(Descr) KMT2A--MLLT3 Foretinib MET, KDR, TIE2, VEGFR3/FLT4, 
RON, PDGFR, FGFR1, EGFR 
3 6.5 sensitive 
(Descr) KMT2A--MLLT3 WHI-P97 JAK3 4 14.1 sensitive 
 
NKD1--ADCY7 KIN001-270 CDK9 3 12.2 sensitive 
 
NPLOC4--PDE6G Cediranib VEGFR, FLT1, FLT2, FLT3, FLT4, 
KIT, PDGFRB 
2 5.1 sensitive 
 
NPLOC4--PDE6G Ibrutinib BTK 2 13.2 sensitive 
 
NPLOC4--PDE6G BIX02189 MEK5, ERK5 2 15.1 sensitive 
(Conf.) PEX1--CDK6 Nilotinib ABL 2 0 sensitive 
(Conf.) PEX1--CDK6 Nilotinib ABL 2 6.5 sensitive 
 
QKI—PACRG RO-3306 CDK1 3 22.7 sensitive 
 
SLC12A7--TERT IOX2 EGLN1 2 4.9 sensitive 
(Conf.) STK24--DOCK9 Gefitinib EGFR 2 21.9 sensitive 
(Conf.) STK24--DOCK9 Afatinib ERBB2, EGFR 2 24.6 sensitive 
 
VPS53--GLOD4 Motesanib VEGFR, RET, KIT, PDGFR 2 0.3 sensitive 
 
VPS53--GLOD4 Axitinib PDGFR, KIT, VEGFR 2 0.3 sensitive 
 




4.4 Gene-centric ANOVA 
Next, I implemented a gene-centric version of the ANOVA model. Here, I consider 
any gene which is fused at the same position (5’ or 3’) multiple times across the cell line 
panel. I am specifically looking for cases where oncogenes can be fused to multiple partner 
genes which can all lead to the same constitutive activation of the oncogene (e.g. through 
removal of auto-inhibitory domains or the fusion of any dimerization domain). An example 
of that would be how constitutive activation of ABL1 can be triggered by either a BCR-
ABL1 or a NUP214-ABL1 fusion, or an activation of EWSR1 by either EWSR1-FLI1 or EWSR1-
ERG as described above (section 4.3.1). 
To achieve this, I use a similar model as for the fusion ANOVA, where the final term 
is substituted to 𝐺𝑒𝑛𝑒𝐺 : 
4.4.1 Input data 
Note, that I take into account the direction of the gene fusion. For example, I find 
9 different fusion constructs involving the ALK gene (brackets represent number of cell 
lines): ALK-AC006486.9 (1), ALK-ERF (1), NPM1-ALK (5), AC016907.3-ALK (6), TERT-ALK (1), 
ALK-AC016907.3 (1), EML4-ALK (2), ALK-PTPN3 (1) and TFG-ALK (1).  
Thus, the model would run two variations of ALK: 1) 3’-ALK would contain NPM1-
ALK, AC016907.3-ALK, TERT-ALK, EML4-ALK and TFG-ALK, and 2) 5’-ALK would contain the 
remaining constructs.  
In total, I used data for 941 genes, of which 98 are tested in both 5’ and 3’ positions, 
for a total of 1,039 features to be tested against 409 drug IDs. There were two criteria for 
inclusion in the gene-centric ANOVA: 1) the gene must be fused in at least two distinct 
fusion constructs and 2) fusions containing the gene must be found in at least 3 different 
cell lines.  
The majority of gene inputs consist of 3 distinct fusions and are present in 3 
different cell lines (Figure 4.11). Genes represented in more than 4 distinct fusions 
disproportionally tend to be fused at the 5’. The three genes involved in the highest 
number of distinct fusions transcripts are Pvt1 oncogene (PVT1), regulator of chromosome 
𝐼𝐶50𝐷 ~ 𝑇𝑖𝑠𝑠𝑢𝑒 𝑇𝑦𝑝𝑒 + 𝑀𝑆𝐼 𝑆𝑡𝑎𝑡𝑢𝑠 + 𝐶𝐸𝐷 + 𝐺𝑒𝑛𝑒𝐺 
Equation 3: Model for gene-centric ANOVA. 
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condensation 1 (RCC1) and neuroblastoma amplified sequence (NBAS), with 44, 22 and 21 
unique fusion constructs, respectively.  
4.4.2 Overview of results 
Of 424,951 potential combinations, 563 passed our previous criteria for large-effect 
significant associations (FDR < 25% and Glass Delta > 1), with 281 sensitising and 282 
resistant associations. Due to the larger set of input features, I decided to implement a 
stricter FDR threshold, raising it from 25% to 5%. Implementing this, we maintain 159 
associations, with 110 sensitising and 49 resistant (Figure 4.11) (Supplementary Table 7).  
 
Figure 4.11: Volcano plots illustrating the results from the gene-centric ANOVA.  
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4.4.3 Known gene-drug associations 
The associations with the lowest p-values are dominated by known associations, as 
the ones described in the fusion ANOVA (Figure 4.12).  
4.4.3.1 ABL1 
Our cell line panel contains only two types of ABL1-fusions with ABL1 at the 3’: the 
well-understood BCR-ABL1 and NUP214-ABL1. Unsurprisingly, grouping the two fusions 
into one variable resulted in highly significant associations (p < 0.001, fdr < 1%) across 8 
different ABL inhibitors, including FDA-approved nilotinib (Figure 4.12A).  
4.4.3.2 BCR 
The most prevalent partner gene in the BCR-ABL1 fusion is fused multiple times at 
the 5’ end. Associations of 5’-BCR and ABL1 inhibitors are highly significant, however when 
I manually inspect the drug sensitivities, it becomes apparent that the association is mainly 
driven by the BCR-ABL1 fusion. Other BCR-fusions, e.g. BCR-ABHD2 and BCR-PI4KA, show 
IC50’s similar to the median of non-fused samples. None of the other BCR fusions have 
previously been reported in patient samples. Running the gene-centric ANOVA model with 
a covariate for BCR-ABL1 status, the association of the remaining BCR-fused genes 
becomes non-significant (p = 0.74).  
4.4.3.3 NUP214 
Another common partner gene to ABL1, NUP214 is fused to several other 3’ 
partners, such as N-terminal Xaa-Pro-Lys N-methyltransferase 1 (NTMT1), PBX homeobox 
3 (PBX3), proline rich coiled-coil 2B (PRRC2B) and XK related 3 (XKR3). 5’-NUP214 is 
significantly associated with nilotinib, however as in the previous case, this significance is 
mainly driven by the NUP214-ABL1 fusion. Only three cell lines of the six cell lines with 5’-
NUP214 fusions were screened under this drug ID. Of those, as expected, the two NUP214-
ABL1 cell lines are sensitive to drug inhibition. While K-562, a chronic myeloid leukaemia 
cell line with a NUP214-XKR3 fusion appears to be sensitive, it also harbours a BCR-ABL1 
fusion, which is more likely to drive sensitivity to nilotinib.  
Further, 5’-NUP214 tested for sensitivity to ABL inhibitors across a larger set of 
fusion-containing cell lines do not show significant associations. For example, imatinib was 
screened also in a NUP214-PBX3-containing Melanoma cell line, where it shows no 
difference in IC50 from non-fused cell lines. In conclusion, 5’-NUP214 fusions are highly 
unlikely to cause a sensitivity to ABL inhibitors outside of the context of the NUP214-ABL1 
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fusion. Neither NUP214-XKR3 nor NUP214-PBX3 have previously been reported in patient 
samples. 
4.4.3.4 ALK 
As described above (section 4.3.1), our cell line panel includes a two distinct 
recurrent fusions involving the tyrosine receptor kinase ALK. While the majority of blood 
cancers with ALK-fusions carry the NPM1-ALK fusion, a smaller subset is fused to other 
partner genes that encode coiled-coil domains that promote dimerization and activation 
of ALK’s tyrosine receptor kinase domains. One example is that of a fusion with Tyrosine 
receptor kinase-fused gene (TFG), a protein with preserved N-terminal coiled-coil domains 
(Greco et al., 1998; Hernández et al., 1999). 
Our cell line panel includes one such instance of a TFG-ALK fusion in SCC-3, a B-
cell lymphoma. Other ALK-fused constructs include AC016907.3-ALK, and TERT-ALK, 
neither of which were previously described in tumours. In our drug screen, SCC-3, but not 
the other two fused-cell lines, shows a sensitivity to alectinib that is comparable to NPM1-
ALK and EML4-ALK fused cell lines (Figure 4.12C). 
 
 




Sensitivity of FGFR3-fused cell lines to FGFR-inhibitors is described in section 4.3.1. 
As expected, the association of 5’-FGFR3 fusions with FGFR-inhibitor PD173074 is highly 
significant in this analysis. 
4.4.4 Confounding factors 
4.4.4.1 FGFR2 
Similarly as in the fusion ANOVA, FGFR2 amplifications are a confounding factor in 
the gene-centric ANOVA. Ten cell lines show FGFR2 fusions, of which 5 cell lines also have 
a copy number gain (PICNIC score = 14) at the segment containing FGFR2. When 
comparing the activity of the FGFR-inhibitor AZD457, I find that the amplification neatly 
divides responding verses non-responding cell lines, regardless of the fusion status (Figure 
4.12). 
4.4.4.2 ERBB2 
Another common confounding factor is that cell lines with amplification of ERBB2 
are associated with ERBB2-inhibitors such as afatinib. In our data-set, associations with 
afatinib sensitivity are found with cell lines with ERBB2-fusion, which like in FGFR2 are likely 
to be a side-effect of ERBB2-amplifciations causing passenger rearrangements and 
translocations. 
  
Figure 4.13: FGFR-amplification separates cell lines that respond to FGFR-inhibitors from those that do not, 
regardless of fusion status.  
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Aside from those, afatinib sensitivity is also associated with 3’ IKAROS family zinc 
finger 3 (IKZF3) and 3’ titin-cap (TCAP) fusions. Both genes are less than 50,000 bp down 
or up-stream of ERBB2. As cell lines with the fusions all carry an ERBB2 amplification, it is 
likely a passenger event from the amplification.  
 
Altogether, the above events demonstrate how fusions in commonly amplified 
oncogenes can be correlated with a drug sensitivity but not causative, due to co-
occurrence with an oncogenic event. Further, these passenger fusions occur commonly not 
only at the oncogene whose amplification is beneficial to tumour growth, but also in the 
surrounding genomic regions.  
Events such as these pose more questions on the frequency of passenger fusion 
events compared to cancer-driving fusion events and how these may be distinguished 
from high-throughput screening.  
 
4.4.5 “Novel” findings 
4.4.5.1 PTEN 
5’-PTEN fusions, found in breast, prostate and biliary tract cell lines, are associated 
with resistance to tankyrase inhibitor AZ6102 (Figure 4.14). Here, PTEN-rearrangement is 
likely to be a mechanism for disruption of the tumour suppressor gene. A previous study 
show that tankyrases ADP-ribosylate PTEN to be promoted for degradation and thus 
tumour growth. Knockdown of tankyrases stabilises PTEN and resulted in downregulation 
of the PI3K/AKT pathway and thus tumour suppression (Li et al., 2015). In cells where PTEN 
is disrupted through a rearrangement, tankyrase inhibition is thus less likely to lead to cell 
death. However, cell lines with PTEN mutations or deletions appear to have similar 
sensitivity to the tankyrase inhibitor as wild type cells (Figure 4.14). This suggests that 
simple deletion of PTEN through fusion events may not be the sole mechanism of 
tankyrase inhibitor resistance in fused cell lines.  
4.4.5.2 FBXW7 
5’ F-box and WD repeat domain containing 7 (FBXW7) fusions are another feature 
associated with resistance to another tankyrase inhibitor, WIKI4. The fusions are present in 
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breast, cervical and head and neck cell lines and do not co-occur with PTEN-fusions. In 
general, FBXW7 targets several known cancer-drivers for ubiquitination and subsequent 
degradation, such as Yes associated protein 1 (YAP1) and Aurora kinases (Tu et al., 2014). 
Interestingly, another study showed the cooperation of FBXW7 and PTEN in tagging 
Aurora kinases for ubiquitination (Kwon et al., 2012). It would be interesting to note in the 
future whether PTEN stabilisation following tankyrase inhibition provides survival benefits 
related to FBXW7 activity.  
 
Altogether, after removing the associations that are either known, confounded or 
described above, 78 significant large-effect associations remain in the list (Supplementary 
Table 7). Further curation efforts are complicated by the lack of prior knowledge of the 
function of the associated genes that could help to establish any causative links with the 
associated drug.  
As I showed in this analysis as the one before, confounding variables unknown to 
the model can further complicate the task of differentiating true fusion-drug associations 
from false-positives, making a manual curation effort based on literature research difficult 




Figure 4.14: PTEN-fusion and sensitivity to the tankyrase inhibitor AZ6102.  
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4.5 Chapter discussion & conclusion 
In this chapter, I sought to discover novel fusion biomarkers of drug response using 
our high-throughput screening data of 409 drug IDs. Any results from such an analysis 
uncover essential pathways in cancer cell lines that may be regulated by gene fusions. 
Moreover, these results may provide a basis for further research into the opportunities of 
screening for novel gene fusions in the clinic to provide improved treatment opportunities, 
along the same veins as the successful previous case studies of ABL1 and ALK-fusions. 
While my analyses reliably recapitulated known and expected findings, after 
curation of novel associations, no strong candidates emerge that warrant a 
recommendation for further study at the current point. Most potential associations that 
are ruled out fall into one of two categories: 1) the presence of confounding factors may 
explain drug sensitivity through fusion-unrelated mechanisms. 2) A lack of prior knowledge 
in low-recurrence fusions puts into question the robustness of the association, as well as 
their relevance in patient populations.  
Despite a lack of emerging candidates, the analyses do provide learnings that may 
become useful when setting up future analyses and drug-screens.  
 
Low recurrence give low statistical power 
Truly recurrent fusions are rare in our dataset. For comparison, our group’s 
previously published analysis of high-throughput drug-screening data used 717 cancer 
mutations and copy number alterations, of which the vast majority was present in at least 
10+ cell lines (Figure 4.15A) (Iorio et al., 2016). However, in my analysis even with over 
8,000 fusions detected in the 1,011 cancer cell lines, only a minority of fusions are recurrent, 
and even less in more than two cell lines (Figure 4.15B). Moreover, the list of 717 CFEs in 
Iorio et al. was curated to include only patient-relevant events, while our fusion analysis 
was not curated to that extent due to a lack of comprehensive databases for the annotation 
of fusion genes described in patients. 
As recurrent fusions are not only rare, but also uncurated, the low numbers of novel 
findings are perhaps unsurprising. Due to the rarity of recurrent fusions, it perhaps 
becomes even more important to be able to separate potentially functional gene fusions 
from passenger events. For example, ALK-fusions are sensitive to ALK-inhibitors only in a 
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subset of detected constructs. For gene fusions of unknown function that may be less 
recurrent, being able to pick out the functional constructs may be the difference between 
a significant association and a false negative for any drug-associations tested in a gene-
centric ANOVA.  
Confounding CFEs complicate interpretation of associations 
What further complicates interpretation is the frequency of confounding events 
whose occurrences are linked to those of fusions. For example, ERBB2 amplified cell lines 
often carry fusions of genes at the same genomic region, which are in turn significantly 
associated with ERBB2-inhibitors. This is a problem that the inclusion of significant hits 
from the CFEs ANOVA (4.2) was designed to solve. Unfortunately, in the event of ERBB2 
amplification, the CFE failed the criteria for large-effect interaction due to the Glass delta 
of ERBB2-amplified cell lines being 0.8. The threshold was originally set following the 
example in Iorio, et al (2016), and is necessary as the inclusion of too many covariates can 
significantly decrease significance of even true associations. However, the frequency of 
ERBB2-amplification being a confounding variable shows that perhaps future iterations of 
this model should re-analyse thresholds for a broader inclusion of potential confounders.  
Similarly, FGFR2-amplifications were another common confounder in my analysis. 
Unfortunately, FGFR2-amplifications were not a feature included in the curated binary CFE 
annotation upon which the CFE ANOVA was based, and thus not flagged to be included 
as a covariate in the fusion ANOVA. Thus, further identifying and annotating this and other 
 
Figure 4.15: (A) Recurrence of 717 curated CFEs and (B) 8,388 fusions in our panel of 1,011 cell lines. 
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unknown confounding factors could contribute significantly to the robustness of future 
iterations of this analysis.  
Lack of prior knowledge in fusion selection  
As implied in the previous paragraph, lack of prior knowledge of fusion function 
can complicate model input decision and interpretation of novel significant associations. 
Firstly due to a community-wide lack of understanding on how to distinguish 
functional from non-functional fusions resulting from high-throughput transcriptome 
sequencing data, the data-set still contains a lot of noise. Unlike point mutations for which 
nowadays there are meticulous filters to determine the likelihood of causing functional 
disruption, there are no comprehensive resources available for gene fusions at this point. 
Though breakpoint predictors such as GRASS are available to predict the genomic location 
of fusions (e.g. intron vs exonic, UTR vs coding) and their likelihood of result in in-frame 
gene products, there are still shortcomings. For one, if we assume that passenger fusions 
occur at random frequencies across the genome, a third of fusions in coding regions would 
be expected to be in-frame. Further, gene fusions may exert functionality beyond the 
production of chimeric proteins, for instance a fusion of a UTR to a coding region may lead 
to differential regulation due to post-transcriptional regulatory events that affect splicing 
or mRNA stability. In other cases, a gene fusion may be functional not through the chimeric 
protein produced but due to a disruption of a tumour suppressor gene, as the case of 5’-
PTEN fusions suggest. Another draw-back of the GRASS algorithm is that it depends on 
the quality of genomic annotations that is used as an input file. For instance, the two well-
studied oncogenic fusions EIF3E-RSPO and UBE2L3-KRAS, are flagged with a GRASS score 
of 100, defined as a “something else to something else” fusion. However when I manually 
aligned breakpoints and reviewed literature, I found strong evidence supporting that the 
fusion should be functionally in-frame.  
Due to the examples described above, I conclude that while the GRASS algorithm 
is a useful tool for annotation of fusions, I would not recommend it as a filtering method 
to exclude any fusion events.  
Available drug compounds are biased towards well-studied oncogenic targets 
Most targeted compounds that are included in our high-throughput screen were 
developed as a response to known oncogenic events. For instance, the development of 
ABL and ALK-inhibitors was sparked by the discovery of the oncogenic activity of the ABL 
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and ALK-fusions. As fusion-discovery using high-throughput transcriptome analyses is still 
a recent endeavour, and due to the rarity of recurrent fusion events, currently unknown 
rare oncogenic fusions may yet to be discovered in the future.  
At the same time, it is important to keep in mind that due to a lack of hydrophobic 
pockets or their subcellular localisation, many appealing molecular targets are currently 
considered undruggable (Verdine and Walensky, 2007).  
Thus, the lack of targeted drugs for potential unknown fusions with oncogenic 
activity may present a blind spot in this type of analysis of high-throughput drug screens.  
 
In conclusion, my analysis recapitulates current knowledge on fusion-drug 
associations. That no strong candidates emerge among novel associations is somewhat 
surprising considering the successes of previous high-throughput drug-screening efforts 
in identifying biomarkers from oncogenic mutations and copy number alterations. I 
speculate that the lack of novel fusion biomarkers is mostly due to 1) the relative lack of 
novel recurrent fusions leading to reduced statistical power and 2) limited prior knowledge 
on fusion genes complicating interpretation of hits.  
Future developments may yield a better understanding of the characteristics of 
functional fusions and broaden the currently limited landscape of gene fusions in patient 
samples. This could then be used to filter out noise in the form of non-functional passenger 
fusions and increase statistical power and confidence for the remaining fusions. Similarly, 
advances in drug development may improve the breadth of pathways and targets available. 
Due to the low recurrence of fusions, expanding the number of models available can also 
increase the statistical power of the biomarker analysis. 
At that point, a similar statistical model querying high-throughput drug-screening 
data may indeed yield valuable insight into therapeutic sensitivities of fusion genes and 










5 Functional analysis using CRISPR/Cas9 whole-genome 
screening data 
5.1 Introduction and concept 
The topic of utilising CRISPR/Cas9 whole genome screening data has been split 
across two different chapters for ease of reading. This chapter will provide an introduction 
to the concept, the methodology of the computational approach and some quality control 
analyses. After that, the next chapter will discuss the results of the approach in more detail, 
putting the focus onto discovering functional gene fusions. 
5.1.1 State-of-art and current challenges 
One of the biggest challenges that high-throughput transcriptome analyses face is 
how to separate the noise from the signal. In the age of genomics, cancer genes and 
specific oncogenic mutations are commonly identified because they are mutated at a 
higher rate than the background. With now tens of thousands tumour genomes sequenced, 
statistical models identifying such mutation hotspots have helped us build comprehensive 
landscapes and databases of cancer driver mutations (Barretina et al., 2012; Forbes et al., 
2017).  
However, as I discussed in the previous chapter, recurrent fusions are strikingly rare. 
Even though more than 10,000 patient samples have already undergone fusion calling, 
analytical methods can still only identify the handful of known recurrent fusions. Similarly, 
even recurrent fusions may represent passenger events of common genetic alterations and 
need not necessarily be functional. Known examples of this are the FGFR2 and ERBB2 
fusions described in the previous chapter, but unknown examples may further confound 
our goal to identify truly oncogenic fusions.  
Innovative solutions that step away from using recurrence to identify cancer driver 
fusions are necessary in order to overcome these challenges. Here, I developed a 
systematic method to query the functionality of unknown fusions using existing 
CRISPR/Cas9 whole-genome screening data.  
5.1.2 Review of CRISPR/Cas9 whole-genome drop-out screening 
CRISPR/Cas9 whole genome drop-out assays are designed to identify genes that 
contribute to cellular fitness, i.e. genes that are necessary for the normal cell function and 
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survival. The cell line is first modified to express functional CRISPR associated protein 9 
(Cas9), which has the ability to introduce double-strand breaks in a genomic region that is 
defined by a sequence given on a short guide RNA (sgRNA). Then, a whole-genome guide 
library is virally transduced into a population of Cas9-expressing cells, so that on average 
one cell will carry one sgRNA. Upon encountering a sgRNA, Cas9 will introduce a double-
strand break at the target site that is complementary to the sgRNA sequence. The double-
stranded break is repaired using non-specific non-homologous repair mechanisms that 
are extremely prone to introducing insertion/deletions which effectively knock-out the 
target gene (Behan et al., 2018; Meyers et al., 2017; Wang et al., 2017). The guide library 
will include several sgRNAs targeting each of a vast majority of known genes in the human 
genome. Typically, whole-genome guide libraries target ~17,000-20,000 genes with 4-10 
sgRNA for each gene. After keeping the cell lines in culture for several days, the sgRNA in 
the population is sequenced to reveal the proportion of remaining sgRNAs. sgRNA that 
target genes required for cellular fitness should be depleted from the population due to 
the deleterious effect of the CRISPR system. Depleted genes can be identified using several 
statistical models, with the most prevalent including MAGeCK and BAGEL (Hart and Moffat, 
2016; Li et al., 2014). 
5.1.3 Applying CRISPR/Cas9 screening data to identify functional gene fusions 
Due to sometimes unpredictable sgRNA efficacy and off-target effects depending 
on the target and PAM sequences (Doench et al., 2014; Munoz et al., 2016), each gene will 
usually have 4-10 sgRNA spread across the target gene. The drop-out values are typically 
then averaged across the sgRNA to produce final essentiality scores for each gene.  
My method takes advantage of the multiple sgRNAs per gene to create a fusion-
specific CRISPR scoring system. For each fusion gene, I map the sgRNAs of both fusion 
partners onto the predicted breakpoint of the gene fusions. I then categorise sgRNAs that 
map onto the predicted fusion-gene as “mapping” and those that fall outside the fused-
region as “non-mapping”. The key concept is that for essential functional fusions, 
CRISPR/Cas9 generated double strand breaks should be lethal at the mapping regions, but 
have no effect at non-mapping regions. Conversely, if the fusion is just a passenger event, 
then disrupting the gene fusion should not yield any essentiality. Similarly, where the 
normal function of a gene is essential rather than the fusion, I expect to see depletion of 
not only mapping- sgRNA but also of non-mapping sgRNA (Figure 5.1).  
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Therefore, in the ideal scenario where both mapping and non-mapping sgRNA are 
present for a gene fusion, the difference between mapping and non-mapping sgRNA will 
be an indication of the essentiality specific to the gene-fusion.  
In this chapter, I describe the development of a computational approach that uses 
CRISPR/Cas9 whole genome drop-out data to query the essentiality of fusion genes. First 
I will outline the datasets that I used for the analysis, then explain the pre-processing and 
the individual steps applied in my computational approach. I then performed a brief quality 
control of the data that looks at the coverage and quality of sgRNA. Finally, I describe the 
results of the analysis and give a few examples of my findings.  
 
5.2 Data-sets and data processing 
5.2.1 Description 
For this analysis, I used three sources of whole-genome CRISPR/Cas9 drop-out 
screening in human cancer cell lines (Table 5-1).  
 
Figure 5.1: Visualisation to illustrate the classification of sgRNA into mapping and non-mapping for each 
fusion transcript.  
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An in-house effort to generate CRISPR/Cas9 whole-genome drop-out screening 
data for our panel of cell lines has to date produced 200 Cas9-expressing cell lines and 
screened them with the Sanger V1 guide library (Tzelepis et al., 2016), with more being 
released in the coming few months. This data will be publishes under the name Project 
Score and covers 206 cell lines which have undergone fusion-calling.  
Next, Project Achilles performed at the Broad Institute has so far screened another 
342 cancer cell lines using the Avana library, of which 243 overlap with my dataset (Meyers 
et al., 2017). I also include a smaller study by Wang et al. on 14 acute myeloid leukaemia 
cell lines (12 overlapping) that were screened with the Wang et al. library.  
The three data-sets used library that covered a similar number of genes (~17,000-
18,500), although the number of sgRNAs per gene varies, with Wang et al. using a median 
of 10 sgRNAs per gene, compared to 4 and 5 used by Project Achilles and Project Score 
respectively. Due to this difference, the data-set produced by Wang et al. contains 
mapping sgRNAs for a higher percentage of fusions called within the screened cell lines 
and may produce higher-resolution data than the other two resources. Conversely, the 
Table 5-1: Comparison of three resources for CRISPR-Cas9 drop-out screening in human cancer cell lines 
 
Project Score Project Achilles Sabatini 
Paper Behan et al. (2018) Meyers et al. (2017) Wang et al. (2017) 
Guide library Human CRISPR library 
v1.0/v1.1 
Avana Wang et al. (2015) 




5 4 10 
Cell lines in 
our panel  
(total 
screened) 
206 243 (342) 11 (14) 
# Fusions 
assessed 





77% 74% 88% 
Reps/Cell 
line 
3 3 1 
Data 
download 











Wang et al. dataset contains only one biological replicate for each cell line screened, while 
both Project Achilles and Project Score generated three replicates per cell line.  
With some exception in the details, the three resources otherwise followed the 
same principles in their screening protocols, transducing Cas9-expressing cell lines with a 
puromycin-selectible lentiviral sgRNA library and leaving the cells in culture for 2-3 weeks.  
Finally, cells were harvested, sgRNA PCR amplified and sequenced. The sequences 
were aligned to the reference genome and raw counts in each cell line for each sgRNA 
RNA were reported. 
 
5.2.2 Processing flow chart 
For my analysis, I downloaded the raw counts reported for each cell line and 
processed the data for all three resources in a standardised manner (Figure 5.2).  
5.2.3 Data download 
I downloaded raw counts for each guide in each cell line and guide annotations 
from the links provided in each of the original publications (Table 5-1). Guide annotations 
for all three resources were based on GRCh37 and to convert them to GRCh38, to which 
our fusion data was aligned, I used the NCBI Genome Remapping Service online tool 
(https://www.ncbi.nlm.nih.gov/genome/tools/remap). 
 
5.2.4 Log-fold change calculation 
First, using the CRISPRcleanR R package that was also used to process the original 
Project Score dataset (Iorio et al., 2018), I calculated log2-fold changes (logFCs) from raw 
counts for each sgRNA. logFCs simply denote the ratio of sgRNA counts in the final 
population over that of the initial population, at log base 2. Note that for the Project Score 
and the Project Achilles resource, the final raw counts were quantified against library 
plasmid-read counts. For the Wang et al. resource, no library plasmid-read counts were 
available. Instead, I followed the methods described in their paper and averaged the read 
 
Figure 5.2: Standardised process for data processing 
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counts obtained from 12 of the 14 cell lines at 72 hours after library transduction and 
before puromycin selection.  
5.2.5 CRISPR-bias correction 
The depletion of guides in CRISPR-screens may be subjected to biases that are 
unrelated to the essentiality of a particular gene. Previous studies have shown that the 
wide-spread DNA damage created by guides that cut at copy number amplified regions 
tend to lead to high depletion levels even when targeting non-expressed genes (Aguirre 
et al., 2016; Munoz et al., 2016). To correct for copy-number biases, the Project Score data 
uses the CRISPRcleanR algorithm, the Project Achilles data used the CERES algorithm, while 
Wang et al. calculate a sliding window score (SWS). 
Of the three, the SWS method is the most simplistic. Each gene targeted by a 
sgRNA is analysed in the context of a “sliding window” of 20 upstream and 20 downstream 
neighbouring genes (after discarding pan-essential genes). Any neighbouring gene that is 
in the top 3% of depleted genes in a given cell line adds a value of 1 to the SWS. Genes 
that have a SWS of > 12 are considered to be in a copy-number amplified region and are 
removed from further analysis. For my analysis, I excluded the SWS from consideration, as 
it does not correct logFCs but simply removes those which are in clusters of highly depleted 
genes.  
The CRISPRcleanR method uses a binary segmentation algorithm to identify 
clusters of neighbouring genes that have fold-changes that are on average significantly 
different from the background (Iorio et al., 2018). The logFCs in each segment are then 
corrected by mean-centering, which therefore allows them to be used in further down-
stream analyses. An advantage of this method is also that this unsupervised algorithm can 
identify and correct unknown region-specific biases other than the copy number-bias.  
The CERES algorithm for copy-number correction was published together with the 
release of the Project Achilles data (Meyers et al., 2017). CERES requires input of a priori 
copy-number information for each cell line. It then uses a computational model to estimate 
the impact of copy-number effects, as well as sgRNA-specific effects shared between all 
cell lines in a screen. CERES then corrects the logFC for each gene so that the mean copy 
number effect is shifted to zero.  
To decide on which algorithm to use for my analysis, I examined the differences 
between the supervised CERES and unsupervised CRISPRcleanR methods. The main 
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difference is that the CERES correction of logFCs depends on a priori data on copy number 
changes in the cell line, while CRISPRcleanR uses a flexible algorithm that corrects logFCs 
based on detected differences between genomic segments.  
A key consideration is that while the number of cuts a guide evokes is strongly 
correlated with depletion of non-expressed genes, variation still exists with some highly 
amplified non-expressed genes showing little lethality and single-cut non-targeting guides 
showing high depletion (Aguirre et al., 2016; Meyers et al., 2017; Munoz et al., 2016). This 
strongly suggests that other factors other than just copy-number can influence CRISPR-
biases. 
In fact, a recent study from our group shows that the cell fitness effect associated 
with copy number amplifications is mainly driven by tandem duplications, rather than 
chromosomal duplications (Goncalves et al., 2018). The authors show that regions that the 
CRISPR-bias is stronger in amplified regions in cell lines with low ploidy, and severely 
reduced in cell lines with high ploidy. This suggests that in fact a large number of DNA-
breaks spread out across the nucleus are less lethal than the same number of cuts within 
a single genomic region.  
As copy number amplifications can results from both tandem duplications and 
chromosomal duplications, correcting them equally, as the CERES algorithm does, may 
introduce further biases into the data, i.e. over-correcting genes at chromosomal 
duplications and under-correcting genes in tandem duplications.  
Further, as CRISPRcleanR makes no assumptions about the cause of CRISPR-biases, 
the algorithm has the ability to take into account any potentially unknown region-specific 
biases. Indeed, the authors of the CRISPRcleanR algorithm identify genomic segments that 
exhibit biased logFCs without any apparent copy number changes (Iorio et al., 2018).  
For the above reasons, I implemented the CRISPRcleanR algorithm for CRISPR-bias 
correction of the logFCs for all three datasets.  
5.2.6 Normalising fold-changes 
Slightly different experimental conditions between different cell lines and 
experimental variation can lead to different ranges of raw counts and the resulting logFCs. 
This means that if no normalisation is performed, the logFCs for the same guides are not 
directly comparable between cell lines. As my down-stream analysis requires a direct 
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comparison of logFCs across different cell lines, I sought to implement a normalisation 
step. 
Normalisation of logFCs was performed by Wang et al. using quantile normalisation, 
while Project Achilles scaled the distribution by a priori essential and non-essential genes. 
The Project Score data was further processed into essentiality scores using BAGEL and 
MAgECK which did not require normalisation.  
Quantile normalisation was first introduced for the analysis of microarrays (Bolstad 
et al., 2003). Essentially, it works by first calculating an average distribution of logFCs across 
all samples and then substituting the sorted logFCs with the equivalent position in the 
average distribution. The result is that the distributions of logFCs of all samples will be 
identical.  
The method developed for CERES to scale logFCs to essential takes as input a set 
of a priori essential and non-essential genes. For each cell line, it then scales a distribution 
of gene effects so that the median score of essential genes is at -1 and the median score 
of non-essential genes is at 0.  
The advantage of scaling the logFCs to essential is that the distribution of guides 
are preserved for each cell line. Additionally, scaling the logFCs to the essential genes 
provides a simple and useful anchor against which the essentiality of unknown guides can 
be benchmarked.  
For these reasons, I decided to scale the CRISPRcleanR-corrected logFCs of all 
datasets using the CERES scale-to-essential R function provided in the CERES github 
repository (https://github.com/cancerdatasci/ceres/blob/master/R/scale_to_essentials.R). 
For the a priori essential and non-essential genes, I used the lists supplied within the CERES 
R package and that were previously defined by Hart et al. (Hart et al., 2014). Scaled and 
CRISPRcleanR-corrected logFCs are abbreviated to “scaled logFCs” in all of the following 
text.  
5.2.7 Mapping guides to fusion transcripts 
For the calculation of a fusion essentiality score, I first needed to classify guides 
into either mapping or non-mapping guides (Figure 5.1). In order to automate this, I 
devised a set of rules that take into consideration (1) the fusion breakpoint and (2) the 
mapping location of the guides. 
125 
 
Guides map onto the 5’ gene if the gene is on the positive strand and the guides 
maps before the position of the fusion breakpoint, or if the gene is on the negative strand 
and the guide maps after fusion breakpoint (red stars in figure Figure 5.1). Guide map onto 
the 3’ gene if the opposite is true (green stars in Figure 5.1).   
 
 
5.2.8 Calculation of fusion fitness score 
In order to calculate the fusion essentiality, I made the following considerations: 
i. At the most basic level, in true essential fusion transcripts, mapping guides 
should be highly depleted, while non-mapping guides should have near zero 
fold-changes. 
ii. Where a fusion transcript has only mapping guides, a direct comparison of 
mapping and non-mapping scores is not possible. However, as only 54.7% of 
the fusion transcripts tested have differentially-mapping guides, I aimed to 
develop a score that could also be applied to fusion transcripts with only 
mapping guides. It is important to note that these types of fusions may suffer 
from potential false positives, as it cannot distinguish between gene-specific vs. 
true fusion-specific effects.  
iii. Mapping guides for true fitness fusion transcripts should be highly depleted, 
but this depletion may be caused by other confounding factors and doesn’t 
take into account the average essentiality and range of essentialities of the 
guide across all cell lines.  
Thus in order to calculate the fusion essentiality score, I take the following steps:  
1) Z-normalise the scaled logFC across all cell lines screened for a given guide. The Z-
score is calculated by taking a scaled logFC, subtracting the mean of all scaled 
logFCs produced by the guide across all cell lines, and then dividing by their 
standard deviation. The Z-score therefore represents the magnitude of deviation 
from the average. Compared to a mean-centred scaled logFC, the Z-score gives 
added weight to guides that deviate from a narrow distribution than for guides that 
deviate from a broad distribution. 
2) Calculate the difference in Z-score between the mean of mapping and the mean of 
non-mapping guides for each gene involved in a fusion transcript (Equation 4). 
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Where a gene has only mapping guides the difference is taken from 0. Where a 
gene only has mapping guides, a high Z-score indicates cell-line specific 
essentiality of a gene, which we expect to see in true essential fusions.  
3) Finally, to calculate the Fusion Essentiality Score (FES), the difference scores 
calculated for both fusion genes is averaged. In fusion transcripts where only one 
gene has mapping guides, the FES = GeneDiff. 
5.2.9 Calculating a significance score for fusion essentiality scores 
In order to estimate the statistical likelihood of a given FES occurring by chance, I 
performed 10,000 randomisations of the scaled logFCs. Randomisations were performed 
on a per cell line basis in order to preserve the distribution of guide effects.  
After each randomisation, a “randomised FES” is calculated using the same 
methods as described in the previous section. For each fusion transcript, I calculated a p-
value as the number of “randomised FES” that were larger than the non-randomised FES, 
divided by the number of randomisations. Finally, p-values were adjusted for multiple 
hypothesis testing using the false discovery rate method.  
Figure 5.3A shows the distribution of FES scores across the entire dataset. The 
scores follow an approximately normal distribution with a mean of mean = 0.21 (sd = 1.01). 
There is a long tail at the positive end of the distribution and a small secondary peak 
around +4, which signifies a slight enrichment in positive scores. More positive scores 
represent fusion transcripts that are more highly depleted.  
Fusion essentiality scores have a similar distribution in the Project Score and 
Achilles data set, while the Wang et al. data set appears to have a narrower range and more 
defined secondary peaks (Figure 5.3B). Means and medians are comparable across all three 
datasets and whether or not fusion transcripts have differentially mapping or non-mixed 
guides.  
A more thorough analysis of the distribution of the FES using functionally relevant 
annotation will follow in chapter 6.2. 
 
𝐺𝑒𝑛𝑒𝐷𝑖𝑓𝑓 =  𝑚𝑒𝑎𝑛(𝑠𝑔𝑅𝑁𝐴𝑚𝑎𝑝𝑝𝑖𝑛𝑔) − 𝑚𝑒𝑎𝑛(𝑠𝑔𝑅𝑁𝐴𝑛𝑜𝑛−𝑚𝑎𝑝𝑝𝑖𝑛𝑔) 
𝐹𝐸𝑆 = 𝑚𝑒𝑎𝑛( 𝐺𝑒𝑛𝑒𝐷𝑖𝑓𝑓5′ + 𝐺𝑒𝑛𝑒𝐷𝑖𝑓𝑓3′) 
Equation 4: Gene difference score and fusion essentiality score calculation.  
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5.2.10 Essentiality prediction with BAGEL 
Apart from calculating the FES, in some of my downstream analysis I require a 
binary annotation on whether a given gene is significantly depleted in a cell line. In order 
to calculate a fitness score for each gene and in each cell line, I implemented the BAGEL 
framework developed by Trevor Hart and colleagues, which identifies essential genes from 
pooled library screens (Hart and Moffat, 2016; Hart et al., 2015). BAGEL is a supervised 
computational algorithm that uses a Bayesian framework to estimate the essentiality of a 
guide RNA. In short, it uses a priori lists of essential and non-essential genes and first 
estimates the distribution of fold changes of guides targeting these genes within each 
sample. Then, using a bootstrap process of 1,000 iterations, it calculates the likelihood of 
the logFC of a given guide to have come from either the distribution of essential or non-
essential genes. The likelihood to come from the essential distribution is captured in a 
Bayes Factor score (BF).  
 




The set of a priori essential and non-essential genes can then be used to generate 
a False discovery rate (FDR), the precision and the recall for each of the computed BFs 
(Equation 5).  
Since the distribution of essential and non-essential genes will differ from sample 
to sample, the FDR of BFs also accordingly vary by sample. In order to create an easily 
comparable score, Iorio and colleagues propose a scaled BF (Behan et al., 2018; Iorio, 2018). 
To calculate this score, for each sample, the BF at which FDR = 5% is subtracted from all 
BFs calculated for the sample. Thus, across all samples, a scaled BF of > 0 means that a 
guide is likely to be essential at 5% FDR, a threshold that was originally adopted by Hart et 
al. (Hart and Moffat, 2016).   
I implemented the method described above using the R implementation of BAGEL 
written by Francesco Iorio (Iorio, 2018) to calculate BFs from the CRISPRcleanR-corrected 
logFCs. To calculate the BF at FDR 5%, I used the ccr.PrRc_Curve function within the 










Equation 5: Equations for FDR calculation. FP = False positives; TP = True positives; FN = False negatives. 
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5.3 Data characteristics & quality control 
5.3.1 Data set coverage 
In total, the screening data from the three data sets encompasses 371 cell lines in 
33 cancer types that were part of our panel (Figure 5.4). Of those, 90 cell lines were 
screened in two separate data sets. No cell line was screened in all three data sets. 
The cell lines harbour 3,598 fusion transcripts (35% of the total). 2,821 transcripts 
(76%) have at least one guide mapping to the predicted protein. Of those, 528 transcripts 
(19%) are in cell lines screened by two resources. 
Fusion essentiality scores were calculated in 339 of the 371 cell lines, because in 24 
cell lines no fusion transcripts were detected and in 8 cell lines the detected fusion 






Figure 5.4: Overview of CRISPR/Cas9 screening data available by cancer type. Number of different cell lines 
screened per resource, number of cell lines replicated between data-sets and number of fusion transcripts 
in the screened cell lines. White fill in bars indicate that no sgRNA were mapped to a fusion transcript. 
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5.3.2 Data quality: precision-recall scores across data sets 
One measure of data quality is to calculate the precision and recall of expected 
essential and non-essential genes for each sample in the CRISPR-screen.  
This is calculated by ordering the values (here, I used the scaled logFC’s) for the 
sgRNA targeting a priori essential/non-essential genes from smallest to largest. At each 
point, one can calculate the precision, which refers to the proportion of true positives 
among all positive values and the recall, which refers to the number of true positives from 
all known essential elements.  
In the ideal sample, all the essential genes will have low scaled logFC’s (i.e. be highly 
depleted), and all non-essential genes will have high scaled logFC’s. In that scenario, 
plotting the precision vs. the recall for that sample at each data point will yield a curve with 
a very high AUC. Conversely, if scaled logFC’s were distributed randomly within a sample, 
the AUC is expected to be at around 0.5, as for each highly depleted essential guide one 
would also draw out a highly depleted non-essential guide.  
Thus, the AUC of precision-recall curves can give an indication of the quality and 
the noise levels for an individual sample, and is indeed a common quality control step 
when analysing CRISPR/Cas9 whole genome drop-out screening data. For this analysis, I 
calculated the precision-recall AUC’s for each sample at both the gene and the guide-level 
across all three data-sets, using the same sets of a priori known essential and non-essential 
genes as described in section 5.2.10. 
 
For both the gene-level and the guide-level precision-recall AUC’s, Project Score 
data outperforms both of the other data-sets (Figure 5.5A-B). For data from Wang et al., 
the guide-level AUC’s are lower than average, while the gene-level AUC’s are narrowly 
higher than that of the Project Score data (mean AUC = 0.902 vs. 0.900). This likely reflects 
that the screen quality is lower than in the other two screens, possibly due to only having 
performed one biological replicate for each cell line. That gene-level AUC’s are 
nevertheless high might be due to the use of 10 guides per gene, which is 2x as many as 
the next data-set, and which would likely yield more accurate gene-level values on average.  
Further, I found that the guide-level AUC’s for the same cell lines between Project 
Score and Achilles (n = 83) are significantly correlated (p < 0.002, Figure 5.5). This suggests 
that certain cell lines are inherently more difficult to screen than others, but even on a per-
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cell line level, more cell line showed higher AUC’s when screened in the Project Score data 
set over the Achilles data set. 
Overall, with some individual exceptions, the majority of precision-recall AUC’s are 
relatively comparable across all samples on both the guide-level (IQR: 0.725-0.805) and the 
gene-level (IQR: 0.862-0.894). Instances for which the AUC’s are low should however be 
kept in mind and should be considered in down-stream analyses during the interpretation 
of findings. This analysis shows that all data sets are of comparable quality. Also 
considering that the sgRNA distribution across fusion genes may vary by data set, I 
included data from all three datasets in my future analyses. This also means that for fusions 
in cell lines tested by multiple datasets I also calculated multiple FES.  
5.3.3 sgRNA coverage 
FES calculation can be performed for any fusion transcript that has at least one 
sgRNA mapping to a fused portion of either partner gene. However, in general the 
calculation will yield a more informative result 1) the higher the total number of mapping 
sgRNAs is and 2) if the number of mapping and non-mapping sgRNA are approximately 
balanced. 
The calculation benefits from a higher number of mapping sgRNA in order to 
reduce noise from known and unknown CRISPR sgRNA biases. Whole genome 
CRISPR/Cas9 screens typically rely on 4-10 sgRNA per gene to give an accurate 
  
Figure 5.5: Precision-recall AUC’s for each sample screened by CRISPR/Cas9, calculated by (A) guide-level 
and (B) gene-level. (C) Correlation of guide-level precision-recall AUC’s for 83 cell lines that were screened 
by both Project Score and Achilles. Purple dots represent cell lines where Project Score has higher AUC than 
Achilles and yellow dots represent the reverse. 
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representation of gene essentiality, but since not all sgRNA in the whole genome sgRNA 
libraries will be transcript-mapping, some FES may be calculated from a low number of 
sgRNA. The Wang et al. CRISPR library has the highest mean number of targeting sgRNA 
per fusion transcript, followed by the Project Score and then Achilles libraries (9.95, 5.0 and 
3.96 respectively, Figure 5.6A). However, the variation is quite large, with 11.1% of tests (n 
= 372) being performed based on only a single mapping sgRNA, and a further 9.5% of 
tests (n = 319) based on two mapping sgRNAs. FES calculations using the lower numbers 
may be more prone to noise and when evaluating the results of the analysis, it is important 
to be aware of these potential caveats. 
Secondly, a FES can be calculated for a fusion transcript where for both partner 
genes only one type of sgRNA is available (i.e. mapping OR non-mapping, but not both). 
In total, 54.7% of the tests conducted involve differentially mapped sgRNA to either the 5’ 
or the 3’ fused gene, though as might be expected, this proportion is highest in the library 
by Wang et al, which has 10 sgRNA per genes (Figure 5.6B). Of the remaining, there is a 
slightly higher percentage of transcripts for which the 5’ gene has only mapping sgRNA, 
compared to the 3’ gene (19.6% vs. 17.2%), although this seems to be driven mainly by the 
trend in the Achilles data (Figure 5.6B). Also interesting to observe is that around a third of 
the fused genes are targeted by not a single mapping sgRNA, this number being slightly 
 
Figure 5.6: Overview of sgRNA coverage across fusion transcripts. (A) Distribution of total number of fusion-
targeting sgRNA per test performed for each data set. (B) Percentage of transcripts with differentially 
mapping sgRNA for either gene (overall), and specifically for the 3’ or the 5’ gene. 
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lower for the 3’ gene in the Wang et al. data set (16.4%) and higher for the 3’ gene in the 
Achilles data set (43.6%) (Figure 5.6B). 
It is important to keep in mind that FES calculations for transcripts with differentially 
mapping sgRNA for neither gene may be more prone to false positives, as fusion-specific 
and gene-specific effects may be difficult to untangle. In those cases, further evidence 
should be considered, for example whether any confounding events are present (e.g. 
amplification events that may lead to local wide-spread structural rearrangements). These 
cases would also benefit from validation experiments to confirm the fusion-specific effects, 
e.g. using CRISPR/Cas9 system with tailored sgRNA. 
5.3.4 sgRNA efficacy 
A further metric to estimate the effectiveness of a CRISPR/Cas9 screen is to examine 
the ability of individual sgRNA to have a deleterious effect in any cell line. One approach 
is to examine the number of cell lines within which a given sgRNA has a low scaled logFC, 
i.e. a high deleterious effect. I used a threshold of -1 to define sgRNAs with high effect in 
a given cell line, since the sgRNA depletion scores were scaled so that on average, essential 
genes would have a scaled logFC of -1. Then counting the number of sgRNA which are 
depleted at a scaled logFC of at least -1, I find that overall, 45.5% of sgRNA are depleted 
in at least one cell line. The proportions are much higher in the Achilles and Project Score 
data sets (66.1% and 60.6%; Figure 5.7), presumably due to the larger number of samples 
tested compared to Wang et al. 
When targeting genes of unknown essentiality, a lack of deleterious effect in any 
cell line can be due to several reasons: 1) the gene is not an essential gene, 2) gene is 
essential in some instances, however those are not captured in the samples tested and 3) 
the gene is essential, but the sgRNA was not effective.  
To focus on cases where the gene should be essential, but the sgRNA was not 
effective, I specifically examined sgRNA that are a priori known essential and non-essential 
(the same set as used to scale logFCs in section 5.2.6). Among 6,465 sgRNA that target 
known essential genes, 83.4% where depleted in at least one cell line, with some variation 
between different data sets (Figure 5.7B). The number of depleted cell lines per sgRNA 
varied greatly, e.g. sgRNA targeting C11orf24 were depleted to that threshold in only 5 
instances, while at the other end RPS3A and RPS8 targeting sgRNA were on average 
depleted in about 90% of samples. However out of the 360 a priori known essential genes, 
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all exhibited a high depletion value with at least one sgRNA, which suggests that the 16.6% 
of sgRNA that are not highly depleted in any cell line may in fact have low efficacy in 
creating gene knock-out.  
On the other hand, the depletion pattern of non-essential guides broadly 
resembles that of all other guides (Figure 5.7C). Of those targeting non-essential genes, 
37.1% of sgRNA still show high depletion in at least one cell line. These observations may 
be due to noisiness of the screen or off-target effects. Similarly, in the original publication 
of this set of reference non-essential genes, the authors selected protein-coding genes 
with expression levels below 0.1 FPKM in 15 of 16 BodyMap tissues and 16 of 17 ENCODE 
cell lines (Hart et al., 2014). As our data set of over 300 CRISPR-screened cell lines is much 
larger than that, it is indeed a possibility that a portion of the a priori non-essential may in 
fact be essential in a low number of cell lines.  
In conclusion, the analysis above gives an indication that a proportion of sgRNA 
are indeed expected to have low efficacy in the screen. This result may impact FES 
calculations performed using very few targeting sgRNA. At the same time, when the FES 
calculation yields non-significant results, it may be useful to check the general efficacy of 
the involved sgRNA across other samples to avoid misinterpreting a false negative. 
  
 
Figure 5.7: Number of guides that show high depletion (scaled logFC < -1) in at least one cell line, for (A) all 
sgRNA, (B) essential sgRNA only and (c) non-essential sgRNA only. 
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5.4 Chapter conclusion 
This chapter outlines my method as well as quality control elements in my approach 
of using CRISPR/Cas9 screening data to generate scores of fusion-specific essentiality in 
cancer cell lines. I showed how I calculated a fusion essentiality score (FES) for 339 cancer 
cell lines for which I had data available, covering 27% (n = 2,821) of the fusion transcripts 
identified overall. Further, my data QC showed that precision-recall AUCs are relatively 
comparable across all samples at the guide-level as well as the gene-level. Importantly, 11% 
of tests are based on only a single fusion-mapping sgRNA and only 54.7% of transcripts 
have differentially mapping sgRNA to a single gene. Either of these may contribute to 
noisiness in the data, which should be kept in mind for future data interpretation. 
Overall, the above chapter provides the basis for the next chapter, which will give 
a general overview of the results as well as some specific examples that illustrate the power 
of the approach. A comprehensive discussion of the important findings and learnings in 






6 Identifying functional gene fusions using CRISPR/Cas9 whole 
genome screening data 
This chapter is based on the concept and methodology described in chapter 0. Here, 
I first provide a general overview of the results and a brief introduction into how to 
interpret the data and graphs in this chapter. I then set out to understand the distribution 
of significantly essential fusion essentiality scores across the data set, show the validation 
of known oncogenic fusions and finally end by highlighting a few specific interesting novel 
findings.  
6.1 Fusion Essentiality Scores 
Using the methods described in chapter 5.2, I calculated 3,349 fusion essentiality 
scores (FES) for 2,821 unique fusion transcripts in 339 cell lines (Supplementary Table 8).   
Across all fusion transcripts in all three data sets, only 4.6% of transcripts had a FES 
with a FDR < 5%, 6.8% at FDR < 10% and 13.7% at FDR < 25%. Within the data-sets, some 
differences could be observed (Figure 6.1). 
The data set by Wang et al shows a particularly high proportion of fusion transcripts 
with highly significant FES. This is likely due to the fact that the 11 acute myeloid leukaemia 
cell lines contain a high proportion of known oncogenic driver fusions. In fact, 8% of fusion 
transcripts tested in the Wang et al dataset are listed in the COSMIC fusion census, 
compared to 2% of the fusion transcripts in the other two datasets.  
  
Figure 6.1: Proportion of significant results in each of the three CRISPR/Cas9 data sets.  
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6.1.1 Two specific examples of the fusion essentiality analysis 
To help interpret the FES analysis, I next describe two examples, of which one is a 
known essential fusion and another a known confounder.  
KMT2A-MLLT3 
As described in the previous chapter, KMT2A-MLLT3 fusions are well studied for 
inducing tumour initiation in acute leukaemias. Previous studied have shown that 
withdrawal of KMT2A-MLLT3 in an inducible in vivo system leads to disease regression 
(Zuber et al., 2011). The MOLM-13 cell line is an acute myeloid leukaemia cell line that 
carries the fusion protein. The fusion transcript brings together exon 8 of KMT2A and exon 
6 of MLLT3.  
MOLM-13 was previously screened in a whole-genome CRISPR drop-out screen by 
Wang et al. (Wang et al., 2017). Their whole-genome CRISPR guide library (Wang et al., 
2014) contains 10 guides that map to KMT2A and another 10 guides that map to MLLT3. 
Of those, 8 guides map to the fused region of KMT2A and 3 to that of MLLT3, while the 
rest map to the unfused portions of the genes (Figure 6.2A). By mapping scaled fold-
changes on a guide-by-guide-basis, as expected from an essential fusion, I find that 
mapping guides have a lower fold-change than non-mapping guides (Figure 6.2B), 
indicating they are preferentially deleted. The FES for this fusion transcript is 1.85 and 
highly significant at p < 0.001 and FDR < 0.001. 
ERBB2-CDK12 
The gastric carcinoma cell line NCI-N87 harbours an ERBB2-CDK12 fusion transcript 
that is likely a passenger fusion due to a copy number gain of ERBB2. NCI-N87 has been 
screened as part of the Project Achilles (Meyers et al., 2017) using a library that contains 
three mapping and one non-mapping sgRNA on ERBB2 and four non-mapping guides on 
cyclin dependent kinase 12 (CDK12) (Figure 6.2C).  
After mapping scaled fold-changes on a guide-level basis, as expected, all sgRNA 
mapping onto ERBB2 are depleted, regardless of whether they target the fused portion or 
not (Figure 6.2D). Thus, as the depletion of sgRNA is not specific to fusion-mapping regions, 
the FES is low at 0.05 and not significant (p > 0.5 & FDR > 85%).  
Here it is important to highlight a potential caveat of the method: since the CRISPR 
sgRNA library was not specifically designed for this usage, for many fusion transcripts, the 
sgRNA mapping locations may be unbalanced. For instance, in NCI-N87, aside from ERBB2-
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CDK12, we also detect another ERBB2-fused transcript, ERBB2-JUP. In this transcript 
however, ERBB2 is fused in a way so that all sgRNA target locations are preserved. When 
calculating the FES, thus all fusion-mapping guides will be depleted due to the essentiality 
of ERBB2, and since for transcripts with no differential mapping guides the difference is 
taken from zero, the FES is high at 4.0 and significant at p < 0.001 and FDR < 0.001 (Figure 
6.2E).  
As we are aware of the oncogenic driver effects and essentiality of amplified ERBB2, 
we can declare this transcript a false positive with high confidence. However in cases where 
the cell-line specific essentialities of genes are not understood, it is important to be aware 
that this type of sgRNA mapping pattern may lead to misleadingly high significance of 
passenger events. 
6.2 Gene set enrichment analysis of fusion essentiality score significance 
In order to find out whether certain categories of gene fusions are enriched for 
significant FES, I next annotated all tested fusion transcripts according to 10 distinct 
categories, as described below, and conducted a gene-set enrichment analysis using the 
piano R package with its default settings (Väremo et al., 2013). I used the p-values of FES 
 
Figure 6.2: Examples for fusion essentiality score calculation for (A,C) a known driver fusion transcript, 
KMT2A-MLLT3 and (B,D,E) for a known confounded fusion transcript. Data source for each set of sgRNA is 




as gene level statistics. Only 2 out of 10 categories were significantly enriched after p-value 
adjustment: 1) fusion transcripts that were listed in the COSMIC fusion census and 2) fusion 
transcripts that had significant associations with any drug in our fusion-drug association 
analysis (Table 6-1, Figure 6.3).  
 
Figure 6.3: Overview of 3,349 fusion essentiality scores. Annotation shows fusion essentiality scores where 
the fusion transcripts belong to a certain category (e.g. fusions includes genes in COSMIC gene census, kinase 
genes, essential genes, etc.).  
 
 
Table 6-1: Gene-set enrichment test scores, ordered by significance of adjusted p-value.  
Name Genes  Stat p p adj. 
COSMIC fusion census 48 0.17736 1.00E-04 0.00035 
Significant in ANOVA 106 0.29554 1.00E-04 0.00035 
In-frame 750 0.4057 0.039796 0.11143 
Patient samples 187 0.40543 0.21268 0.33083 
Deleted 50 0.38332 0.18128 0.33083 
COSMIC gene census 443 0.41159 0.20428 0.33083 
Recurrent in patient samples 63 0.40188 0.29697 0.41576 
Amplified 299 0.41573 0.34647 0.44096 
Essential gene 105 0.42031 0.46345 0.5407 




In the next paragraphs, I describe the definition and context of annotation sets, and 
the results from this analysis. 
Amplified/deleted  
For this annotation, I used the gene-level PICNIC (predict integral copy number in 
cancer) scores, published by COSMIC for each cell line (Greenman et al., 2010), for both of 
the partner genes involved in a fusion event. PICNIC scores represent the total number of 
copies found for a gene in the genome of a given cell line. A fusion event is annotated as 
deleted or amplified, if the PICNIC score of either one of the two partner genes is either -
1 (deleted) or higher than 8 (amplified). The threshold of 8 to define amplified genes was 
used to follow the classification used for the COSMIC cell line data (Forbes et al., 2017).  
The annotation mainly served as a negative control. As amplified genes are known 
to cause CRISPR-screen biases (as discussed in chapter 5.2.5), although I already performed 
a correction of CNV regions using CRISPRcleanR (see section 5.2.5), I still wanted to test 
whether fusion events containing amplified or deleted genes may showed biased FES FDR’s. 
P-values were not significant for either (adj. p = 0.44 and 0.33 respectively), which showed 
that the FES calculation was not biased by copy number status. 
Essential genes  
Here, I annotated fusion transcripts where either partner gene is part of the list of 
high-confidence pan-essential genes published by Hart and colleagues (Hart et al., 2014). 
An enrichment of essential genes at higher significance level might have indicated that 
genes that are universally highly essential could cause biased FES for reasons unrelated to 
the fusion transcript. After performing the gene set enrichment analysis, I observed no 
such enrichment (adj. p = 0.54). 
Kinase genes  
Kinase genes, which include ALK and ABL1, are commonly fused oncogenes, and 
previous publications specifically analyse the landscape of kinase fusions in cancer 
genomes (Gao et al., 2018; Stransky et al., 2014). A list of kinase genes was published by 
Gao and colleagues as part of their work to landscape fusion events in patient tumours 
(Gao et al., 2018). I annotated any fusion event that includes a kinase gene in either the 5’ 
or 3’ partner gene, but there was no significant enrichment (adj. p = 0.92). This suggests 
that although known oncogenic fusions commonly involve kinase genes, simply detecting 
a fusion involving a kinase gene gives no indication of functional relevance. In those cases, 
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the identity of the partner genes, the predicted breakpoint and the tissue context should 
be considered and functionality needs to be confirmed in further analyses. 
In-frame  
The frame of fusion transcripts is predicted using the GRASS score (see section 3.4). 
Any fusion transcript that is called with a GRASS flag of 880 and above is defined as in-
frame (Cancer IT, 2018b) and thus annotated. The gene set enrichment analysis shows that 
in-frame fusions are not significantly enriched across the FES FDR (adj. p = 0.11). This is 
perhaps not surprising, since if we assume that non-oncogenic breakpoints are randomly 
distributed across the genome, a third of breakpoints within coding regions would be in-
frame simply by chance. Since only about 4.5% of fusion transcripts have significant 
essentiality using our analyses, the majority of in-frame fusion transcripts are likely to be 
passenger events. 
COSMIC fusion census 
Here, I annotated any fusion transcript between two specific partner genes that are 
listed in the COSMIC fusion census. The census is a manually curated database for gene 
fusions for which there is published evidence of their involvement in cancer processes 
(https://cancer.sanger.ac.uk/cosmic/fusion). There is a clear and significant enrichment of 
fusion transcripts that are listed within the COSMIC fusion census (p < 0.0004). This 
enrichment suggests that my computational approach is able to detect functional cancer 
driver fusion with good sensitivity. Fusion transcripts that match the COSMIC fusion census 
are discussed in further detail in section 6.3 below. 
COSMIC gene census  
This category includes fusion events that involve a gene that is listed in the COSMIC 
gene census, a data-base of manually curated cancer driver genes 
(http://cancer.sanger.ac.uk/census). Known cancer driver genes that are fused may have 
cancer-related functionality. For example, fusions of oncogenes can lead to constitutive 
activation of a kinase, e.g. in the case of BCR-ABL1 and NPM1-ALK, or of a transcription 
factor binding site, e.g. in CRTC1-MAML2. Nonetheless, I observe no enrichment of fusions 
involving cancer driver genes in the FES FDR’s (p = 0.33). This suggests that gene fusions 
in cancer driver genes might be common and researchers that observe such fusions in 
individual samples should be careful not to over-interpret those findings without 
additional evidence of functionality.  
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(Recurrent in) patient samples 
Here, I annotated any fusion that was reported by Gao et al. (Gao et al., 2018) in 
their high-throughput RNA-seq analysis of almost 10,000 TCGA patient samples. A 
recurrent patient sample is any fusion that is reported in at least two or more different 
samples. That neither category was significantly enriched for low FES FDR’s (p = 0.33 and 
0.42 respectively) underscores the fact that mere observation of a fusion, even if recurrent, 
is not a good predictor of potential functionality of a fusion.  
Significant in ANOVA 
This category contains any fusion that is significantly (FDR < 25% and Glass Deltas > 
1) associated with any drug as part of the fusion-drug-association analysis (see chapter 3). 
That this category is significantly enriched is perhaps not surprising, as it contains several 
known oncogenic driver fusions.  
In total, 57 fusions fall under this category, making up 130 fusion transcripts. 10 of 
those fusions have at least one transcript that is significant at FDR < 5%. Five of the ten are 
well-known oncogenic drivers (EML4-ALK, EWSR1-FLI1, KMT2A-MLLT3, CRTC1-MAML2, 
FGFR3-TACC3). Two of the ten (FGFR2-ATE1, ERBB2-JUP) are known confounded events, 
as described in chapter 3.  
A further 3 fusions belong to neither category (APIP-SLC1A2, SLC12A7-TERT, LRP5-
RP11-554A11.9). However, it is important to note that mapping sgRNA were unequally 
distributed across the fusions. In APIP-SLC1A2 and SLC12A7-TERT, mapping sgRNA were 
concentrated in a single gene that also had no non-mapping sgRNA (Figure 6.4A). Unlike 
fusions with differentially mapping sgRNA within the same gene, this type of mapping 
status makes false positives more likely when the gene with mapping sgRNA is essential in 
the cell line regardless of the fusion status, as in Figure 6.4B. Similarly, the LRP5-RP11-
554A11.9 fusion only has sgRNA mapping onto the LRP5 gene, as the 3’ portion aligns to 
an uncharacterised mRNA RP11-554A11.9. The significance of non-protein forming mRNA 
is currently unknown.  
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While these fusions have been found in multiple cell lines, CRISPR-screening data 
was only available in a single cell line. Future CRISPR-screening data in the untested cell 
lines may reveal either opposing or supporting evidence for the functionality of these 
fusions. 
6.3 Detection of known oncogenic gene fusions 
Across all tests performed, 61 transcripts involved genes in the COSMIC fusion 
census. This involves 30 unique fusion events with 20 unique fusions. The remaining 31 are 
fusion transcripts with alternative breakpoints (n = 18) and the same fusion transcripts 
tested with data from another data set (n = 13). 
Of the 30 unique fusion events, 16 (53%) have a significant FDR of < 5% in at least 
one transcript in one data set. These include extensively studied oncogenic fusions, 
including EWSR1-FLI1, KMT2A-MLLT3, EML4-ALK and others (Figure 6.5A). Two more fusion 
events, KMT2A-MLLT3 in NOMO-1 and NPM1-ALK in KARPAS-299, narrowly miss the FDR 
threshold at FDR = 11.8% and 13.5% respectively (Figure 6.5B).  
A further twelve (40%) fusion events that match the COSMIC fusion census have an 
insignificant FDR at > 25%. However when I manually curated these fusions, they were 
linked to single publications (Figure 6.6). Six of the seven (PLXND1-TMCC1, EIF3K-CYP39A1, 
PLA2R1-RBMS1, NFIA-EHF, MBOAT2-PRKCE and SLC26A6-PRKAR2A) were detected in the 
  
Figure 6.4: Visualisation of selected fusions with high significance in both the drug-association analysis and 
the fusion essentiality analysis. (A) uncharacterised fusions and (B) known confounded fusions. 
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same paper which described somatic rearrangements in 24 human breast cancer genomes 
(Stephens et al., 2009). Notably, none of the six fusion transcripts were described or even 
named in the main text, so the inclusion into the COSMIC fusion census is likely to have 
been due simply to detection. Further, three of the above fusions were tested in two 
different data-sets and the lack of significance is in agreement in all tests conducted (Figure 
6.6B-D) 
A seventh fusion, an ARID1A-MAST2 fusion in the breast cancer cell line MDA-MB-
468, was described in a publication by Robinson and colleagues (Robinson et al., 2011) in 
the exact same cell line. In their publication, siRNA knock-down of microtubule associated 
serine/threonine kinase 2 (MAST2) mRNA led to reduced cell growth of MDA-MB-468, and 
introduction of MAST2-fused gene vectors into a control cell line produced accelerated cell 
growth. The authors did not perform experiments that tested whether this effect was 
caused by the specific fusion transcript, or whether these cell lines are simply more reliant 
on MAST2. By chance, MDA-MB-468 was screened across two different data-sets, Project 
Score and Achilles and the FES for the ARID1A-MAST2 fusion is significant in neither (Figure 
6.6A). Notably, several MAST2-targeting sgRNA in both the Achilles (n = 2), as well as the 
Project Score (n = 3) data show high depletion levels (i.e. scaled logFCs < -1) in at least 2 
other samples, which suggests that the sgRNA are functional and the lack of depletion is 
 
Figure 6.5: Visualisation of scaled log fold-changes across well-studied oncogenic gene fusions for both (A) 
highly significant examples at 5% FDR and (B) less significant examples at FDR < 25%. 
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not a false negative. Considering the negative finding and that aside from the original 
publication in 2011, no other publication has since been published on ARID1A-MAST2, I 
conclude that the evidence for functionality of the ARID1A-MAST2 gene fusion in breast 
cancers is unclear and the fusion may constitute a passenger event rather than an 
oncogenic driver.  
To sum up the above two paragraphs, I argue that for the seven fusions described 
above, despite their inclusion in the COSMIC fusion census, evidence for their functionality 
is weak and that they should thus be removed when considering the sensitivity of my 
computational approach to detect true positive fusions. 
Thus considering only the remaining 23 fusion transcripts, my approach detects 16 




Figure 6.6: Visualisation of scaled log fold changes for seven fusion transcripts that match the COSMIC fusion 






Table 6-2: All 30 fusion events that match the COSMIC fusion census, ordered by FDR. Thick black borders 
denote stringent threshold (FDR < 5%), permissive threshold (FDR < 25%), not significant fusion events and 
not significant fusion events excluded for reasons described in section 6.2. In patient samples refers to fusions 
found in TCGA samples by Gao and colleagues (Gao et al, 2018). Excl refers to fusions which are excluded 
due to weak evidence of functionality. 
Cell line Fusion name FES p-value FDR In patient tumours? Excl? 
ES4 EWSR1-FLI1 1.82 0 0 No 
 
ES6 EWSR1-FLI1 2.43 0 0 No 
 
ES8 EWSR1-FLI1 1.97 0 0 No 
 
EW-16 EWSR1-FLI1 2.18 0 0 No 
 
EW-7 EWSR1-FLI1 1.96 0 0 No 
 
KM12 TPM3-NTRK1 1.92 0 0 Yes 
 
MC-IXC EWSR1-FLI1 2.32 0 0 No 
 
MHH-ES-1 EWSR1-FLI1 2.69 0 0 No 
 
MOLM-13 KMT2A-MLLT3 2.31 0 0 Yes 
 
NB4 PML-RARA 2.12 0 0 Yes 
 
NCI-H3122 EML4-ALK 4.47 0 0 Yes 
 
OCI-AML2 KMT2A-MLLT4 3.05 0 0 No 
 
RT-112 FGFR3-TACC3 4.18 0 0 Yes 
 
SBC-3 BRD4-NUTM1 3.84 0 0 No 
 
THP-1 KMT2A-MLLT3 1.41 0 0.31 Yes 
 
H3118 CRTC1-MAML2 4.4 0 0.78 No   
NOMO-1 KMT2A-MLLT3 1.89 0.005 11.77 Yes 
 
KARPAS-299 NPM1-ALK 0.76 0.006 13.48 No   
RT4 FGFR3-TACC3 2.62 0.102 46.82 Yes   
HCC-78 SLC34A2-ROS1 2.35 0.146 51.12 Yes 
 
EGI-1 PTPRK-RSPO3 0.64 0.363 73.38 No 
 
SUP-M2 NPM1-ALK 0.08 0.436 81.64 No 
 
ESO51 EIF3E-RSPO2 -0.9 0.644 88.68 No   
HCC38 SLC26A6-PRKAR2A 0.29 0.156 52.52 No Y 
HCC1395 EIF3K-CYP39A1 0.77 0.165 53.26 No Y 
HCC1937 NFIA-EHF 0.29 0.155 59.92 No Y 
HCC1395 PLA2R1-RBMS1 0.24 0.264 69.85 No Y 
MDA-MB-468 ARID1A-MAST2 0.16 0.373 74.32 No Y 
HCC38 MBOAT2-PRKCE 0.05 0.458 79.48 No Y 




6.4 Reproducibility of significant FES across data sets 
In order to understand the reproducibility of significant FES in different testing 
conditions and with different sgRNA libraries, I next examined the significantly essential 
fusion events tested in different data sets. In total, 27 significantly essential (FDR < 5%) 
fusion events were tested in two different data sets. None was tested by all three data 
sources. Of those, only 10 (37%) were significant at a less stringent FDR < 25% threshold 
in both data sets (Figure 6.7A). Among those that replicate across multiple data sources, I 
observe a large number of known cancer drivers, e.g. KMT2A-MLLT3, PML-RARA, TPM3-
NTRK1.  
In previous chapters I showed that non-differentially mapping sgRNA may be more 
prone to false positive errors. Thus, I was interested to examine whether there would be 
differences in reproducibility from FES calculated from differentially mapping and non-
differentially mapping sets of sgRNA. Indeed, I found that significantly essential fusion 
events called from non-differentially mapping sgRNA are less likely to reproduce in a 
different data set (one-tailed t-test: p = 0.033, t = -2.1; Figure 6.7B). This corresponds to 
71% of differentially mapping transcripts validating, vs. 30% for the remaining transcripts.  
An example of that is the FGFR2-MRPL13 fusion in NCI-H716, a colorectal cancer 
cell line with a known FGFR2 copy number gain (Forbes et al., 2017). In the Project Score 
data, all 8 sgRNA targeting FGFR2 and mitochondrial ribosomal protein L13 (MRPL13) are 
fusion-mapping and on average highly depleted (p < 0.001 & FDR < 0.001, Figure 6.7C). 
In the Achilles data, only a single sgRNA targeting MRPL13 maps to the fusion, while the 
non-fusion-targeting sgRNA for FGFR2 are still highly depleted, thus giving an insignificant 
result (p = 0.089; FDR > 44%).  
On the other hand, a non-reproducing result may also be caused by screening 
noise. For instance, a fusion between phosphatidylinositol binding clathrin assembly 
protein (PICALM) and MLLT10 is detected in about 7.5% of patients with T-cell acute 
lymphomas and leukaemias (Nigro et al., 2013). A previous study showed that RNAi-based 
knock-down of PICALM-MLLT10 leads to reduced viability in vitro and decreased invasive 
ability when transplanted in vivo (Okada et al., 2006). A PICALM-MLLT10 fusion in P31-FUJ, 
an acute myeloid leukaemia cell line, is significantly essential according to the Achilles data, 
but not the Wang et al data. Although in the latter, the majority of targeting guides show 
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relatively consistent high depletion, some noisiness in the data on MLLT10 non-fusion-
mapping guides yields a lower scaled logFC (Figure 6.7D).  
A third source of noisiness could arise from the Z-normalisation that I apply on 
scaled logFCs that seeks to consider how much the effect of a sgRNA differs in a given cell 
line compared to all other samples. The Z-normalisation identifies and gives weight to true 
outliers from a population. Most scaled logFCs, depending on the genes in question, are 
distributed approximately normal, with significantly depleted sgRNA often producing a 
secondary peak. However, in a noisy screen, highly exceptional depletion effects may arise 
through one-off technical artefacts, especially when a sgRNA overall shows a narrow 
 
Figure 6.7: Examination of reproducibility of significantly essential fusion transcripts across multiple data sets. 
(A) 27 fusion events that are significantly essential in at least one dataset. Numbers represent the FDR (%). 
The black line separates fusion events for which the two data sets are in concordance (top) and those in 
opposition (bottom). (B) Where two FES are available for the same fusion transcript, the FES with the higher 
FDR was assigned as “replicate” (y-axis), while the FES was assigned as either differentially mapping, or other, 
based on its mapping status. Significantly essential fusion events are more likely to be reproducible if they 
were based on differentially-mapping sgRNA (one-tailed t-test; p = 0.033; t = -2.1). (C) Non-differentially 
mapping sgRNA lead to the false positive calling of the FGFR2-MRPL13 fusion in the Project Score data. (D) 
Screening noise leads to the likely false negative result in the Wang et al. data for PICALM-MLLT10. 
150 
 
distribution of low depletion effects. In such cases, a Z-normalisation may distort data and 
yield false positives. In the short-term, this issue can be circumvented by manually 
inspecting the scaled logFCs to confirm that an assumed high depletion is also found in 
the non-normalised data. In the long-term, it would be advisable to conduct an analysis to 
compare the impact of the Z-normalisation on data distortion, and whether there may be 
better methods to solve the question of outlier-identification. 
In conclusion, while previous sections showed that my computational approach is 
able to detect known oncogenic fusions with high sensitivity, this section shows that noise 
is nonetheless expected to exist and may add false positives as well as false negatives. 
Non-differentially mapping sgRNA are especially prone to calling false positives. However, 
as due to the pre-determined sgRNA library design and as they are still effective in calling 
known true positives (e.g. TPM3-NTRK1, FGFR3-TACC3 etc; see section 6.3), I decided to 
retain these tests. However, when evaluating those results, it is important to be aware of 
any confounding factors, and consider stringent validation experiments to confirm that 
findings are indeed true positives. 
 
6.5 Overview of less studied significant fusion transcripts 
After establishing some aspects of the sensitivity and specificity of my 
computational approach in identifying true known oncogenes, I return to the aim of 
discovering novel functionality of fusion events.  
In total, 138 of the 3,349 tests returned a significant FES at FDR < 5%. Next, because 
I am specifically interested in fusions that are highly essential, but a high FES can be caused 
by non-mapping guides showing positive selection, I also filter out fusion transcripts for 
which the mean scaled logFCs of mapping guides is larger than -0.45. This leaves 93 high 
effect, significantly essential tests. The threshold of -0.45 was chosen to retain known 
oncogenic fusions. 
Out of those, 14 tests confirmed the same fusion transcripts across two data-sets.  
A further 49 of them tested the same fusion events across an alternative breakpoint. Thus, 
the number of fusion events that have at least one significant transcript from any data set 
at FDR < 5% is 65.  
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The 63 unique fusion events constitute 56 unique fusions. In total, and nine of the 
56 (16%) are COSMIC fusions (Figure 6.8). 37 (66%) fusion events involve a gene in the 
COSMIC gene census. 12 fusion events (21%) were previously observed in the ~10,000 
TCGA patient samples (Gao et al., 2018). However, here it is worth noting that some known 
oncogenic fusions are also not observed in that set of patient samples, e.g. EWSR1-FLI1, 
NPM1-ALK. This indicates that although that set of patient samples brings valuable insight 
into the landscape of fusions, it is by all means not comprehensive in representing all true 
oncogenic fusions. 4 fusion events (7%) involve a gene that is amplified and a known 
oncogenic driver and are thus likely to be false positives (ERBB2-JUP, ERBB2-LTBP4, PVT-
MYC and FGFR2-COL14A1).  
Notably, only 3 fusions are detected as significantly essential in more than a single 
cell line (Figure 6.8). These are EWSR1-FLI1 (n = 7), YAP1-MAML2 (n = 3) and KMT2A-MLLT3 
(n = 2). EWSR1-FLI1 and KMT2A-MLLT3 are both well-studied oncogenic fusions, and their 
essentiality is present in cell lines from cancer types consistent with the clinical profile, i.e. 
EWSR1-FLI1 fusions appear only in Ewing’s sarcoma and KMT2A-MLLT3 only appear in 
Acute myeloid leukaemia cell lines. The third recurrent fusion, the previously 
 
Figure 6.8: Overview of high effect significant (FDR < 5%; mean scaled logFC < -0.45) fusion transcripts from 
CRISPR/Cas9 analysis for fusion essentiality.  
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uncharacterised YAP1-MAML2 is an interesting case, which, I examine in further detail in 
the next paragraph. 
 
6.5.1 YAP1-MAML2 
Unlike any other fusion of unknown background, I found significant essentiality in 
all three cell lines in which YAP1-MAML2 was detected, AM-38 (glioblastoma), ES-2 (ovarian 
carcinoma) and SAS (head and neck carcinoma). Further, one of the samples, ES-2, was 
tested and YAP1-MAML2 was found as significantly essential in both the Achilles and the 
Project Score data, thus adding robustness and confidence in this being a true positive 
observation. Further, depletion of fusion-mapping sgRNA targeting MAML2 is specific to 
the three cell lines with the YAP1-MAML2 fusion (Figure 6.9B). One notable exception is 
the head and neck cell line H3118, which harbours the known oncogenic CRTC1-MAML2 
fusion.  
While multiple transcripts are found in AM-38 (n = 2) and SAS (n = 3), one of the 
breakpoints is conserved across all three cell lines. This breakpoint of position 102,206,074 
and 96,093,517, both on chromosome 1, produces an in-frame transcript that brings 
together exons 1-5 of YAP1 and exons 2-5 of MAML2 (Figure 6.9C). In order to confirm the 
presence of the fusion transcript, we performed PCR validation using cDNA purified from 
the cell lines, interphase FISH and fibre-FISH (Figure 6.9D-E) 4.  
Interestingly, although YAP1-MAML2 has never been functionally characterised to 
date, it was previously reported in a nasopharyngeal carcinoma, a sub-type of head and 
neck carcinomas, where the authors showed that the fusion is likely to result from a 
coupled inversion (Valouev et al., 2014). A YAP1-MAML2 fusion was also detected in a skin 
cancer sample analysed as part of the ~10,000 TCGA patient samples (Gao et al., 2018). 
Strikingly, in both of those patient samples, the breakpoint of the fusion is conversed and 
identical to that found in our cell lines. 
                                                 
4 The follow-up work on the YAP1-MAML2 fusion was performed in close collaboration with 
Gabriele Picco, a post-doctoral researcher at the Wellcome Sanger Institute. Gene set enrichment 
analysis, PCR validation and FISH were planned and performed by him. Methods are described in 
Picco* and Chen*, et al (manuscript under review). 
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The evidence above strongly suggest that it is indeed the YAP1-MAML2 fusion and 
not the individual genes themselves that are essential for cell line survival. YAP1 
overexpression has previously been linked to oncogenic effects in multiple solid tumours. 
For instance, an expression signature related to YAP1 overactivation is associated with poor 
prognosis in colorectal cancer (Lee et al., 2015b). In pancreatic carcinomas YAP1 activation 
 
 
Figure 6.9: Novel functionality for YAP1-MAML2 fusion found in three cell lines. (A) CRISPR profiles in all 
three cell lines. ES-2 was tested in both Project Score and Achilles guide libraries. All p < 0.001 & FDR < 
0.001. (B) Fusion-targeting sgRNA for MAML2 are uniquely depleted in MAML2-fused cell lines. (C) Exons 1-
5 of YAP1, which contain the TEAD binding domain, are fused to exons 2-5 of MAML2, which contains a 
transcription activation domain (TAD). (D) Interphase FISH in AM-38 and Fibre-FISH in AM-38, ES-2 and SAS 
confirm the presence of the YAP1-MAML2 fusion in all three cell lines. (E) PCR validation of the fusion in all 
three cell lines. HCT116 is a negative control without the fusion. (F) Gene set enrichment analysis shows YAP-
conserved signature as the top most enriched gene set in cell lines with YAP1-MAML2 fusion (adj. p < 0.001). 
(G) YAP-conserved signature is enriched when comparing ES-2 against all other ovarian cancer cell lines and 
SAS against all other head and neck cell lines. Conversely, the tissue prototypic signatures (i.e. oestrogen 
response and KRAS signature respectively) are negatively enriched in the fused cell lines.  
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bypassed KRAS addiction (Kapoor et al., 2014). In oesophageal cancer, YAP1 upregulation 
led to EGFR expression and resistance to chemotherapy (Song et al., 2015).  
The oncogenic function of YAP1 is typically attributed to its role as a transcriptional 
co-activator that activates the Hippo pathway. Previous work shows that Hippo pathway 
activation is driven in particular with binding to the TEA domain transcription factor 1 and 
2 (TEAD1/2) (Harvey et al., 2013). On the other hand, MAML2 is a transcriptional co-
activator normally involved in NOTCH signalling (Kitagawa, 2016). MAML2 is also known 
in the context of the well characterised CRTC1-MAML2 fusion. There, the CREB binding 
domain encoded in the exon 1 of CRTC1 is fused to the transcriptional activation domain 
on exons 2-5 of MAML2, leading to constitutive activation of the CREB signalling pathway. 
As a direct result of that, a ligand to EGF receptors, AREG, is upregulated, which thus 
induces oncogenic activity through the EGFR signalling pathway (Chen et al., 2014). 
As the protein resulting from the YAP1-MAML2 fusion contains both the 
transcriptional activation domain of MAML2 and the TEAD-binding domain of YAP1, I 
hypothesised that the fusion may lead to constitutive activation of the YAP1/TEAD 
signalling pathway. In accordance with that, we performed a gene-set enrichment analysis 
comparing the three YAP1-MAML2 fusion positive cell lines against all others. Of 189 
pathways tested, the YAP1-conserved signature was the top most significantly enriched 
(adj. p < 0.001) (Figure 6.9F). YAP1-conserved signature was also enriched when ES-2 was 
compared against all other ovarian cancer cell lines and SAS against all other head and 
neck cell lines, while expression of prototypic tissue-specific oncogenic signatures, such as 
oestrogen receptor signalling in ovary, were depleted (Figure 6.9G).  
In summary, my data suggests strongly that recurrent YAP1-MAML2 fusions are 
associated with increased YAP1 signalling and essential for cell fitness. In the future, it 
would be interesting to follow-up the question of whether YAP1-MAML2 fused tumours 
respond to inhibitors of YAP1 and other members of the Hippo-signalling cascade.  
 
6.5.2 RAF1 fusions 
Another interesting vignette revolves around RAF1 fusions, of which two instances 
are significantly essential in the CRISPR/Cas9 analysis. Rare RAF1 fusions have been 
reported in several patient tumours across multiple tissue types, including a SRGAP3-RAF1 
fusion in pilocytic astrocytoma, a HACL-RAF1 fusion in pancreatic acinar cell carcinoma and 
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an ESRP1-RAF1 fusion in prostate adenocarcinoma (Chmielecki et al., 2014; Jones et al., 
2009; Palanisamy et al., 2010) (Figure 6.10A). The fusions all preserve the kinase domain in 
RAF1 while removing an N-terminal auto-inhibitory domain, which likely leads to MAPK 
pathway activation. In particular, fibroblast cells transduced with the SRGAP3-RAF1 showed 
increased phosphorylation of MEK1/2 and exhibited anchorage-independent growth 
(Jones et al., 2009). Similarly, ESRP1-RAF1 transduced cells showed increased cell 
proliferation and were sensitive to RAF and MEK inhibitors (Palanisamy et al., 2010).  
In our cell line panel, we detect a MBNL1-RAF1 fusion in the acute myeloid 
leukaemia cell line OCI-AML2, which is consistent with two previous high-throughput 
analyses (Klijn et al., 2015; Wang et al., 2017). We also identify a previously unreported in-
frame ATG7-RAF1 fusion in a pancreatic adenocarcinoma cell line, PL-5. Both fusions are 
significantly essential at p < 0.001 and FDR < 0.5% (Figure 6.10B).  
An ATG7-RAF1 fusion was previously also found in another KRAS wild type 
pancreatic cancer cell line, PL5, which is not in our cell line panel (Giacomini et al., 2013). 
There, the authors already showed that cell growth of PL5 was inhibited upon siRNA 
knockdown of ATG7.  
To characterise ATG7-RAF1 in PL-18, we confirmed the presence of the fusion of 
autophagy related 7 (ATG7) to RAF1 by Sanger sequencing across the breakpoint and 
interphase FISH (Figure 6.10C) 5. Like the RAF1-fusions found in patients and in PL5, the 
breakpoint of ATG7-RAF1 leads to deletion of the N-terminal regulatory domain while 
preserving the kinase domain (Figure 6.10D). Unlike most pancreatic cell lines, PL-18 also 
retained wild-type KRAS (28 of 32 cell lines are mutated in KRAS). In our high-throughput 
drug screening data, PL-18 nonetheless showed high sensitivity to MEK-inhibitors 
trametinib and PD0325901 (Figure 6.10E), which suggests that MAPK pathway signalling is 
still essential. The result from the high-throughput drug screening was validated by 
exposing both PL-18, OCI-AML2 (MBNL1-RAF1 fused) and a negative control cell line, 
SU8686 to trametinib over 72 hours and observing viability compared to the same cell lines 
exposed to DMSO. Both PL-18 and OCI-AML2 showed similarly strong loss of viability 
                                                 
5 Validation experiments for RAF1-fused cell lines were performed in collaboration with 
Gabriele Picco. He designed and performed/delegated validation drug screens, FISH and Sanger 
sequencing. Methods are described in Picco & Chen, et al. (manuscript under review). 
156 
 
(Figure 6.10F). Furthermore, PL-18 was the only pancreatic cell line in our panel for which 
sgRNA targeting the fused portion of ATG7 were significantly depleted (Figure 6.10G). 
The above experiments provide strong evidence that the ATG7-RAF1 fusion is 
essential for the viability of the PL-18, likely through the upregulation of the MAPK pathway. 
By mining sequencing data for 126 pancreatic adenocarcinoma PDX models, we identified 
one KRAS wild-type tumour with a PDZRN3-RAF1 fusion (PA2409; supplied by CrownBio), 
which suggests that RAF1 fusions are likely to also be found in clinical pancreatic 
adenocarcinoma.  
 
Figure 6.10: Essential ATG7-RAF1 fusion identified in pancreatic cancer cell line PL18. (A) Tissue types where 
RAF1 fusions have previously been identified. (B) RAF1 fusions are significantly depleted in the CRISPR/Cas9 
analysis. (C) Capillary sequencing and FISH confirm the presence of a fusion breakpoint. (D) Exon 18 of ATG7 
is fused to exon 7 if RAF1. (E) Across 29 pancreatic cancer cell lines, PL18 is among the most sensitive to MEK 
inhibitors trametinib and PD0325901. (F) Drug response curves of OCI-AML2, PL18 and a negative control 
pancreatic carcinoma cell line SU8686. (G) Among pancreatic carcinoma cell lines, PL18 is the only one for 
which sgRNA targeting sgRNA are depleted. 
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Thus, our data provides evidence for the second instance of a functional ATG7-
RAF1 fusion in pancreatic cancer cell lines. This indicates that RAF1 fusions in pancreatic 
cancer cell lines may have a higher incidence than previously believed. Further, we show 
for the first time that cell lines carrying the fusion are sensitive to MEK inhibition, 
highlighting that this rare subtype of KRAS wild-type pancreatic carcinomas is potentially 
clinically actionable. 
6.5.3 BRD4-NUTM1 
The BRD4-NUTM1 fusion typically characterises a rare and aggressive disease 
termed NUT midline carcinoma, a subtype of head and neck carcinomas (French, 2010). It 
involves the fusion of the N’-terminal bromodomains of bromodomain containing 4 (BRD4) 
at exon 9 with virtually the entire NUT midline carcinoma family member 1 (NUTM1) gene 
at exon 2. Although usually only expressed in testis, the fusion puts NUTM1 under the 
control of the BRD4 promoter, leading to ubiquitous expression (French et al., 2003). 
Through siRNA knock-down, the fusion has been shown to prevent differentiation and 
proliferation, although the exact mechanism of action is currently poorly understood 
(French et al., 2008). Importantly, in an initial study four fusion-positive patients responded 
well to the BET inhibitor OTX015/MK-8628, with resulting disease stabilisation and tumour 
regression (Stathis et al., 2016). 
Curiously, in our cell line panel, we find two cell lines with BRD4-NUTM1 fusions. 
One, RPMI-2650 is a known cell line of NUT midline carcinoma that is sensitive to BET 
inhibitors (Stirnweiss et al., 2017). Another, SBC-3 is a small cell lung cancer cell line, which 
carries a BRD4-NUTM1 fusion with the canonical break point (Figure 6.11A). Intriguingly, 
BRD4-NUTM1 has a significant fusion essentiality score in SBC-3 (Figure 6.11B), which 
suggest that it is necessary for tumour maintenance. Follow-up experiments by 
collaborator Gabriele Picco confirmed that NUTM1 is highly expressed in the cell line and 
that SBC-3 is just as sensitive to BET inhibition as RPMI-2650 (Figure 6.11C-D).  
This observation is in line with a previous study that found NUTM1 fusions in small 
cell lung cancer patients (Taniyama et al., 2014). Together, our findings suggest that rare 
BRD4-NUTM1 fusions may play a functional role in small cell lung cancers and may indicate 






Figure 6.11: Essential BRD4-NUTM1 fusion identified in small cell lung cancer cell line SBC-3. (A) Illustrated 
fusion breakpoint. (B) BRD4-NUTM1 fusions are significantly depleted in the CRISPR/Cas9 analysis. (C) 
NUTM1 is highly expressed in SBC-3 and RPMI2650 compared to all other cancer cell lines. (D) Drug response 




6.6 Chapter summary and discussion 
6.6.1 Summary and implications of findings 
In this chapter, I described the development and implementation of a novel 
computational approach to identify functional gene fusions using existing CRISPR/Cas9 
whole genome screening data. I applied the approach on 371 cell lines for which screening 
data was available and tested the functional essentiality for the 2,821 fusion transcripts for 
which at least one sgRNA was available.  
My method of mapping sgRNA effects on a per-transcript basis was able to identify 
78% of known oncogenes as essential at FDR < 25%. I also highlighted several cases of 
recurrent fusions in the COSMIC fusion census with weak evidence of oncogenic activity 
(section 6.3).  
Across all transcripts tested, the method identified 59 fusions in 63 events as being 
high-effect significantly essential (FDR < 5% and mean scaled logFC < -0.45). This 
represents just 2.7% of all fusions tested. I also found that within fusion essentiality scores 
with highly significant FDR, there was an enrichment only for known oncogenic fusions and 
fusions with significant drug associations. No such enrichment was found for other 
categories, e.g. in-frame fusions, kinase genes or fusions found in patients. Together, the 
evidence strongly suggests that in tumours, out of all detectable fusion transcripts, the vast 
majority are likely to be passenger events resulting from wide-spread structural 
rearrangements.  
In this chapter, I described two instances where my approach identified new 
oncogenic roles for 1) a previously uncharacterised fusion and 2) a fused oncogene in a 
novel tissue context.  
I showed that the fusion of the TEAD-binding domain of YAP1 and the transcription 
activation domain of MAML2 is likely to lead to constitutive activation of YAP signalling 
pathways in a fashion that is essential to tumour viability. Unlike most oncogenic fusions 
that are tissue-specific (e.g. EWSR1-FLI1 in Ewing’s sarcoma, BCR-ABL1 in chronic myeloid 
leukaemia etc), YAP1-MAML2 is detected and predicted to be essential in multiple tissue 
types including head and neck carcinomas, glioblastoma and ovarian carcinomas. This is 
perhaps less surprising considering that YAP1 overexpression has been linked to 
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oncogenic function ranging from poor prognosis, chemoresistance and bypass of KRAS 
addiction in multiple types of solid tumours. Several YAP1 inhibitors are currently in 
development, and in the future it would be interesting to test whether they would cause 
decreased viability cell lines, xenografts and tumours harbouring YAP1-MAML2 fusions. 
Positive results in these types of experiments would provide evidence to support testing 
and treating patients for YAP1-MAML2 positive tumours. 
In a second case, the ATG7-RAF1 fusion in a KRAS wild-type pancreatic 
adenocarcinoma cell lines describes a RAF1 fusion with a novel fusion partner in a novel 
tissue context. Like previously described RAF1 fusions, the upregulation of the MAPK 
pathway are likely driven by the deletion of N-terminal auto-inhibitory domain on RAF1. 
Cell lines with RAF1 fusions were indeed extremely sensitive to MEK1/2 inhibition by 
trametinib. The ATG7-RAF1 fusion demonstrates an alternate and potentially 
therapeutically targetable mechanism of MAPK pathway activation in a tissue type for 
which the majority of cancers are driven by KRAS mutations.  
6.6.2 Limitations of approach 
My computational approach of calculating fusion essentiality has a number of 
caveats. The most obvious caveats stem from the fact that the CRISPR/Cas9 whole genome 
guide libraries were of course originally designed with different objectives in mind.  
Skewed sgRNA distribution across fused genes  
In the ideal experiment, sgRNAs should be distributed equally across both fused 
and un-fused portion of the involved genes. However, in 45% of tests conducted (chapter 
5.3.2), I observe skewed distributions where one of the fused partners has sometimes 
exclusively mapping guides, while the other gene partner has exclusively non-mapping 
guides.  
In situations like those, without additional knowledge, it is difficult to call fusion-
specific essentiality. False positives are more likely to occur, when a gene is essential 
regardless of fusion status, which is illustrated in the example of the ERBB2-JUP fusion 
which has a significant FES despite being a passenger fusion event (section 6.1.1). 
Additionally, in section 6.4 I show that reproducibility for unknown fusion transcripts is 
lower when the sgRNA are not differentially mapping. 
A more suitable sgRNA library design would potentially include equal numbers of 
sgRNA that target the 5’ and 3’ regions of the genes. In the present situation, it is important 
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to bear in mind the distribution of sgRNA when analysing the results of this analysis. For 
fusions of potential clinical interest, it would be advisable to use follow-up validation 
experiments to confirm the fusion-specific essentiality before drawing strong conclusions.  
Noise and unpredictability of CRISPR/Cas9 whole-genome screens 
In addition to the distribution and number of sgRNA on fusions, the effectiveness 
of sgRNA is also a source of potential biases. Effectiveness of sgRNA can be biased by 
screening noise, as well as by sgRNA design effected by both known and unpredictable 
biases. Different sgRNA targeting the same genes can exhibit large variation in term of 
depletion effect size, with biases emerging for example from GC content of the guide 
target sequence, position of the target sequence along the gene and even the nucleotide 
identity at specific guide RNA positions (e.g. a guanine at position 20 is strongly preferable 
and adenines at positions 9-19 are favourable) (Doench et al., 2014; Wang et al., 2014).  
For that reason, whole genome CRISPR/Cas9 screens prefer to deploy multiple 
sgRNA’s per gene, ranging from 4-10 across the three data-bases. In chapter 5.3.2 I showed 
that screens using 5 sgRNA per gene can give good retrieval of essential genes (possibly 
improved by performing multiple biological replicates). In this analysis, only 76% of fusion 
transcripts in the screened cell lines have any mapping sgRNA. Where tests were 
conducted, although the median number of sgRNA are very similar (~4-5 sgRNA per 
fusion), the distribution is much broader and about 20% of fusion transcripts have only 
one or two mapping sgRNA (see chapter 5.3.2). 
Improving computational techniques 
Inefficiencies in sgRNA library design could be addressed through a redesign of the 
library. However, this is perhaps unrealistic, considering the time, resources and specialist 
knowledge necessary to undertake that task and to subsequently carry out the 
CRISPR/Cas9 drop-out screens. Instead, the computational approach could be improved 
to consider and highlight any potential short-comings. 
In relationship to the noisiness around screening data addressed above, it would 
for example be interesting to be able to approximate the effectiveness of a single sgRNA 
across the entire gene. This may mean calculating how much it varies compared to the 
depletion effect on the gene as a mean of all sgRNA, or more simply by setting a threshold 
on the number of samples an sgRNA has a strong deleterious effect on (for instance, this 
could be achieved by calculating a sgRNA-level BAGEL score). sgRNAs with low 
162 
 
effectiveness could then be removed from the down-stream calculations, which should 
lead to lower noise and more accurate fusion essentiality calling.  
Further, part of the analytical process involves calculating a Z-score of the scaled 
logFC’s across all cell lines for a given sgRNA. This Z-score may distort data when there are 
screening artefacts leading to extreme outliers (see chapter 5.3.4). To reduce noise from 
distortion, it may be useful to remove cell lines with particularly bad data quality, for 
instance by implementing a threshold on the AUC of the precision-recall curves (see 
chapter 5.3.2). Also, one could investigate alternative methods to scaling corrected log 
fold-changes and/or to Z-normalisation. In particular, it would be interesting to see 
whether mean-centring instead of Z-normalising, or whether Z-normalisation after taking 
the difference of mapping and non-mapping sgRNA would yield better results. Good 
benchmarks to use would be the recovery of known oncogenic fusions and any skew 
towards potential biases such as amplified/deleted/essential genes (see section 6.2). 
6.6.3 Future directions & conclusion 
Implementing solutions to the potential caveats above may reduce noise and 
improve signal for any potential current false negatives. Moreover, CRISPR/Cas9 whole 
genome drop-out screening projects are still on-going, both at the Broad Institute (Achilles 
data), and here at the Sanger Institute (Project Score data). Thus, in the nearby future, we 
may fill out further gaps in the 640 cell lines for which there is currently no screening data 
available. Similarly, a joint project is currently underway that looks at the comparability and 
possible integration of the Achilles and Project Score data (F. Iorio, personal 
communications). sgRNA libraries share less than 2% of target locations across their sgRNA, 
and thus may complement each other where one of the libraries lack differentially mapping 
sgRNA. Similarly, the ability of being integrated in the future can lead to higher numbers 
of sgRNA per test, thus increasing robustness and reliability. 
 
Concluding, in this chapter I have demonstrated that my computational approach 
is able to 1) detect known oncogenic fusions with high accuracy and 2) provide leads for 
novel oncogenic functionality of previously unknown fusions. My findings also suggest that 
truly functional, oncogenic fusions are exceedingly rare (< 2.7% in my data), and thus that 
the vast majority of detected fusions are likely to be passenger events. As my approach 
leverages high-throughput data to examine the essentiality of fusions in a large-scale 
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manner to examine even rare (n = 1) events, it opens up new possibilities of oncogene 
detection. Future advances in data collection will hopefully allow us to discover more 







7 Discussion and conclusion 
At the beginning of this dissertation, I stated the aim of identifying functional gene 
fusions in cancer. To achieve the goal, I created a catalogue of gene fusions and developed 
computational approaches that integrated data from several high-throughput screens.  
In this final chapter, I will first briefly summarise and discuss the important learnings 
and implications of the previous chapters. Finally, I conclude by reflecting on the overall 
contribution that this work has made and discussing the opportunities that are opening 
up in the future.  
7.1 Interpreting fusion-calling algorithms to create a catalogue of gene fusions 
(Chapter 2) 
I filtered and annotated processed RNA-Seq data and created a catalogue of 8,354 
gene fusions in 1,011 cancer cell lines (chapter 2). My benchmarks of 945 PCR validations 
and two independent sets of RNA-Seq data in 23 cell lines showed that fusion transcripts 
called by individual algorithms can be unreliable and contain a large proportion of false 
positive fusions. Using multiple different fusion-calling algorithms and only considering 
the overlap of different fusions returned the most reliable set of fusions based on my 
analyses. 
These conclusions are in line with other studies that examined fusion transcripts 
identified from RNA-Seq data. Meta-analyses of multiple fusion-calling algorithms found 
large discrepancies in performance, not only between fusion-calling algorithms, but even 
within the same algorithm depending on the type of sample (Carrara et al., 2013; Haas et 
al., 2017; Kumar et al., 2016). Similarly, recently published papers are now also starting to 
utilise multiple fusion-calling algorithms for an individual study (Gao et al., 2018). 
Altogether, the reliability of the algorithms is currently a weak point in the interpretation 
of RNA-Seq fusion calling data, and the community should be cautious when interpreting 
otherwise unvalidated lists of gene fusions called using single algorithms.  
As of now, different analyses use different ways of benchmarking the validity of 
gene fusions. Some choose to validate a small subset of gene fusions by PCR, some 
consider breakpoints confirmed by whole genome sequencing as true positives and yet 
others only validate a small number of fusions that are of particular interest due to a pre-
existing connection to cancer. Each approach has its own weaknesses and validation rates 
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are often incomparable across different studies. The community has yet to construct a 
gold-standard set of techniques, quality controls or benchmarks. This is further 
complicated by the fact that different samples can have vastly different characteristics, be 
it read length, read depth, sequencing type (single vs. paired-end), which may cause further 
discrepancies between samples called even by the same algorithm.  
Altogether, fusion-calling algorithms still have a way to go before being able to 
reliably minimise false negatives and false positives. However, the first algorithms were 
only developed in 2009, and at the speed at which technologies are being developed, we 
may soon see rapid improvements. Most algorithms were developed with samples 
sequenced with ~30 M read pairs. The average RNA-Seq data used in my dissertation 
contains 70-230 M read pairs (corresponding to ~36-89X) that were made possible by the 
large-scale sequencing pipelines that are developed both by CCLE, as well as here at the 
Wellcome Sanger Institute. Algorithms trained on samples like this, once the correct 
parameters and filtering criteria are identified, may be able to utilise the high read-depth 
to return more accurate results as well as picking up gene fusion that are lowly expressed. 
For now, the validation rate of the fusions used in my analysis is approximated at 
~70%. While it is important to be mindful of potential false positives that will be found in 
the data, it is nonetheless possible to extract meaningful biological information on cancer-
related fusions, as I showed in my subsequent analyses.  
7.2 Landscape of the occurrence and recurrence of gene fusions in the cancer 
cell line panel (Chapter 3) 
Next, I examined the landscape of this catalogue of gene fusions. I found that the 
occurrence of gene fusions in cancer cell lines of different tissue types of origin correlated 
well with those found in patient samples. Similarly, the fusions that are known to be cancer-
related (e.g. BCR-ABL1, ALK fusions, EWSR1-FLI1), are found almost exclusively in cell lines 
of the expected tissue type of origin. Overall, this indicates that the cell line panel can be 
a useful model for gene fusions in cancer.  
In this chapter I also describe how recurrent fusions are incredibly rare, with 96% 
of the gene fusions in our catalogue only occurring in a single cell line. In fact, only 237 
fusions (1%) were recurrent in three or more samples. I found a similar pattern of 
recurrence in the gene fusions identified in almost 10,000 patient samples, which shows 
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that it is not a specific characteristic of the genomic instability of cell lines. Importantly, I 
found that some commonly observed known oncogenic fusions are found in our cell line 
collection, but not in the almost 10,000 patient samples, e.g. EWSR1-FLI1, NPM1-ALK and 
BRD4-NUTM1. This is likely to be due to a bias in tissue representation, illustrating that 
even with large overall sample sizes and with the low recurrence of gene fusions, current 
resources are unlikely to be comprehensive. Increasing our number of sequenced cancer 
types and models will likely provide opportunities to increase representation of missing 
cancer subtypes.  
Finally, I examined the representation of gene fusions according to the predicted 
frame of the breakpoints. Overall, known functional fusions were overwhelmingly in-frame 
events, which is to be expected considering that most chimeric proteins must retain intact 
catalytic domains. On the other hand, the remaining gene fusions had a much wider spread 
of predicted fusion outcomes, including out-of-frame fusions, UTR fusions and others. As 
most not in-frame events are likely to be passenger events, this further underscores that 
the many of the fusions found in this analysis are likely to be passenger events.  
Overall, this chapter was a mainly descriptive look into the occurrence and 
recurrence of gene fusions across our panel of 1,011 cancer cell lines. In order to delve 
deeper into the analysis of functional fusions, it is necessary to involve other data sets that 
can link the occurrence of fusions to meaningful phenotypic indicators, e.g. of cell viability. 
7.3 Biomarker analysis with high-throughput screening data (Chapter 4) 
In this chapter, I used high-throughput drug screening data of over 400 drug IDs 
to find fusions that are biomarkers of drug response. My analysis reliably identified known 
cancer-related drug biomarkers, with the top hits being a sensitivity of BCR-ABl1 fused cell 
lines to ABL1 inhibitors such as Imatinib and the sensitivity of NPM1-ALK fused cell lines 
to ALK inhibitors. The detection of true positives suggest that the approach is correct, but 
unfortunately, no novel candidates showed strong enough evidence to warrant intensive 
further investigation.  
A major challenge in this analysis is probably the relatively low number of recurrent 
gene fusions reducing the statistical power of the analysis. This low sample size also means 
that even statistically significant hits are difficult to interpret, as the associations may be 
significant due to other confounding factors or simply by chance despite having performed 
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multiple-hypothesis correction. At the same time, the screened drug compounds are 
limited largely to those that were selected for showing promise in different cancer-related 
settings and targets that are currently druggable. These characteristics would have aided 
the rapid translations of any novel findings, but also mean I only test a relatively narrow 
set of potential molecular targets of cell line dependencies.  
These types of high-throughput drug screens have previously been successful at 
identifying molecular biomarkers of drug sensitivity in cancer cell lines (Barretina et al., 
2012; Garnett et al., 2012), which is also demonstrated by the efficient identification of 
known fusion-drug biomarkers. However, in the context of identifying unknown rare gene 
fusions that could play a functional role in cancer, perhaps a different approach is needed.   
7.4 Identifying essential fusions using CRISPR/Cas9 screening data (Chapter 5/6) 
In the final chapter, I developed a novel computational approach to identify 
functional gene fusions based on CRISPR/Cas9 whole genome drop-out screening data for 
339 cell lines. By mapping the coordinates of sgRNA of the CRISPR/Cas9 guide library to 
the coordinates of the gene fusions I was able to create fusion-specific depletion scores 
for 2,821 fusion transcripts (27% of total).  
My approach was able to correctly identify many known oncogenic fusions in this 
data set, including EWSR1-FLI1, PML-RARA, KMT2A-MLLT3 and EML4-ALK. Importantly, this 
method also highlighted novel fusions which produce a loss-of-fitness phenotype when 
knocked out in cell lines.  
The most interesting is perhaps a fusion in YAP1-MAML2, which has previously 
been described in patient samples of head and neck carcinoma origin, but have never 
before been functionally validated. YAP1-MAML2 was significantly essential in all three cell 
lines in which it was identified in our cell lines. YAP1 has previously been linked to cancer 
in multiple solid tumours, and I hypothesise that the functionality of the fusion is driven by 
the activation of the TEAD binding domain of YAP through the transcriptional activation 
domain of MAML2. Indeed, the YAP conserved gene expression signature is significantly 
enriched in the three cell lines compared to all other cell lines.  
That the fusion has been previously identified in the clinic gives hope that this 
finding may help real patients in the future. What is further interesting is that the fusion is 
found in three cell lines of different tissue types (head and neck, glioblastoma and ovarian 
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carcinoma), and appears to be significantly essential in all. This suggests that the 
functionality of the fusion may be tissue-type independent and argues for a broadly 
scoped approach to diagnosis and treatment. It would be interesting to test next whether 
fusion-carrying cell lines and tumours are sensitive to small molecule inhibition of YAP1 as 
well as transforming activity of the fusion. Further, understanding the frequency of this 
fusion in cancer patient populations will be important for the realisation of any treatment 
plans. 
My analysis also identified two further clinically interesting functional fusions. The 
first was an ATG7-RAF1 fusion in pancreatic cancer cell line PL-18. While this fusion has 
been identified previously in another pancreatic cancer cell line, PL5 (Giacomini et al., 2013), 
we provided evidence for the first time of the sensitivity to MEK inhibition in fused cell 
lines. Together, this indicates that RAF1 fusions in pancreatic cancer cell lines are 
potentially clinically actionable and clinically actionable in pancreatic cancer patients, 
supporting further research into the clinical use of this fusion as diagnostic marker for 
personalised treatment. 
Finally, I identified a functional BRD4-NUTM1 fusion in small cell lung cancer cell 
line SBC-3. Similarly to nut midline carcinomas in which the fusion is usually found, we 
showed that SBC-3 is sensitive to BET inhibitors. The data thus supports that using BRD4-
NUTM1 as a biomarker may provide treatment benefit in a subset of small cell lung cancer 
cell patients. 
My computational approach of identifying essential fusions from CRISPR/Cas9 data 
was able to facilitate some novel findings. Overall however, it is striking how few fusions 
(~3%) have evidence of significant essentiality in the cell lines. This strongly suggests that 
the vast majority of fusions identified in cancer models and samples are passenger events 
that are unlikely to contribute to cancer maintenance. This likely complicates the 
interpretation of RNA-Seq fusion-calling data in research and the clinic, as potentially 
important impactful fusions may be metaphorical needles in the haystack. Taken together 
with the low recurrence of even some known oncogenic fusions (e.g. BRAF and RAF1 
fusions), this means that identifying novel oncogenic fusions will need novel approaches 
beyond simply looking for highly recurrent fusions (as is currently the standard of 
identifying cancer-related mutations).  
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Using CRISPR/Cas9 data in cell lines represents one way of approaching this. There 
are still caveats that can be ironed out that may make the approach more impactful (for 
instance using larger sgRNA libraries, developing thresholds and indicators of potential 
false positive fusions, etc.). As more cell lines are being screened across large institutions 
such as the Wellcome Sanger Institute and the Broad Institute, the discoveries to be made 
with this computational approach may yet grow. The coverage of this analysis will also 
depend on the availability of models. As RNA-Seq is collected and CRISPR/Cas9 screening 
data is generated in cancer organoids, this approach can easily be transferrable into 
different model systems as well.  
7.5 Final impressions 
With the aim of the thesis in mind, as finding functional gene fusions in cancer, my 
PhD work makes the following specific contributions to the community: 
1. A catalogue of gene fusions in a panel of 1,011 cancer cell lines that will be 
released into the public domain. In the future, this resource can be 
integrated with further molecular and phenotypic annotations to make 
scientific discoveries, and may also be used by scientists who are interested 
in finding cell lines with a particular gene fusions.  
2. A computational approach to determine the specific essentiality of gene 
fusions. This approach can be replicated in future studies that generate 
RNA-Seq and CRISPR/Cas9 screening data, potentially leading to the 
discovery of further novel functional gene fusions. 
3. Evidence of the functionality of the YAP1-MAML2 fusion in three different 
cancer cell lines. My results suggest that knock-out of the fusion may lead 
to loss-of-viability in tumour, which may have direct implications for any 
future patients that present with this fusions in the clinic.  
4. The observation that only a small proportion of gene fusions have 
 evidence for functionality. Perhaps an expected result, my 
computational approach provides hard evidence that most gene fusions do 
not contribute significantly to the viability of cancer cell lines. This suggests 
that the interpretation of gene fusions identified in cancer cells should be 
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treated with caution, and that developing better approaches of identifying 
functional cancer-related gene fusions could be valuable and worthwhile.  
Overall, these contributions are only a small step towards a larger goal of providing 
a better diagnosis, treatment and care environment for cancer patients. My findings have 
been built on the work of a lot of literature before me and it is my hope that they can 







8 Supplementary tables 
Here follows an index of the supplementary tables and titles. All supplementary 
tables are included as a supplement to the thesis on a USB stick. 
 




1 Annotation of 1,034 human cancer cell lines used in our study and the source of 
RNA-seq data. All cell lines are part of the GDSC cancer cell line project (see 
COSMIC IDs). 
2 List of primers sequences used to validate gene fusions. 
3 List and annotation of 10,514 fusion transcripts found in 1,011 cell lines. 
4 High-throughput cell line drug sensitivity data (IC50’s) used in this study together 
with compound annotation. Column names are COSMIC id’s of cell lines. 
5 Significant results from the drug-association analysis using cancer functional 
events. 
6 Significant results from the drug-association analysis using gene fusions. 
7 Significant results from the gene-centric drug-association analysis. 
8 Fusion essentiality score and significance calculation for all 2,821 fusion transcripts 
with mapping guides. For 525 fusion transcripts where multiple data sets 
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